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CHAPTER 1
INTRODUCTION
1.1 The biology of cytomegalovirus
Cytomegaloviruses (CMVs) are classified as members of the betaherpesvirus subfamily
of the Herpesviridae family (183). Infection with CMVs is not restricted to humans but also
affects many other animals. The individual CMVs are, however, highly species-specific.
The CMV genomes consist of double-stranded, linear DNA and are encapsidated. The size
of the genome ranges from 180 kilobase pairs (kbp) for equine CMV to 230 or 240 kbp for
human, simian, guinea pig, murine and rat CMV (183, 265). The capsid is surrounded by a
tegument or matrix. These components are enclosed in a lipid bilayer envelope carrying a
number of virally-encoded glycoproteins (Fig. 1).
The replication cycle of CMV is a complex process of regulatory cascades (183).
Principally, gene expression during productive replication can be divided into three
temporal phases: the immediate early (IE), early and late phase (Fig. 2). IF transcription
starts after entrance of the virus into a cell. In contrast to transcription in the earlv and late
phases, the transcription of IF genes does not depend on de novo protein synthesis. The
proteins encoded by the IE proteins are important regulators of transcription of viral early
genes. The proteins that are synthesized in the early phase of infection are mainly involved
in the synthesis of new viral gcnomic DNA, whereas most late proteins are structural
proteins necessary for the assembly of new virus particles, e.g. (glyco)proteins ol the
capsid, matrix and envelope. The whole replication cycle of human CMV (HCMV) is
completed within approximately 48 to 72 hours, whereas murine CMV (MCMV) yields
Membrane glycoproteins
Envelope (phospholipid bilayer)
Tegument or matrix
Icosahedral nucleocapsid
Linear double stranded DNA
150-200 nm
F/G. I. Sdinnafif Km o/ Mr CMV
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[~j~l Entrance of virus into a cell through fusion of the virus envelope with the cell.
The virus capsid is absorbed into the cytoplasm of the cell After proteolysis
of the capsid proteins, the viral DNA is transported into the cell nucleus.
|M I The viral proteins are synthesized in a temporal sequence
[jiT] Replication of viral DNA and assembly of the virus take place within the nucleus.
[|\/| New virus particles leave the infected cell via the endoplasmic reticulum.
F/C. 2. 77ie o/CMV.
infectious progeny in 24 to 3b hours (183). Cytomegalovirus replication characteristically
produces cell enlargement with intranuclear inclusions. This is reflected in the name for
end-stage in vivo infections as cytomegalic inclusion disease or owl's eyes inclusions (270).
These names were defined even before the causative agent was isolated.
1.2 HCMV as a pathogen
Infections with HCMV are very common. The prevalence of anti-HCMV antibodies
ranges from 40'; to 100'3 (13b). Socio-economic factors, high density of the population and
hygiene seem tu correlate with higher infection rates (42). In healthy individuals, infection
is limited by the protective response of the immune system. As a consequence, these
infections usually remain asymptomatic. Only occasionally, primary infection of
immunocompetent individuals results in the onset of clinical symptoms such as a
mononucleosis syndrome, persistent fever, hepatitis and pneumonia (121). Although
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infections usually remain asymptomatic, the immune system does not succeed in the
complete clearance of the virus from the host and latent virus will remain present lifelong.
Intermittent reactivation of HCMV results in shedding of infectious virus in saliva, urine,
cervical and vaginal secretions, semen, breast milk, tears, faeces and blood. In this way. the
virus can be transmitted by direct or indirect person-to-person contact. The perinatal phase
and the phase in which people become sexually active an* the two periods in life in which
the risk of primary infection with HCMV is very high (121, 243).
Whereas HCMV infection in healthy, immunocompetent individuals usually remains
asymptomatic, in immunocompromised patients, such as organ transplant recipients and
people with AIDS, active viral replication can result in the onset of severe clinical
symptoms (51, 105, 199, 233). These observations point to the important role of cell-
mediated immune defenses in the lifelong control of HCMV infection. Therefore, bone
marrow transplant recipients in whom the complete immune system is replaced are at high
risk for symptomatic infection. Symptoms of CMV infection in transplant patients are
usually prolonged fever, leukopenia, thrombocytopenia, atypical lymphocytosis, and
elevated levels of hepatic transaminases. Life-threatening symptoms include
gastrointestinal tract involvement and pneumonia, especially in bone marrow transplant
patients (70,177). HCMV also appears to be associated with allograft dysfunction /rejection
and decreased graft survival in solid organ transplant recipients, although this association
is still controversial (28, 97, 109, 118, 137, 193, 258). The main organs involved in HCMV
infections in AIDS patients are the lungs, the central nervous system (CNS) and Ihe
gastrointestinal tract (51). Blindness caused by HCMV retinitis is frequently occurring in
AIDS patients, but is rarely encountered after organ transplantation. Finally, HCMV
infection can be further complicated by the onset of opportunistic infections with fungal,
protozoal, bacterial and other viral pathogens (73, 188, 203, 220, 267).
In general, the onset of HCMV infection and the possible development of clinical
symptoms in organ transplant patients is correlated with the type and degree of
immunosuppression (15, 61, 153, 167, 197, 209, 218, 220, 228, 262). Furthermore, primary
infections are usually correlated with more severe clinical manifestations than secondary
infections or reactivations (108, 222, 235, 237, 239, 269). Variables which also contribute to
infection in the posttransplant period include the source of the allograft (living-related
versus cadaveric), HLA matching of donor and recipient, and type and amount of blood
products used (30,74, 77,193,1%, 239,273). In general, liver, pancreas, lung, intestinal, and
heart transplant recipients have a greater incidence of symptomatic HCMV infection than
kidney transplant recipients (107,120,199). Allogeneic bone marrow transplant patients are
usually considered as a distinct group of patients, because of the graft versus host disease
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(GVHP), which is only encountered in this group of transplant patients, and their highly
immune suppressed state. In addition, mortality rates due to HCMV infections are higher
in these patients than in other transplant patients (156, 219, 272, 274). GVHD appears to be
an important additional risk factor for development of symptomatic HCMV infection in
bone marrow transplant recipients, although its role is still controversial (29, 64, 66, 122,
178, 186). The incidence and severity of symptomatic HCMV infection after autologous
bone marrow transplantation is comparable to the situation described for solid organ
transplant recipients (213).
1.3 HCMV disease management in transplant patients
The onset of HCMV infection in organ transplant recipients occurs primarily in the first
three months after transplantation, when immunosuppression is most intense (120). The
current strategies for the treatment and prevention of HCMV infection and disease were
recently reviewed by Sia and Patel (233).
The first approach in disease management is the determination of the serostatus of the
donor and recipient using serological assays (see below), to identify patients with a possible
primary or secondary infection. Due to the fact that patients with a primary infection have
no existing cellular immunity against HCMV, they are at a higher risk for the onset of
symptomatic infection than patients with a secondary infection. Patients with a primary
infection should therefore be carefully monitored for the onset of CMV infection.
Reduction of the level of immunosuppression upon detection of CMV infection is
considered to be the most simple and effective approach towards inhibition of viral
replication, since it allows the natural clearance of HCMV infection by the immune system
(94, 187). 1 lowever, this inherently increases the risk of graft rejection and is not an option
in patients with severe impairment of the specific antiviral immunity, as is the case for bone
marrow transplant recipients.
The current availability of antiviral drugs allows the maintenance of the established
level of immunosuppression during antiviral therapy. Ganciclovir is the most commonly
used antiviral drug for the prevention and treatment of symptomatic HCMV infection in
organ transplant recipients and AIDS patients (48). Two main strategies for the prevention
of symptomatic infection can be distinguished, which are different with respect to the time
point at which the antiviral drug is administered to the patient.
The prophylactic therapy approach is based on standard administration of ganciclovir to
a transplanted patient regardless of the outcome of the laboratory tests for HCMV detection.
However, many discrepancies in the reported effectivity of this approach exist (2,6,8,43,59,
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79,149,166,173,189). In particular, early inhibition of viral replication will not stimulate the
development of cellular immunity against HCMV. This could be a dis.uiv.int.jgf tor the
acute and long-term control of the infection by the patient. Furthermore, the need for
intravenous administration of ganciclovir, its adverse effects, e.g. leukopenia,
thrombocytopenia, and renal toxicity (54, 75, 233), as well as the chance of development of
drug-resistant virus strains (3,17,71,138,154,217), do not favor prolonged prophylactic use
of this drug in every transplant recipient. Thus, unnecessary prophylaxis in patients who are
not at risk for symptomatic HCMV infection should be avoided. Instead, initiation of
antiviral therapy is preferably based on detection of aberrant HCMV activity by laboratory
tests, prior to the onset of symptomatic infection. This would also allow limited viral antigen
expression which may trigger immune responses that contribute to improved acute and
long-term immunological control of infection. This concept is the rationale of the preemptive
therapy approach. However, it strongly depends on the availability of a sensitive and rapid
diagnostic assay, with a high positive predictive value (I'PV) for the onset of symptomatic
infection (39, 62, 155, 201, 221). Moreover, besides positive laboratory tests, additional risk
factors have to be considered by the clinician to identity possible symptomatic infections.
For example, patients with a primary infection or anti-rejection therapy, are at increased risk
for the development of symptomatic infection. Thus, a positive laboratory test for IICM V in
these patients has additional predictive value and justifies the start ofantivir.il therapy (1,2,
117, 126, 158, 209, 256). Finally, the ideal diagnostic assay for HCMV disease management
should be able to mark the endpoint of HCMV infection which allows discontinuation of
antiviral therapy, without relapse of symptomatic infection.
1.4 HCMV diagnostics
Currently, many techniques are available for the detection of HCMV in patient
specimens. The owl's eyes inclusions, which are characteristic for CMV-infected cells, can
be detected in tissue biopsies. Nevertheless, this is not a standard technique that is suitable
for early diagnosis of HCMV infection, since it is quite insensitive and inclusions are
usually only observed at a late stage of symptomatic infection with organ involvement (11,
44). Preferably, HCMV is detected before the onset of symptoms in samples which can
easily be obtained from the patient, such as blood and urine. However, prolonged shedding
of HCMV in urine, even after the phase of active HCMV infection, makes detection of
HCMV in urine quite nonspecific for diagnosis of a clinically significant IICMV infection
(233). The presence of infectious HCMV in the blood (viremia) is considered as the hallmark
of active CMV infection leading to disease. Therefore, preferably blood samples have to be
investigated for the presence of HCMV. The clinical use of different diagnostic assays for
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the detection of HCMV was reviewed by Sia and Patel (233) and Boeckh and Boivin (19).
The advantages and disadvantages of the most relevant assays are summarized in Table 1.
The procedures and diagnostic values of these assays are outlined in more detail below.
1.4.2 Sero/o#y
Detection of HCMV for diagnostic purposes is usually based on detection of infectious
virus or the different viral components, i.e. DNA, mRNA and proteins. Alternatively, the
virus can be detected indirectly by demonstration of the presence of anti-HCMV IgG and
IgM antibodies. These antibodies were found to be directed mainly against the outer
membrane glycoproteins gB (32) and gH (234) and the tegument proteins pp28 (UL99),
pp6S (UI.82) and pplSO (UL32) (125, 144) The assays for detection of antibodies include
complement fixation tests, enzyme-linked immunosorbent assays (EL1SA), enzymatic
immuno assays (EIA) and latex agglutination tests. Although these assays can be
performed in a relatively short time and allow automation in routine diagnostic
laboratories, they appear to be quite insensitive markers for monitoring HCMV infection in
immimooompromised hosts, in particular in patients that are already seropositive at the
moment of transplantation. Due to the fact that antibodies are formed against antigens that
are expressed during infection, the immune response is by definition delayed relative to the
onset of infection. Moreover, the immune response is usually further delayed due to the
treatment of tho patient with immunosuppressive drugs. Furthermore, results of the assay
can be blurred by blood transfusions and antibody-based therapy. Serology is therefore of
limited diagnostic use in preemptive antiviral strategies and for monitoring the effect of
antiviral therapy (164, 195, 202, 215, 238, 248). However, the serological assays are used to
determine a previous infection with HCMV, and thus potential carriership status, in
transplant donors and recipients. This is valuable information, since primary infection is
considered to be an important risk factor for development of symptomatic infection.
1.4.2 Virrt/ oi/ri/re
Active viral replication results in shedding of the virus into various bodily secretions, as
discussed above. The presence of infectious virus in these secretions can be demonstrated
by inoculation of samples on cells which are highly permissive for CMV replication, i.e.
human fibroblasts. These cultures are screened frequently for the appearance of the typical
cytopathogenic effect (CPE) caused by active replication of the virus. However, it can take
up to h weeks before the CPE is observed. Therefore, this technique is unsuitable for rapid
diagnosis of HCMV infection and early start of preemptive antiviral therapy. Results can be
obtained much faster by an immunohistochemical staining procedure which is performed
T/
tfl
LE
 
7.
 
/W
rfi
sa
<f
tw
nt
o£
fii
 
o
f a
w
m
o
«
/y
 
i/.s
e<
/ m
rt
/io
rf
s 
/o
r 
/h
e 
rff
ffc
fiO
H
 
o
f H
C
M
V
 
IM
 
W
oo
rf
to
 
=
 
rfw
ec
fio
n 
n
/r
aW
y-
a/
i f
 
ig
e»
/J
i/
or
rs
m
if 
/o
r/
).
M
et
ho
d
Ta
rg
et
A
dv
an
ta
ge
Di
sa
dv
an
ta
ge
Se
ro
lo
gy
C
on
ve
nt
io
na
l 
v
ir
al
cu
ltu
re
D
R
A
I-
'F
'o
r 
sh
el
l v
ia
l
cu
ltu
re
A
nt
ig
en
em
ia
PC
R
RT
-P
CR
NA
SB
A
H
CM
V
 
sp
ec
ifi
c 
a
n
ti-
bo
di
es
In
fe
ct
io
us
 
v
ir
us
In
fe
ct
io
us
 
v
ir
us
, 
IE
-1
pr
ot
ei
n
Th
e 
pp
t>
5 
te
gu
m
en
t
pr
ot
ei
n
Vi
ra
l g
en
om
ic
 
D
N
A
Vi
ra
l 
m
R
N
A
V
ira
l m
R
N
A
R
ap
id
; 
su
ita
bl
e 
fo
r 
a
u
to
m
at
iz
at
io
n;
 
de
te
r-
m
in
at
io
n
 
of
 
th
e 
se
ro
st
at
us
 
of
 
o
rg
an
 
do
no
r
a
n
d 
re
ci
pi
en
t 
(e.
g. 
pr
im
ar
y 
in
fe
ct
io
n
 
is 
a
n
im
po
rt
an
t 
ris
k 
fa
ct
or
 
fo
r 
th
e 
o
n
se
t 
of
 
a
sy
m
pt
om
at
ic
 
in
fe
ct
io
n)
D
et
ec
tio
n
 
o
f c
o
m
pl
et
e 
in
fe
ct
io
us
 
v
ir
us
D
et
ec
tio
n
 
of
 
co
m
pl
et
e 
in
fe
ct
io
us
 
v
ir
us
; f
as
-
te
r 
th
an
 
co
n
v
en
tio
na
l 
v
ira
l c
u
ltu
re
.
 
R
es
ul
ts
ar
e 
qu
an
tif
ia
bl
e
R
es
ul
ts
 
ca
n
 
be
 
o
bt
ai
ne
d 
w
ith
in
 
1 
da
y;
qu
an
tit
at
iv
e 
re
su
lts
; 
m
o
re
 
se
n
si
tiv
e 
th
an
v
ir
al
 
cu
ltu
re
; l
es
s 
se
n
si
tiv
e 
th
an
 
PC
R
Ve
ry
 
se
n
si
tiv
e;
 
re
su
lts
 
ca
n
 
be
 
o
bt
ai
ne
d 
w
it-
hi
n
 
1 
da
y;
 
qu
an
tit
at
io
n
 
po
ss
ib
le
, 
in
 
pa
rt
ic
u-
la
r 
a
pp
lic
at
io
n
 
of
 
re
a
l-t
im
e 
qu
an
tit
at
iv
e
PC
R
 
se
em
s 
to
 
be
 
pr
om
is
in
g,
 
bu
t 
is 
in
ve
st
i-
ga
tio
na
l
Ve
ry
 
se
n
si
tiv
e:
 
re
su
lts
 
ca
n
 
be
 
o
bt
ai
ne
d 
w
it-
hi
n
 
1 
da
y;
 
qu
an
tit
at
io
n
 
po
ss
ib
le
 
(ap
pli
ca
-
tio
n
 
of
 
re
a
l-t
im
e 
qu
an
tit
at
iv
e 
PC
R
 
is 
in
ve
s-
tig
at
io
na
l)
Ve
ry
 
se
n
si
tiv
e;
 
re
su
lts
 
ca
n
 
be
 
o
bt
ai
ne
d 
w
it-
hi
n
 
1 
da
y:
 
sp
ec
ifi
c 
a
m
pl
ifi
ca
tio
n
 
or
 
R
N
A
,
n
o
t 
D
\A
; 
iso
th
er
m
al
 
a
m
pl
ifi
ca
tio
n
 
pr
oc
e-
du
re
; q
ua
nt
ita
tio
n
 
o
f m
R
N
A
 
u
si
ng
 
N
A
SB
A
is 
in
ve
st
ig
ab
on
al
In
se
ns
iti
ve
, 
e.
g.
 
tr
an
sp
la
nt
 
pa
tie
nt
s 
o
fte
n
ha
ve
 
im
m
un
ol
og
ic
al
 
dy
sf
un
ct
io
n;
 
of
 
lim
i-
te
d 
u
se
 
fo
r 
m
o
n
ito
ri
ng
 
th
e 
ef
fe
ct
 
of
 
a
n
tiv
ir
-
al
 
th
er
ap
y
L
ab
ou
r-
in
te
ns
iv
e,
 
lo
ng
 
tu
rn
ar
ou
nd
 
tim
e
(1-
A
 
w
ee
ks
); 
lo
w
 
se
n
si
tiv
ity
; 
u
n
su
ita
bl
e 
fo
r
m
o
n
ito
ri
ng
 
a
n
tiv
ir
al
 
th
er
ap
y
La
bo
ur
-in
te
ns
iv
e;
 
tu
rn
ar
ou
nd
 
tim
e 
st
ill
 
24
-
48
 
ho
ur
s;
 
qu
ite
 
in
se
ns
iti
ve
; 
u
n
su
ita
bl
e 
fo
r
m
o
n
ito
ri
ng
 
a
n
tiv
ir
al
 
th
er
ap
y
H
ig
h 
n
u
m
be
rs
 
o
f 
bl
oo
d 
ce
lls
 
ar
e 
n
ee
de
d 
to
m
a
ke
 
cy
to
sp
ot
s;
 
th
e 
bl
ix
id
 
sa
m
pl
es
 
m
u
st
be
 
pr
oc
es
se
d 
im
m
ed
ia
te
ly
 
af
te
r 
co
lle
ct
io
n;
po
si
tiv
e 
re
su
lts
 
do
 
n
o
t 
a
lw
ay
s 
pr
ed
ic
t
sy
m
pt
om
at
ic
 
H
C
M
V
 
in
fe
ct
io
n.
 
Pr
ot
oc
ol
n
ot
 
st
an
da
rd
iz
ed
Po
ss
ib
le
 
de
te
ct
io
n
 
of
 
la
te
nt
 
v
ir
us
; 
ri
sk
 
o
f
la
bo
ra
to
ry
 
co
n
ta
m
in
at
io
n
 
ca
u
si
ng
 
fa
ls
e
po
si
tiv
e 
re
su
lts
; 
la
ck
 
of
 
st
an
da
rd
iz
at
io
n
be
tw
ee
n
 
th
e 
di
ffe
re
nt
 
PC
Rs
R
isk
 
of
 
la
bo
ra
to
ry
 
co
n
ta
m
in
at
io
n
 
ca
u
si
ng
fa
lse
 
po
si
tiv
e 
re
su
lts
.
 
La
ck
 
o
f 
st
an
da
rd
iz
a-
tio
n
 
be
tw
ee
n
 
th
e 
di
ffe
re
nt
 
PC
Rs
.
 
D
et
ec
tio
n
o
f 
u
n
sp
lic
ed
 
tr
an
sc
ri
pt
s 
ca
n
 
be
 
di
ffi
cu
lt
a
n
d 
n
ee
ds
 
to
 
be
 
co
n
tr
ol
le
d
R
isk
 
of
 
la
bo
ra
to
ry
 
co
n
ta
m
in
at
io
n
 
ca
u
si
ng
fa
lse
 
po
si
tiv
e 
re
su
lts
; c
o
n
tr
ol
le
d 
pr
os
pe
ct
i-
v
e 
st
ud
ie
s 
o
n
 
th
e 
di
ag
no
st
ic
 
v
a
lu
e 
o
f
N
A
SB
A
 
a
re
 
st
ill
 
in
 
pr
og
re
ss
o a
CHAPTER 1
after only one or two days of culture (91). This technique is called detection of early antigen
fluorescent foci (DEAFF) or shell vial culture. The monoclonal antibodies used in this
procedure are directed against the IE-1 protein of the virus. The presence of infectious
HCMV in the blood of immunocompromised individuals, as detected by the viral culture
procedures, is a significant risk factor for the onset of symptomatic infection, especially in
bone marrow transplant recipients (162, 179). However, due to the relatively low levels of
infectious virus in blood and secretions, the sensitivity of both slow (detection of CPE) and
rapid (DEAFF) viral culture techniques appears to be low (184, 198, 248). In addition, viral
culture results often become negative during therapy, regardless of the outcome of the
infection (20, 65).Thereforc, viral culture is also of limited value for monitoring HCMV
infection during antiviral therapy.
1.4J /Wigfiifmia
The pp65-antigenemia assay, developed by Van der Bij et al. (261) is used in many
diagnostic laboratories for monitoring HCMV infections. This assay is performed with
polymorphonuclear leukocytes (I'MNL) which are isolated from bkxxl samples of the
patient and cytixentrifuged onto glass slides. The slides are subsequently used in an
immunohistochemical procedure using monoclonal antibodies directed against the major
early-late protein pp65 (56). The assay can be performed in one day and generates
quantitative results, usually expressed as the number of pp65-antigen positive cells/50 x
10' leukocytes. The major disadvantage of the antigenemia assay is that blood samples
have to be processed in a short period of time (6 hours), in order to prevent a significant
decrease in the number of positive cells (23, 229). In addition, the test may be difficult to
perform after bone marrow or stem cell transplantation, or during a period of severe
neutropenia, since high numbers of granulocytes are needed to make the cytospots.
It was recently demonstrated that the presence of HCMV antigens in PMNLs are not the
result of a complete viral replication process, but are the result of a direct transmission of
previously assembled infectious virus and synthesized viral material to PMNLs through a
cell-to-cell contact mechanism with productively infected endothelial cells (86). Thus, the
detection of pp65-antigen in circulating PMNLs is not a direct indicator of HCMV
replication in vivo and therefore does not always predict the onset of symptomatic HCMV
infection (146, 233, 248, 260). Nevertheless, high numbers of positive cells in blood samples
obtained from solid organ transplant recipients appear to correlate well with a symptomatic
HCMV infection (87, 89, ^3, 253, 2M». This suggests that a cut-off value in the number of
ppf)5-antigen positive cells may be used as a marker for initiation of preemptive therapy.
Unfortunately, there does not appear to be a universal cut-off value, since it was found to
10
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vary among different types of transplant patients and among different anrigenemia
protocols (19, 80, 142, 253). Furthermore, such a cut-off value is of limited value for
allogeneic bone marrow transplant patients with severe GVHD. Rapid progression towards
symptomatic HCMV infection in these patients requires the start of antiviral therapy upon
the finding of the first antigenemia positive sample, even if the number of pp65-antigen
positive cells in this sample is low (22).
In general, the antigenemia assay is more sensitive than viral culture for the detection of
HCMV in blood (85, 146, 261). Compared to the polymerase chain reaction (PCR, see
below), the sensitivity of the antigenemia assay is usually lower (22, 85, 253). Furthermore,
antigenemia results appear to correlate well with the HCMV DNA content in both plasma
and leukocytes as determined by quantitative PCR assays (24, 84, 85). The antigenemia
assay is also suitable for monitoring the effect of antiviral therapy, although intermittent
rises in the number of pp65-anligen positive cells, which do not seem to correlate with
clinical findings, are possible (22, 106, 259). In addition, recurrence of antigenemia positive
results after termination of antiviral therapy can predict the relapse of symptomatic HCMV
infection (259).
1.4.4 /»CR
With the polymerase chain reaction (PCR) it is possible to amplify low concentrations of
DNA exponentially to levels which can easily be detected. This is achieved by repetitive
cycles of denaturation of DNA, annealing of specific primers and DNA synthesis. Each of
these steps requires a different temperature. Characteristic for this procedure is the use of
the enzyme 7m/ DNA polymerase which can withstand the high temperatures used for
denaturation of DNA. The procedure is outlined in more detail in Fig. 3. PCR was found to
be a very sensitive assay for the detection of HCMV DNA in many studies. However,
detection of HCMV DNA does not always predict the onset of symptomatic infection,
because DNA of latent virus can be detected as well (55, 89, 280). The determination of the
viral load by means of quantitative PCR assays appears to be more predictive than
qualitative PCR for the onset of symptomatic HCMV infection. Also, quantitative PCR is
suitable for monitoring HCMV during antiviral therapy (68,69,72, 78,88,162,171, 216,225,
263, 268). A disadvantage of most quantitative PCR assays is that they are very laborious
and results are sometimes difficult to reproduce. Nevertheless, commercially available kits
are relatively easy to perform (24, 26, 57, 119, 135). Alternatively, the development of real-
time PCR offers the possibility to determine the viral DNA load in a fast and convenient
manner (160, 185, 191, 192, 249, 278). The preliminary results obtained with this technique
appear to be promising. The equipment to perform these assays is (still) quite expensive,
12
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and standardized calibration methods need to be established. Nevertheless, it is expected
that this approach will be become standard in more routine diagnostic laboratories.
Although HCMV is mainly a cell-associated virus, HCMV DNA can also be detected in
cell-tree body fluids, such as serum and plasma (5, 38, 242). Most PCR methods are not
standardized, which makes it difficult to compare the different studies in which the
diagnostic value of PCR was evaluated. However, the detection of viral DNA in serum and
plasma of solid organ transplant recipients appears to correlate better with symptomatic
HCMV infection than detection of viral DNA in leukocytes, particularly in transplant
recipients with secondary infections (21,49,60, 72, 123). On the other hand, leukocytes may
be more appropriate than plasma or serum for monitoring the effect of antiviral therapy,
since residual viral DNA can be detected for a longer period ot time in these cells (85).
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mRNA
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Also, the detection of viral DNA in whole blood appeared to be a good marker for
monitoring the effect of antiviral therapy in both bone marrow transplant recipients (67)
and solid organ transplant recipients (255).
1.4.5 RT-PCi? and N/ISBA
As discussed above, it is possible to detect DNA of latent virus with PCR. Positive PCR
results are therefore not always correlated with the onset of a symptomatic HCMV
infection. It was suggested that the demonstration of actively replicating virus by the
detection of viral mRNA would correlate better with symptomatic infection (18). In
particular, detection of late mRNA could allow the differentiation between latent and active
infection because the former lacks the synthesis of structural proteins.
Two major techniques are available for the detection of mRNA: reverse transcriptase (RT)-
PCR and nucleic acid sequence-based amplification (NASBA). The detection of RNA by RT-
PCR has been outlined in Fig. 4. Briefly, the initial step in the RT-PCR procedure consists of
the conversion of mRNA into cDNA performed by the RT enzyme. The cDNA is
subsequently amplified by PCR In contrast, NASBA is an isothermal amplification reaction
which is based on the concerted action of three enzymes: ribonuclease H, RT and a DNA-
dependent RNA polymerase (Fig. 5) (47). The final product of this transcription-based
amplification method is single-stranded RNA. RT-PCR has to be performed preferentially
using primers which span an intron, to be able to differentiate amplified cDN A from genomic
DNA dig. 4). In contrast, any single-stranded RNA can be used as a substrate in the NASBA
reaction, which enables the detection of both spliced and unspliced transcripts in a
background of DNA. NASBA and other transcription-based amplification methods have
been used in both research and diagnostics of several pathogens, including HCMV (40).
RT-PCR and NASBA were used in various studies to detect HCMV IE, early or late
mRNA in the blood of immunocompromised patients. These mRNAs represent different
phases in the replication cycle of HCMV. The correlation between the presence of these
mRNAs and the onset of a clinically significant HCMV infection was investigated as
outlined below.
7.4.5./ M(>mh>nn^ ' of/E »iRI\M c.v/>ri'ss/(>»
Transcription of IE mRNA is one of the first events occurring in an HCMV-infected cell.
Detection of this mRNA is therefore expected to be an early marker of infection. The UL123
mRNA, which encodes the 1E-1 protein (246), was the main target for detection of IE
transcription by RT-PCR (18, 143, 150, 174, 176, 200, 211, 264). However, the correlation
between IE mRNA detection and the onset of symptomatic HCMV infection was found to
vary considerably in different studies. The reported sensitivity of IE RT-PCR ranged from
14
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25% to 100%. The low sensitivity of 25% was found in a study in which mononuclear cells
were used for extraction of RNA (200). In all other studies whole blood or total leukocyte
cell fractions were used. The specificity of IE RT-PCR was found to vary from 100% to 0%.
It was suggested that the low specificity of this assay was due to the detection of abortive
infection, most probably induced by allogeneic stimulation of blood cells harbouring
HCMV after blood transfusion (143, 180, 241). Compared to the antigenemia assay, the
sensitivity of IH RT-PCR was found to be either similar (18, 176), higher (143, 264) or even
lower (174). Compared to PCR, the sensitivity was found to be either similar (18, 264) or
lower (176, 2(X), 211), but never higher. These variations are most probably explained by the
lack of standardization of the different RT-PCR methods that were used for the detection of
II: mRNA.
Alternatively, a standardized NASBA assay was used for the detection of IE-1 mRNA in
the blood of immunocompromised patients. IE NASBA was found to be more sensitive
than the antigenemia assay, PCR and viral culture for detection of a HCMV infection in
allogeneic bone marrow transplant recipients (81, 82). It was therefore suggested that IE-1
mKNA detection by NASBA could well serve as a new parameter for the start of early
preemptive therapy in bone marrow transplant recipients, since these patients are at high
risk for the development of symptomatic infection. In contrast, JE NASBA was /ound not
to be suitable for guiding preemptive antiviral treatment in solid organ transplant
recipients, in particular in patients with a secondary infection (81, 82,194). Due to the high
sensitivity of the assay, positive IE NASBA results obtained for these patients are not
necessarily correlated with the onset of a symptomatic infection. Nevertheless, a
quantitative NASBA assay was recently developed for monitoring IE-1 mRNA expression
(102). It was shown that measuring the dynamics of the IE-1 RNA levels in blood samples
lit lung transplant patients with this assay is useful for monitoring disease progression
(104). Quantification otters the possibility to determine cut-off levels for IE-1 mRNA
expression that discriminate between asymptomatic infection and the onset of a
symptomatic infection.
1.4.5.2 Mi>njfor/M£ of
Only a few studies were reported in which the correlation between the detection of early
mRNA and symptomatic infection was investigated. The detection of early UL112-113
mRNA appeared not to be unsuitable for monitoring symptomatic HCMV infection, due to
low sensitivity and specificity of the assay (174). In contrast, detection of the same
transcript was found to be a sensitive and specific marker for symptomatic infection when
other primers were used and a nested RT-PCR protocol was performed (143). Moreover,
early mRNA detection preceded pp65-antigen detection by at least 1 week for most
16
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patients. Similar results were obtained for the detection of the early tf2.7 mRNA by N ASBA
(4, 194). In addition, detection of this transcript also appeared to be useful for monitoring
HCMV infection during antiviral therapy. Nevertheless, additional studies should be
performed to evaluate the diagnostic value of monitoring the expression of early mRNA
expression.
1.4.5.3 Mt)H/7on>i^  o/tofi* mRN/\ expess/'o/i
As mentioned above, the detection of late mRNA could possibly allow the
differentiation between latent and active infection because late mRNA is not likely to be
expressed during latency. In the majority of the reported RT-l'CR methods, cither the UL32
mRNA, encixiing the major tegument protein pp151) (125), or the ppULSh mKNA, encoding
the major capsid protein (MCP) (41), was detected. In addition, assays were developed for
the detection of mRNA transcribed from the natural killer cell decoy gene UL18 (112, 113)
and for mRNA transcribed from the R2708ÜS gene, which codes for a protein of unknown
function (212). Detection of MCP mRNA by RT-l'CR appeared to be a sensitive and specitic
marker for symptomatic HCMV infection in organ transplant patients and AIDS patients
(80, 95, 96). In addition, MCP mRNA could be detected in most cases betöre the onset of a
symptomatic HCMV infection (80, 95). Therefore, it appears to be a promising marker for
the initiation of preemptive therapy. Similar results were found for monitoring the
expression of the r27080s transcript (143, 190). In contrast, detection of pplSO mKNA or
UL18 mRNA did not appear to be a very good marker for symptomatic infection. Due to
the relatively low transcription rates of these transcripts, the sensitivity of the assays was
low (18, 25, 112, 113, 176).
NASBA was used for the detection of pp67 mRNA, which is one of the most abundantly
transcribed late transcripts (52, 53). However, the antigenemia assay was found to be more
sensitive than pp67 NASBA for the detection of symptomatic HCMV infection in renal
transplant recipients (204). Furthermore, pp67 NASBA appeared to be inappropriate for a
preemptive therapy approach in a group of bone marrow transplant recipients and solid
organ transplant recipients with a primary infection, because the sensitivity was relatively
low (81,83). In contrast, it has been reported that pp67 mRNA could be detected in all solid
organ transplant recipients with a secondary infection (82, 83). These patients were treated
preemptively with ganciclovir when >100 pp65-antigen-positive cells per 2 x lO** leukocytes
were detected in blood samples. The detection of pp67 mRNA preceded this antigenemia
treshold level by a mean time of 3.5 ± 2.6 days. Similar findings were reported for thoracic
organ transplant patients using a clinically relevant cut-off of >10 pp65-antigen-positive
cells per 2 x 1CP leukocytes (194). Nevertheless, cut-off values for the antigenemia assay are
not commonly used and vary between different labs, most probably due to the lack of
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standardization of the assay. This may also underlie the apparent low sensitivity of th(
pp67 NASBA assay compared to the antigenemia assay in some reports.
In general, the detection of pp67 mRNA correlates strongly with the peak of infection
Therefore, in contrast to the quantification of IE-1 mRNA using NASBA (see above)
quantification of pp67 mRNA levels appears to have no additional value compared to th<
qualitative assay for the prediction of the possible onset of a symptomatic infection (104).
1,4.5.4
Monitoring of IICMV infection during antiviral therapy is necessary to determine a saft
endpoint for discontinuation of the treatment. It was found that the clearance of HCM\
mRNA from the blood after the start of antiviral therapy, corresponded with th(
disappearance of clinical symptoms (18, 25, 80, 143, 174, 176, 190). In most cases, this wa;
accompanied by the clearance of the pp65-antigen (18,80,81,83,176) or infectious virus (81
190). In contrast, I"C'R positive results usually outlasted clinical symptoms and antivira
therapy for weeks (18, 25, 80, 176, 140). Similar findings were reported for the detection o
Hi-1 mRNA using NASBA (81, 104). It was found that persistence of late mRNA durinj
therapy, as well as renewed detection of late mRNA shortly after termination of therap)
could indicate a relapse of HCMV infection, either symptomatic (80) or asymptomatic (143
194). It should be noted that in most studies the follow-up after initiation of antiviral therapy
was limited to a few samples or patients. In addition, these studies were retrospective
studies, which implies that RT-PCR or NASBA results were not known at the time it was
decided to initiate or terminate antiviral therapy. The true value of RT-PCR and NASBA in
the management of antiviral therapy should therefore be investigated in prospective studies.
These studies are currently in progress.
1.5 Localization of CMV in blood cells during active infection
In the previous part of the introduction, the diagnostic value of different assays for
monitoring HCMV infection in the blood of immunocompromised patients was discussed.
By separate analysis of the different blood cell populations of these patients, it was found
that HCMV can be detected in the polymorphonuclear leukocytes (PMNLs) as well as in
peripheral blood mononudear cells (PBMCs) (50, 90, 175, 266). A higher load of virus
appeared to be present in the PMNLs compared to the PBMCs, as determined by higher
quantities of viral DNA (224, 225) and antigens (90, 101). In addition, infectious virus could
be isolated more frequently from PMNLs than from monocytes (90, 224). However, as
discussed above, it was recently shown that HCMV abortively infects PMNLs (86).
Infectious vims or viral products in the PMNLs were found to be acquired from other
18
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permissive cells, e.g. infected endothelial cells, mainly bv microfusion events with these
cells. Therefore, it was concluded that the detection of virus or viral products in PMNLs
preparations from immunocompromised patients with disseminated infection, e.g. pp65-
antigen detection by the antigenemia assay, cannot be considered as direct indicators of
HCMV replication in blood cells (86).
In contrast to PMNLs, PBMCs were reported to be the major infected leukocvte cell type
during acute infection. This was concluded from the finding that lli-1 mRNA and IE-1
protein could be detected predominantly in PBMCs (99, 257). Nevertheless, infection of
these cells appears to be primarily abortive both in vivo (224, 232, 257) and in vitro (58, 63,
90, 214). Thus, viral DNA and IE-1 mRNA can be detected in PBMCs but this is not
necessarily correlated with the production and release of infectious progeny virus. Studies
in which the presence of CMV in different PBMC populations was investigated showed
that mainly monocytes could be infected in vitro (148, 240). HCMV DNA was rarely
detected in lymphocytes (50, 90, 266).
A possible confounding factor in the results described above for the presence of CMV in
PBMCs and PMNLs, could be contamination of these tractions with circulating IICMV-
infected endothelial cells (ECs). These cells were shown to contain viral transcripts and
proteins from all three stages of the viral replication cycle, as well as numerous virus
particles (98-100). Moreover, the number of CMV-infected ECs was reported to correlate
with the severity of infection and presence of organ involvement in CMV infection (100,
205).
Like HCMV, MCMV is also associated with leukocytes during acute infection (7,46,163,
247). It is likely that CMV-infected cells circulating in the blood play a crucial role in the
dissemination of the virus throughout the infected host. For example, after injection of
MCMV in the tail veins of mice, infectious MCMV cannot only be recovered from whole
blood, but also from bone marrow, spleen, lungs, and salivary glands during the acute
phase of infection (277). Similarly, active replication of HCMV is not restricted to blood cells
and can occur in various organs of immunocompromised patients. In particular,
transplanted organs appear to be frequently involved in CMV infection (233).
1.6 Localization of CMV during latent infection
In contrast to HCMV infections of immunocompromised patients, infections of healthy
individuals usually remain asymptomatic. Like all other herpesviruses, CMV can cause
acute, persistent and life-long latent infections. Nevertheless, exact sites of viral latency or
persistence remain to be defined. In general, the term latency is used when genomic CMV
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DNA is present, while infectious virus cannot be detected. Detection of low levei
production of infectious virus is usually described as persistence. Thus, the distinctior
between latency and persistence has primarily relied on the sensitivity of the assays that are
used to detect infectious virus.
CMV can usually not be isolated from the blood of healthy donors (250, 251)
Nevertheless, CMV can be transmitted by blood transfusion, and leukocyte depletioi
reduces the incidence of infection (147). It is therefore likely that CMV is present in tht
blood in a latent form. It was found that CD14+ monocytes are a major site of latency, ii
contrast to PMNLs and lymphocytes (250, 251). In latently-infected monocytes, the viral
genome appears to be present as a circular plasmid, similarly as described for other
herpesviruses (27). HCMV IE, early and late gene transcription could not be detected ii
freshly isolated monocytes from healthy HCMV seropositive individuals, although HCMY
DNA was readily detected in these cells (252). Similar findings were reported for MCMY
(206). Because monocytes circulate in the blood only for several hours and infectious viru>
is not isolated from the blood during latent infection, it is unlikely that the monocytes have
obtained the virus by primary infection in the bUxxi circulation. It was therefore suggested
that bone marrow progenitor cells may act as a reservoir for HCMV and can transmit thf
viral genome to peripheral' 6i'oou' monocyfes, in fhe aösence o/i'ytiv* gerw expressiurr v'MJ,
182, 277, 279). This theory is supported by the finding that bone marrow cells obtained from
healthy seropositive individuals appear to be a site of latency (133, 170, 182). In particular,
cells which express the myeloid surface markers CD14, CD15 and CD33 along with the
dendritic markers CDla and CDU) contained HCMV DNA (110, 133). These cells serve as
progenitors for monocytes. The dendritic cells and cells of the monocytic lineage play an
important role in the immune system as antigen presenting cells (APCs). The predominant
presence of latent CMV in these cells is expected to play a key role in the ability of CMV to
evade the immune system of the host and to prevent its own eradication. In fact, it was
found that 1ICMV gene products interfere with the activation of MHC class I- and class II-
rvstricted T cells, modify the function of cytokines and their receptors, interact with
complement factors and modulate signal transduction and transcription factor activity
(157). Furthermore, viral mRNAs transcribed from the immune evasion genes US3, US6,
USll were found to be actively expressed in blood during the acute phase of infection as
well as after clinical recovery (103). It was therefore suggested that these genes may play a
role in the long-term control of HCMV infection in vivo.
Interestingly, a novel class of HCMV transcripts was detected in experimentally and
naturally intected hematopoietic progenitor cells. These transcripts appear to be produced
exclusively during latent infection (110, 133, 134, 236). In addition, antibodies directed
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against the proteins encoded by these transcripts have been detected in serum from healthy
seropositive blood donors (134, 145) and patients with active HCMV infection (145).
However, it was reported that at least one of the latency-associated proteins is dispensable
for both productive and latent HCMV infection (271). Furthermore, these transcripts were
recently also shown to be expressed in a variety of HCMV-infected cell types during
productive infection in vitro (15*>). Thus, until now the function of the latency-associated
transcripts and their encoded proteins is still enigmatic.
In vitro infection of bone marrow progenitor cells resulted in the spread of the virus
through the progeny of these cells as they replicate and differentiate (161). Permissiveness
of bone marrow progenitor cells for prtxluctive infection appeared to be dependent on their
state of differentiation. Early after infection of the progenitor cells, infectious virus could
not be detected in the supernatant of the culture (274). Moreover, IK and late gene products
were absent at that time. However, differentiation of the bone marrow cells resulted in
productive CMV infection. This is consistent with the observation that HCMV replication
and gene expression in monocytes could be stimulated upon differentiation of these cells
into macrophages using granulocyte colony stimulating factor or hydrocortisone (124, 151,
252). Moreover, full virus replication could be demonstrated after in vitro allogeneic
stimulation of latently infected peripheral blood mononuclear cells (241). Thus, immune
activation can provide a stimulus which is sufficient for complete reactivation of HCMV. In
this respect, cytokines are thought to play an important role. For example, TNF-alpha is
able to stimulate the activity of the CMV IE enhancer/promoter region in the human
monocytic cell line, HL-60 (76, 245). Also, for MCMV it was found that macrophages are
able to support complete virus replication (31,129,181). Thus, blood cell progenitors in the
bone marrow may act as the main source of latent CMV. The virus can reactivate and
disseminate from the bone marrow to other organs via monocytes as they leave the
circulation and undergo tissue-specific differentiation to macrophages (206, 247).
In addition to the findings of latent CMV in the bone marrow, latent MCMV was
reported to be present in various other organs. Moreover, it was hypothesized that cells of
the myeloid lineage are only a temporary site of CMV latency and that long-lived stromal
and/or parenchymal cells are the cellular site of prolonged latency in organs (140). This
theory is supported by the finding that virus is eventually cleared from the blood (9, 10). In
addition, mature lymphocytes, macrophages, or dendritic cells did not appear to be sites of
latency in spleens of latently infected mice (172). Determination of sites of latency or
persistence of HCMV in organs of healthy humans has been difficult to perform because of
the limited availability of tissue samples. To circumvent this problem, samples were
obtained from previously healthy trauma victims. In these samples, CMV DNA and
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antigens could be detected in brain, kidney, spleen, lung, liver and arteries (114, 115, 169,
254). Like HCM V DNA, MCMV DNA could be detected in a variety of organs such as heart,
kidney, liver, lung, spleen, brain and salivary gland during latent infection (45, 131, 208,
231). Latent virus could be reactivated from these organs by prolonged co-culturing with
permissive cells or by transplantation of tissue to seronegative recipients or SCID mice (42,
111, 172,207,223,230,277).
In most studies it was demonstrated that little or no infectious virus is present in organs
of chronically infected mice, except in the salivary glands (10, 16, 127, 128, 132, 168, 172).
This indicated that the long-term presence of MCMV in mice does not require continuous
low level production of infectious virus. Nevertheless, 1E-1 and early-late pp50 mRNA have
been detected in latently infected spleens (116, 276), lungs (139, 277) and salivary glands
(16, 276), suggesting that there can be some viral trancriptional activity in the absence of
detectable levels of infectious virus. Interestingly, upon induction of immunosuppression
in latently infected mice by gamma-irradiation, a switch from focal to generalized IE-1
transcription was found to occur in the lungs (140). In addition, late IE-3 and gB transcripts
wen- generated (141). Nevertheless, infectious virus was not necessarily detected together
with late mKNA expression. It was therefore proposed that several sequentially ordered
control points exist in the transition from MCMV latency to recurrence, at least in the lungs.
1.7 Rat CMV
The rat cytomegalovirus (RCMV) infection model proved to be valuable for studying
aspects of CMV infection in relation to organ transplantation (130,152,165,275). Compared
to mice, rats are more convenient in transplantation studies, because the organs of rats are
easier to handle during surgical procedures than those of mice. The isolation of the
Maastricht strain of RCMV from wild rats was reported by Bruggeman et al. in 1982 (35).
At about the same time, the English strain of RCMV was isolated by Priscott and Tyrrell
(210). However, the two RCMV strains appear to represent different betaherpesvirus
species rather than strains (12). This conclusion was based on the results of the comparison
of the genomic sequences comprising the major immediate-early genes. The availability of
sequences ot the English strain is very limited (226, 227). In contrast, the complete genomic
sequence of the Maastricht strain was recently determined and compared to that of HCMV
and MCMV (265). The RCMV genome was found to have counterparts of all but one of the
open reading frames that are conserved between MCMV and HCMV.
The pathogenesis of RCMV infection in rats was found to be similar to that of HCMV
infection in humans (244). Typically, infection of immunocompetent rats with RCMV is
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usually not life-threatening (34, 244), even when a high dose of virus is used (33, 34). In
contrast, induction of immunosuppression by gamma-irradiation before RCMV infection
results in high mortality rates (244). During the first week after primary infection of rats
with RCMV, infectious virus can be isolated from most organs, except the salivary glands
(14, 34, 244). In general, no infectious virus can be isolated from the salivary glands before
day 10, although RCMV DNA can be detected in this organ as early as day 3 (14). In the
following weeks, virus titers increase in this organ up to 28 days post infection (p.i.),
whereas infectious virus can no longer be detected in the other organs. Nevertheless,
studies in which latently infected renal allografts were transplanted to seronegative rats,
showed that virus could reactivate from these organs (36, 37). Similar findings were
reported with cardiac allografts, although vims reactivated less frequently compared to the
renal allografts (36). Apparently, the presence of RCMV in organs of latently infected rats
needed to be further characterized, in particular at the level of RCMV DNA and viral
mRNA expression. In a preliminary study, RCMV DNA could be detected with a high
frequency in salivary glands and liver at 330 days after infection (13). Incidentally, DNA
could also be detected in kidney, lungs, pancreas, and thymus at that time-point. I lowever,
these studies did not include a similar analysis during acute infection, nor was the
expression of viral mRNA determined.
1.8 Aims of the thesis
Preemptive therapy approach is a promising concept in the management of HCMV
infection following organ transplantation, although it strongly depends on a sensitive assay
with a high positive predictive value for the onset of symptomatic infection (62, 221). I'CR
as well as the antigenemia assay appear to be helpful in early diagnosis of active HCMV
infection. However, with PCR it is possible to detect latent virus which is not necessarily
correlated with the onset of a symptomatic infection (55, 89, 280). The antigenemia assay is
a relatively sensitive method for the detection of HCMV infection, although positive results
do not always predict the onset of a symptomatic HCMV infection (146, 233, 24H, 260). It
was suggested that the demonstration of actively replicating virus by the detection of viral
mRNA would correlate better with symptomatic infection (18).
The first aim of this thesis was to evaluate the diagnostic value of monitoring the
expression of HCMV pp67 and IE-1 mRNA in blood samples using NASBA, as markers for
HCMV infection in kidney and liver transplant patients. The NASBA assays were
compared to assays which are routinely used in the laboratory, such as the antigenemia
assay, viral culture and serology. The results obtained with pp67 NASBA and IE NASBA for
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kidney transplant patients are described in chapter 2 and 3, respectively- These were the
first published reports on the technical procedure of the N ASBA assays and their diagnostic
value. The evaluation of the pp67 and IE NASBA assay for monitoring HCMV infection in
liver transplant patients is presented in chapter 4. Together with the published data for
other organ transplant patients, the suitability of IE and pp67 NASBA for monitoring
HCMV infection is discussed in chapter 6.
Monitoring of immunocompromised patients for the onset of HCMV infection is usually
performed by screening blood samples for the presence of infectious virus or viral
constituents. However, CMV infection is not restricted to the blood compartment, since
various organs can be involved in an active CMV infection (233). The fact that CMV can be
transmitted by organ transplantation from seropositive donors, indicates that CMV also
resides in organs from immunocompetent individuals. It is virtually impossible to perform
extensive studies on active and latent CMV infection in human organs, because the
availability of tissue biopsies is usually limited to transplanted organs or organs obtained
after autopsy. In the latter organs, the integrity of the purified RNA is usually questionable
due to post-mortem changes in the cellular environment. This KNA is therefore unsuitable
to perform reliable expression studies. Alternatively, infection of rats with RCMV proved
to be a convenient animal model to study aspects of CMV infection in relation to organ
transplantation (130,152,165, 275). The molecular biology as well as the in vitro and in vivo
growth characteristics were found to be highly similar between RCMV and HCMV (34, 244,
265). Nevertheless, .is for HCMV, the mechanisms which play a role in the maintenance of
a latent RCMV infection are still unclear. Therefore, the second aim of this thesis was to
obtain a more detailed picture of acute and latent RCMV infections in vivo. For this
purpose, immunocompetent rats were infected and subsequently sacrificed at defined time
points after infection. The presence of RCMV genomic DNA, mRNA, and infectious virus
in various tissues and blood was determined. As a result, viral replication and
transcriptional activity during acute, persistent and latent infection could be defined
(chapter 5). These data as well as the findings from other studies are discussed in chapter 6.
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DETECTION OF HCMV INFECTION BY NASBA
ABSTRACT
The diagnostic value of monitoring human cytomegalovirus (HCMV) late pp67
mRNA expression by nucleic acid sequence-based amplification (NASBA) after renal-
allograft transplantation was evaluated. RNAs were isolated from 484 whole-blood
specimens of 42 patients for the specific amplification of the late pp67 (ULbS) mRNA.
NASBA results were compared to results from the pp65 antigenemia assay, virus
isolation by cell culture, and serology. The sensitivity value for NASBA proved to be
higher than that for the antigenemia assay (50 versus 35%) for the detection of HCMV
infection, while the sensitivity values of cell culture and NASBA were comparable (54
and 50%, respectively). NASBA detected the onset of HCMV infection simultaneously
with cell culture and the antigenemia assay. Both the antigenemia assay and NASH A are
very specific (100%) and highly predictive (100%) for the onset of HCMV infection.
Antiviral therapy with ganciclovir resulted in negative results for cell culture, the
antigenemia assay, and NASBA. In conclusion, monitoring HCMV pp<>7 mRNA
expression by NASBA is a highly specific method for the detection of HCMV infection
in renal-allograft recipients and is more sensitive than the antigenemia assay.
Furthermore, NASBA can be used to monitor the progression of HCMV infections and
the effect of antiviral therapy on viral activity.
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INTRODUCTION
Human cytomegalovirus (HCMV) belongs to the group of betaherpesviruses. Primary
infection of immunocompetent individuals with HCMV usually does not lead to
complications. In contrast, immunocompromised patients, like AIDS and transplantation
patients, may suffer severe complications during primary infection and to a lesser degree
during secondary infection. In fact, HCMV infections are the most common single cause of
death in allograft recipients (9). Detection of HCMV at an early stage of infection is a
prerequisite for effective preemptive antiviral therapy (22). Currently, several routine
diagnostic tests are available for the direct or indirect detection of HCMV infection. Direct
isolation of HCMV by cultivation of permissive human fibroblasts with samples from
blood or urine is a sensitive method, but results are obtained rather late. The cytopathic
effects (CPF.) of replicating virus in the cells can be detected only after several days or
weeks of cultivation. The presence of virus can be detected much earlier in cell cultures by
detection of early-antigen fluorescent foci (DEAFF) with monoclonal antibodies directed
against immediate-early 1 antigen of the virus (8). Although the cell culture assay was
previously considered the "gold standard," the HCMV antigenemia assay is more
commonly used to monitor patients for HCMV disease. The antigenemia assay was
developed by Van der Bij et al. (24) to detect the viral lower matrix protein pp65 (UL83) in
blood leukocytes. By this immunocytochemical technique, test results can be obtained
within 1 day, but it requires direct processing of fresh clinical specimens. The number of
ppd5-positive cells was shown to correlate with HCMV disease (26, 28). PCR is another
method to detect the presence of HCMV. Although amplification of the viral genome by
PCR proved to be a highly sensitive technique (up to 100%), it does not necessarily correlate
with active infection, due to the possible amplification of latently present viral DNA
and/or incomplete viral genomes (17, 24, 27). It was suggested that the detection of viral
immediate-early and late mRNAs in blood leukocytes may improve HCMV diagnosis (1),
as it directly reflects viral transcriptional activity. Indeed, reverse transcriptase PCR (RT-
PCR) of viral late mRNA was found to have a high positive predictive value for HCMV
disease, although sensitivity appeared to be low (6, 16, 21). The detection of mRNA by
nucleic acid sequence-based amplification (NASBA) is a highly sensitive method. Unlike
RT-IVR, NASBA allows detection of unspliced mRNA in a background of DNA (3). A
qualitative and quantitative NASBA assay is currently available for the detection of human
immunodeficiency virus (HIV) RNA (10, 30). The technique has now been used for the
detection of HCMV RNA in blood leukocytes. In contrast to the methods just mentioned,
serologii.il diagnosis gives only indirect evidence of the presence of the virus and can be
problematic because of the immunological disorders occurring in most patients at risk of
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developing HCMV infection (13, 23). However, detection of HCMV-specific antibodies can
provide supportive evidence for the diagnosis of HCMV infection. Detection of
immunoglobulin M (IgM) especially can be used as a diagnostic tool during both primary
and secondary infections (7, 12).
Using a qualitative NASBA assay, we evaluated retrospectively the diagnostic value of
monitoring late pp67 mRNA expression as a marker for HCMV infections after renal-
allograft transplantation. The results of the NASBA assay were compared with the results
of prospectively performed standard virological techniques, i.e., dettvtion of the presence
of infectious virus in blood by cell culture (CPE and DEAFF), testing tor ppr*5 antigenemia,
and serology.
MATERIALS AND METHODS
Patients. From January 1995 to July 19%, a total of 60 kidney transplantations were
carried out at the Department of Internal Medicine, University Hospital Maastricht. For this
study, we selected 42 patients, from whom a minimum of four blood specimens were
collected during the first three months after transplantation. Patients could be grouped
according to the HCMV serostatus of the recipient before transplantation and the IICMV
serostatus of the donor, which resulted in the following distribution of patients with
different serogroups: 13 D+ and R+ patients, 8 D+ and R- patients, 13 D- and R+ patients,
and 8 D- and R- patients, where D+ and D- indicate seropositive and -negative donors,
respectively, and R+ and R- indicate seropositive and -negative recipients, respectively.
Maintenance of immunosuppression consisted of treatment with cyclosporin or
tacrolimus together with low-dose prednisolone. In addition, some patients received
azathioprine. Allograft rejection was assessed clinically and confirmed by needle core
biopsy. Treatment for allograft rejection consisted of a 10-day course of rabbit anti-
lymphocyte globulin (National Institute of Public Health and the Environment, Bilthoven,
The Netherlands) or three doses of methyl-prednisolone.
HCMV infection was defined by positive results for at least two samples for one or more
of the following items: cell culture, antigenemia, seroconversion of anti-HCMV IgM,
and/or a significant rise (at least fourfold) in the anti-HCMV IgC level compared to the
pretransplantation titer. HCMV infection could be further classified as a primary or
secondary infection, depending on whether the patient was HCMV seronegative or
seropositive before transplantation, respectively.
Ganciclovir (Cymevene; Hoffmann-La Roche Ltd., Basel, Switzerland) was given
intravenously for 2 weeks, in case HCMV infection was detected and the patient showed
clinical signs suggesting HCMV disease. The perioperative protocol did not include
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routinely prophylactic anti-HCMV therapy. If possible, the dosage of the
immunosuppressive drug was diminished in case of HCMV infection. However, if a patient
was treated with ATG or methylprednisolone and HCMV infection was indicated by
positive laboratory tests, ganciclovir was given for 2 weeks intravenously, even when there
were no clinical signs of HCMV disease.
Specimens. Heparini/ed whole-blood and serum specimens were collected weekly
during the clinical period after transplantation. After this period specimens were collected
monthly or more frequently if the patient showed clinical symptoms of HCMV infection.
Specimens were screened prospectively for the presence of HCMV by routine cell culture
and the pp65 antigenemia assay. In addition, 1 ml of heparini/ed blood was added to 9 ml
of NASUA lysis buffer (4.7 M guanidium thiocyanate, 46 mM Tris |pH 6.4], 20 mM EDTA,
1.2'/< |wt/vol| Triton X-KH)), and the mixture was stored at -70°C. From the 42 patients, a
total of 484 blood specimens was collected.
Cell culture. For the detection of infectious HCMV in blood, both conventional cell
culture and PEAFF were performed as described previously (11). Briefly, leukocytes were
separated from heparini/ed whole blood with dextran and screened for the presence of
IK'MV by inoculation of human embryo fibroblasts monolayers. Cell cultures were
observed weekly during a period of 6 weeks for the appearance of a typical CPE of
replicating HCMV. DEAFF was performed after 2 days of cultivation with the monoclonal
antibody E13 (Biosoft, Paris, France) to the HCMV immediate-early 1 antigen. For analysis,
DEAFF and CPE results were combined to give one outcome for the cell culture assay.
Results nrt presented for either the day on which a positive specimen was obtained or the
day on which a positive result could be reported to the clinic.
pp65 antigenemia assay. The pp65 antigen was detected immunocytochemically
essentially as described by Van der Bij et al. (24). Briefly, 45 x 10"* leukocytes were isolated
from heparini/ed whole blood with dextran and centrifuged onto a glass slide within 4 h
of collection. The cells were subsequently fixed for 10 min in methanol and incubated with
mouse monoclonal antibodies, namely, anti-pp65 IgG (produced in our laboratory). After
incubation with horseradish peroxidase-coupled rabbit anti-mouse IgG (DAKO A/S,
Glostrup, Denmark), the substrate 3-amino-4-ethylcarba/ole was added to stain the pp65-
positive cells. Finally, slides were examined microscopically. Results are expressed as
numbers of pp65-positive cells per 15 x 10"* leukocytes.
Serology. Sera were tested retrospectively to obtain more information about viral
activity, in addition to the antigenemia assay and cell culture results. For the qualitative
detection of lgM against IICMV in serum, the lMx CMV assay (Abbott Laboratories, North
Chicago, HI.) was used, and for the semiquantitative detection of IgG against HCMV, the
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AXSym assay (Abbott Laboratories) was used. Both tests are based on microp.irticle
enzyme immunoassay technology. Results from the IMx CMV assay were exprvssed as
index values. Sera with index values of >0.500 were considered positive. Levels of anti-
HCMV lgG were expressed as numbers of antibody units (AU) per milliliter. Sera with lgG
levels of >15 AU/ml were considered positive. The detection limit of 250 AU/ml could be
obtained for sera with high levels of IgG.
NASBA SC RNA. A transcription vector was constructed to generate system control
(SC) RNA, which served as a positive control during isolation, amplification, anil detection
of RNA in the NASBA procedure. The vector was constructed essentially as described by
Morre et al. (18). Briefly, part of the pp67 region from strain AD169 (nucleotides 45920 to
96247) was cloned into the vector pG3O, downstream of a 77 RNA polymerase promoter
region. pG3O is a pGEM3 derivative (Promega, Madison, Wis.) lacking the I'stl and Sphl
sites in the multiple-cloning sequence. In addition, a new BamHI site was introduced alter
the BamHI site in the multiple-cloning sequence was removed. A I'stl site downstream ol
position 96073 and an Sphl site upstream of position 96094 were generated by PCR for the
insertion of an additional DNA sequence. This 134-bp fragment, with 5' Pstl and 3' Sphl
ends, comprised nucleotides 1015 to 1146 from the 5' noncoding region of the HIV-1 pv22
sequence (19). This resulted in a plasmid from which the 20-bp wild-type 1ICMV sequence
was deleted and replaced by the 134-bp HIV-1 pv22 fragment. This plasmid was linearized
with BamHI, and in vitro RNA was generated by using T7 RNA polymerase (25). The RNA
was treated with DNase I to remove plasmid DNA and purified on an anionic-exchange
column (Qiagen, Leusden, The Netherlands). The recovered in vitro-generated SC RNA
was quantified spectrophotometrically and stored at -70"C.
Nucleic acid isolation for NASBA. For analysis, 1 ml of the lysed-whole-blood
suspension, which equals 100 pi of whole-blood input sample, was used. Twenty
microliters of SC RNA containing 3,000 copies of pp67 SC RNA in 1.0 mM Tris buffer, pi I
8.5, was added. Nucleic acid isolation was performed essentially as described by Boom et
al. (2). Briefly, lysates were incubated with 50 pi of activated silica (0.4 g of suspension in
0.1 N HC1 per ml). Subsequently, the silica particles carrying adsorbed nucleic acids were
washed twice with 1 ml of wash buffer (5.25 M guanidium thiocyanate, 50 mM Tris |pl I
6.4]), twice with 1 ml of 70% ethanol, and once with 1 ml of acetone. Finally, after the silica
was dried at 56°C for 10 min, the nucleic acids were eluted in 50 pi of 1.0 mM Tris buffer,
pH 8.5, and stored at -20°C.
Qualitative NASBA. The primers CMVpp67-1.2 and CMVpp67-2.4 were designed to
amplify part of the mRNA encoding pp67 (Table 1). NASBA reactions were carried out as
described by Kievits et al. (10), with minor modifications. Reactions were performed with
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T/4BLE 1. SrtjweMC« 0/ N/4SB/4 primers ami probes us«/, rt"s;«ec<izv/i/,
/or amp////caf ION and <fcfi'c//on 0/ pp67 WT a/irf SC
Function Sequence
CMVppA7-l.2 T7 primer 5 -AATTCrAATACCACrCACTATAGGGAGAGGGTCGATTCAGACrGA-3'
C"MVpph7-2.4 Primer 2 5-CrGCACATATATGTTGACCA-3'
CMVpp67CAPI Captun- probe for WT 5'<iGATTCGGACmCCGTTCGA-3'
and« KNAs
CMVpp67FX:i.1 ECI, probe for WT RNA 5 •CCAAAAAGCrAGCCGTCACG-3'
SI Lt LI ECI. probe for SC RNA 5-GAAAAAAGCACAGCAAGCACCAGG-3'
a 20-ul reaction mixture containing 40 mM Tris (pH 8.5; Sigma, St. Louis, Mo.); 12 mM
MgC'l2 (Sigma); 70 mM KC1 (Baker, Concord, Ontario, Canada); 15% (vol/vol) dimethyl
sulfoxide (Sigma); 5 mM dithiothreitol (Sigma); 1 mM each deoxynucleoside triphosphate
(I'harmacia, Uppsala, Sweden); 2 mM ATP, CTP, and UTP; 1.5 mM GTP (Pharmacia); 0.5
mM ITP (Boehringer, Mannheim, Germany); 2 ug of bovine serum albumin (Boehringer);
0.08 U of KNase H (Pharmacia); 32 U of T7 RNA polymerase (I'harmacia); 6.4 U of avian
myi'loblnstosis RT (Seikagaku, Ijamsville, Md.); 0.2 uM each primer; and 5 ul of the isolated
nucleic acids. The NASBA reaction mixtures were incubated for 5 min ,it f>5 C. beton- the
enzymes were added, to allow destabilization of secondary RNA structures and
subsequently cooled down for 5 min to 41 °C to allow primer annealing. After the enzymes
were added, reactions mixtures were incubated at 41°C for 90 min and subsequently stored
at -2()"C.
ECL-based detection. A twofold dilution of the amplification products was made in
detection diluent (1.0 mM Tris ipH 8.5], 0.2 g of 2-methylisothiazolone HC1 per liter).
Subsequently, 5 ul of the diluted amplification products (wild type |WT] and SC) was
incubated for 30 min at 41C with 0.084 uM pp67 mRNA-specific biotine probe
(CMVppb7CAPl) (Table 1) bound to 5 ug of streptavidin-coated magnetic beads (mean
diameter ± standard deviation, 2.8 ± 0.2 urn; Dynal, Great Neck, N.Y.) and 3 x 10"
molecules of an electriKhemiluminescence (ECL) complex (tris[2,2-bipyridinelruthenium
|ll|)-labeled oligonucleotide probe, specific for either pp67 WT RNA (CMVpp67ECLl) or
SC" RNA (SC-l-CLl), in a total volume of 25 pi of 5x SSC (Ix SSC is 0.15 M NaCl plus 0.015
M sodium citrate). As negative controls, detection diluent was also incubated with the
different boad-oligonucleotide and ECL complex-probe mixtures for WT and SC RNA
detection. During incubation, tubes were agitated every 10 min to keep the beads in
suspension. Subsequently, 300 ul of assay buffer solution (100 mM tripropylamine, pH 7.5)
was added and the tubes were placet! in an ECL detection instrument (N ASBA QR system,
model 2000; Organon Teknika B.V., Boxtel, The Netherlands). In order to check the
instrument and to be able to compare ECL signals from different runs, a tube with reference
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solution containing 66.67 ug of streptavidin-coated magnetic beads per ml in assay buffer
solution was included. ECL signals for WT and SC RNA were adjusted with the values
obtained for the reference solution [(ECL signal for reference solution/40 x H>*) \ ECL
signal for WT or SC RNA] and for background signals (i.e., negative controls). ECL signals
higher than 6(X1 (1.5% of 41) x 1(V) were considered positive.
Statistical analysis. Statistical analysis was carried out by the Wilcoxon matched-pair
signed-rank test. P values of <0.05 were considered significant.
RESULTS
Incidence of HCMV infection and disease. A group of 42 patients was monitored for
the occurrence of HCMV infection and HCMV disease after renal transplantation.
Seropositive patients receiving a kidney from a seropositive donor showed the highest
incidence of HCMV infection (85% 111 of 13 patients!). For patients of the P+ and R-
serogroup and those of the D- and R+ serogroup, the incidence of HCMV infection was
75% (6 of 8 patients) and 69% (9 of 13 patients), respectively. HCMV was not detected by
any of the assays in blood samples from patients from the D- and R- serogroup. For four
patients, HCMV disease was diagnosed according to the criteria of Metselaar (15), namely,
fever for at least three consecutive days, leukocytopenia, thrombocytopenia, liver
abnormalities, and organ involvement, and was confirmed by concomitant positive cell
culture and/or antigenemia assay results. Three of these patients belonged to the D+ and
R- serogroup (38% |3 of 8 patients]), while one belonged to the D+ and R+ serogroup (8%
[1 of 13 patients]). All patients with HCMV disease underwent antiviral therapy with
ganciclovir. Two additional patients received ganciclovir when HCMV infection was
detected during treatment for rejection.
Detection of HCMV infection. HCMV infection could be classified as primary or
secondary, depending on whether the patient was seronegative or seropositive before
transplantation, respectively. In each patient with a primary infection (H = 6), HCMV was
detected by cell culture, the antigenemia assay, and NASBA. In 20 patients, a secondary
infection was detected. Forty percent of these infections were detected by cell culture,
whereas 35% were detected by NASBA. The antigenemia assay appeared to be the least-
sensitive assay (15%).
A total of 489 blood specimens was collected from the 42 patients. In one sample,
NASBA repeatedly failed to amplify both WT RNA and the added SC RNA. This result was
considered invalid. Antigenemia assay results could be compared to NASBA results for 173
samples. In this study, we found 56% of the positive antigenemia results to be positive also
by NASBA (Table 2). Of 141 antigenemia assay-negative samples, 134 were NASBA
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7VIBLE 2.
Test
pp67 N/4SB.4 resu/fc compw
Result
irai ro flMfi^enCTwifl i
No. of test
samples'"
No.
nd c«/ CM/I
(7,) of test
ted result
Positive
fare resw/fs
samples
by pp67
with indica-
NASBA
Negative
Antigenemia assay Positive 32 18(56) 14(44)
Negative 141 7(5) 134(95)
No result 315 11(4) 304 (%)
Cell culture * Positive 36 16(44) 20(56)
Negative 422 19(5) 403(95)
No a-sult 30 1 (3) 29 (97)
d DF.AI-T and C'PK results were combined.
f> The total number of test samples was 4HH (I sample was invalid for NASBA).
negative (95%). Cell culture and NASBA results could be compared for 458 of the 489
samples. Of 36 positive cell culture results, 44'/, were found to be positive by NASBA. There
was 96'/. agreement of negative cell culture results with negative NASBA results.
Table 3 shows sensitivities, specificities, and positive and negative predictive values
(ITV and NPV) of NASBA, the antigenemia assay, and cell culture for HCMV infection (see
Materials and Methods for (he criteria used to diagnose HCMV infection). The sensitivity
values of NASBA (5O';<) and cell culture (54'/<) are comparable, while the sensitivity value
of NASBA proved to be higher than that of the antigenemia assay: 50'7< versus 357c
Comparable results were obtained for the NPV. Specificity and PPV of cell culture for
HCMV infection were 94 and 93%, respectively, whereas for NASBA and the antigenemia
assay they were as high as l(K)'/{.
Time of detection of HCMV infection. In this study, 26 of the 42 patients (62'/<)
developed signs of 11CMV infection. The onset of HCMV infection was detected by NASBA
at a median of 36 days after transplantation (range, 21 to 75 days). For the antigenemia
assay and cell culture, detection occurred at 35 days (range, 28 to 69 days) and 65 days
(range, 27 to 103 days), respectively. Results of NASBA and the antigenemia assay were
Test
pp67 NASBA
Coll culture
Antigenomi.i «iss.iv
f/V !>ii/ii('s for /»!(• ii
iv// (»//wr«'. mil
'X Sensitivity
50
54
35
/ f/ic or
•;
» of HCMU oifirfio
lf/yi7l«*WII(l (ISSlll/ "
Specificity
100
94
HX)
» . P
'JPPV
100
93
100
<* NPV
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ii See Materials and Methods for the criteria used to diagnose HCMV infection.
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found to be positive for HCMV infection simultaneously in four cases, while results of the
antigenemia assay indicated positivity earlier than those of NASBA in three cases.
However, this difference appeared not to be statistically significant (P = 0.ID. Results of
NASBA were found to be positive before those of cell culture were found to be positive in
seven cases, while results of cell culture went' earlier in throe cases. This difference also
appeared not to be significant (P = Ü.11). In five cases, results of the antigenemia «tss.iv were
found to be positive before positive cell culture results could be reported to the clinic.
Although this appears to be significant (P = 0.04), the numbers art low.
Figure 1 shows representative examples of NASBA results, compared to antigenomia
assay, cell culture, and serology results. Patient 1 (D+ and R+) was treated twice for rejection
with methylprednisolone from days 18 to 22 and days 30 to 33. The onset ot HCMV
infection was first detected at day 36 by the antigenemia assay, followed by NASBA at day
39. The first cell culture-positive result (CPE) could be reported to the clinic at day 76
(specimen was obtained at day 41). Serology confirmed the onset of a secondary infection,
with a rise in IgM levels from day 33. No significant rise in IgC levels was detected because
assay results were as high as the detection limit of 250 AU/ml during the tested period
(results not shown). HCMV disease was not diagnosed, and the patient did not receive
antiviral therapy with ganciclovir. By NASBA, pp67 mRNA was detected up to day 64,
while positive antigenemia assay and cell culture specimens were obtained up to day 71.
Patient II (D+ and R-) was also treated twice for rejection with methylprednisolon from
days 9 to 13 and days 33 to 35. The onset of HCMV infection was detected by the
antigenemia assay and NASBA at day 29. A cell culture-positive specimen was also
obtained at day 29, although this result was not known before day 5ft. Serology results
indicated the onset of a primary infection, with seroconversion of IgM and IgG at days 33
and 40, respectively. HCMV was detected during the period that the patient was treated for
rejection. In addition, the patient had fever at day 37, indicative of HCMV infection.
Therefore, antiviral therapy with ganciclovir was started at day 37 and maintained until
day 50, although HCMV disease was not diagnosed for this patient. During that period, the
samples became antigenemia assay, cell culture, and NASBA negative.
DISCUSSION
In this study, we evaluated the diagnostic value of monitoring late pp>67 mRNA
expression by NASBA as a marker for HCMV infection. The expression of HCMV late
mRNA, such as pp67 (UL65), in circulating blood leukocytes is considered to directly reflect
HCMV replication and dissemination in the infected host and should cease upon effective
blockage of viral polymerase by antiviral agents, such as ganciclovir (14). The mRNA
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encoding the viral structural protein pp67 is one of the most abundant late transcripts (5).
It was suggested that pp67 may have important functions in the replication cycle of 1 1CMV,
such as protein kinase activity, DNA binding, and possible transeriptional activity of
immediate-early genes (4). In contrast to what occurs in RT-l>CR, the unspliced pph7
mRNA can be specifically amplified by NASBA in a background of DNA (3).
We evaluated the sensitivity of pp67 NASBA by testing blood specimens collected limn
42 patients after renal-allograft transplantation. HCMV infection is defined in Materials
and Methods. According to this definition, the combined results for cell culture (CPE and
DEAFF), the antigenemia assay, and serology are considered the gold standard for the
calculation of the sensitivity, specificity, and ITV and NPV of the NASBA assay. For 2ft
patients (62%) HCMV infection was diagnosed according to these criteria, and 4 of these
patients (15%) developed HCMV disease.
Table 2 shows that 44% of antigenemia assay-positive samples were NASBA negative. It
should be noted, however, that for all these samples, only weakly positive antigenemia
assay results had been obtained (1 to 3 positive cells/15 x 10"' leukocytes). Furthermore, for
all patients in whom HCMV infection was detected by the antigenemia assay, the results of
NASBA were also found to be positive. Importantly, for four patients, HCMV infection was
detected by NASBA but not by the antigenemia assay, which resulted in a higher sensitivity
value for the NASBA assay than for the antigenemia assay (50 versus 35%). The sensitivity
values of cell culture and the NASBA assay for HCMV infection were comparable (54 and
50%, respectively), although 56% of cell culture-positive samples were NASBA negative
(Table 2). However, cell cultures were maintained for a minimum of 21 days before being
reported as CPE negative, or for 2 days in case of DEAFF, while the NASBA assay can be
performed in 1 day. In addition, there appears to be no significant difference between the
moment at which positive cell culture results can be reported to the clinic and the moment
at which HCMV infection is detected by NASBA. Furthermore, results of NASBA and the
antigenemia assay were also found positive simultaneously. It should be noted, however,
that the results of the statistical analysis in this study are based on low numbers.
pp67 NASBA was also evaluated as a prognostic marker of HCMV disease in thoracic
organ transplant recipients (20). A PPV of 100% was found for HCMV disease. Also,
NASBA-positive results occurred in 84% of cases before a clinically significant number of
antigenemia assay-positive results occurred (>10 positive cells/2 x 10^ leukocytes). In our
study, only four patients developed HCMV disease. HCMV infection in these patients was
detected by all assays.
Six patients received ganciclovir to treat HCMV infection. Figure 1 shows the data for
one of these patients (patient II). Ganciclovir therapy was started at day 37, while the
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patient was being treated for rejection and had fever suggesting HCMV infection,
confirmed by concomitant positive antigenemia assay results (the first cell culture-positive
result was not known before day 56). Results of NASBA were found to be positive
simultaneously with those of the antigenemia assay, which demonstrates that pp67 NASBA
results can be conclusive enough for the clinician to initiate antiviral therapy. Antiviral
therapy was sustained for 2 weeks. During that period, leukocytes became pp65 antigen
negative. Comparatively, pp67 mRNA expression was no longer detected. Thus, reduction
of vir.il activity can also be monitored by pp67 NASBA, which was expected, because
ganciclovir inhibits replication by acting on the viral DNA polymerase (14) while late
mRNAs, including pp67 mRNA, are transcribed only after replication of the viral genome.
Patient I was not treated with ganciclovir. However, negative cell culture and antigenemia
assay results after d.iy 71 indicated reduction of viral activity. Again, NASBA results were
comparable to cell culture and antigenemia assay results.
Meyer-König et al. (16) and Bitsch et al. (1) used RT-PCR to detect immediate-early and
late pplSO mRNAs in the pheripheral blood leukocytes of renal-allograft recipients. Bitsch
et al. found immediate-early mRNA to be present in almost every patient with HCMV
infection. Lite pplSO mRNA was detected only in leukocytes from a patient with HCMV
disease who showed very high numbers of pp65-antigen-positive cells. Meyer-König et al.
also found the presence of HCMV mRNA to correlate positively with the number of pp65-
antigen-positive cells. However, their RT-PCR assay was not superior to the pp65
antigenemia test for diagnosis and monitoring of HCMV disease.
The NASBA assay otters some practical advantages compared to other tests. For
example, 100 ul of whole blood is sufficient to perform one NASBA assay. The blood sample
does not need to be processed before uptake in the NASBA lysis buffer. In addition, it is
possible to store whole-blood samples in NASBA lysis buffer at -70°C until they are needed
for further processing tor nucleic acid isolation. For the antigenemia assay, leukocytes have
to be isolated from the whole-blood sample within a few hours after it is taken from the
patient. The pp67 NASBA assay will be commercially available as a ready-to-use kit, named
the NucliSens CMV pp67 assay kit (Organon Teknika B.V.) and will contain all primer and
enzyme mixes needed. One person can perform the NASBA assay for 20 blood samples in
1 day, using the kit and the ECL detection instrument. In the near future it will also be
possible to use an automated extraction instrument for isolation of nucleic acids from blood
samples, with which more blood samples can be handled in 1 day.
From our study it can be concluded that NASBA of late pp67 mRNA is more sensitive
than the antigenemia assay for the detection of HCMV infection in renal-allograft
recipients. Both the antigenemia assay and pptv NASBA are very specific and highly
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predictive of the onset of HCMV infection. Furthermore, pp67 NASBA can be used to
monitor progression of HCMV infections and the effect of antiviral therapy, with results
comparable to those of the antigenemia assay. Alternatively, detection and monitoring of
immediate-early or early antigen mRNA expression by NASBA may pa>vide an additional
protocol for early identification of infection. Such studies ,m> in progress.
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EARLY DETECTION OF HCMV INFECTION
ABSTRACT
/. The early detection of human cytomegalovirus infection after organ
transplantation is a prerequisite for effective antiviral therapy. We evaluated the
diagnostic value of monitoring the viral immediate-early (It) 1 mRNA expression in
blood leukocytes by nucleic acid sequence-based amplification (NASBA).
M(>f/io</s. Nucleic acids were isolated from 489 blood samples collected from 42
kidney transplant recipients and subjected to amplification by IE NASBA. The IE
NASBA results were compared to those from pp67 NASBA, pp65 antigenemia, cell
culture (DEAFF and CPE), and serology.
Rcsu/fs. IE NASBA proved to be the most sensitive assay which detected the onset of
both primary and secondary cytomegalovirus infection significantly earlier than the
other assays.
COMC/USIOMS. The early detection of cytomegalovirus infection with IENASBA would
enable the start of effective antiviral therapy at an early state of infection to prevent
cytomegalovirus disease in patients at risk.
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INTRODUCTION
In immunocompromised individuals such as neonates, and AIDS and transplantation
patients, cytomegalovirus (CMV) infection can cause severe symptoms and even lead to
death. Early detection of the onset of CMV infection after organ transplantation is a
prerequisite for effective antiviral therapy to prevent CMV disease. Cell culture, pp65
antigenemia and serology are commonly used as diagnostic tools. In a previous study, we
investigated the diagnostic value of nucleic acid sequence-based amplification (NASBA)
for the detection of CMV. By this technique the viral pp67 late mRNA expression in blood
leukocytes of kidney transplant recipients was monitored (1). We found pp67 NASBA to be
more sensitive than the pp65 antigenemia assay (50% vs. 35%). However, both assays were
very specific (100%) and detected the onset of infection simultaneously. The goal of this
study was to investigate whether monitoring the expression of immediate-early (IE) 1
mUNA by NASBA, has additional value as a marker for CMV infection in kidney
transplant recipients. The IHI protein plays an essential role in the initiation of the viral lytic
replication cycle (6). The mRNA encoding this protein is synthesized during the very early
stages of viral lytic gene expression.
MATERIALS AND METHODS
A total of 60 patients received a kidney allograft during the period January 1995 to July
1996, at the Department of Internal Medicine, University Hospital Maastricht. For a group
(if 42 patients, a minimum of four blood specimens was collected during the first 3 months
after transplantation. These patients were included in this study and were also used in the
previous study for the evaluation of the pp67 NASBA assay (1). Twenty-six patients were
seropositive before transplantation. Half of these patients received a kidney from a
seropositive donor and the other half received a kidney from a seronegative donor. Eight
patients were seronegative before transplantation, whereas the kidney originated from a
seropositive donor. For eight other patients, both donor and recipient were seronegative.
Maintenance immunosuppression consisted of treatment with cyclosporine or tacrolimus
together with low-dose prednisolone.
CMV infection was defined by at least two positive results for one or more of the
following items: cell culture, antigenemia, seroconversion of anti-CMV IgM, and/or a
significant rise (at least four times) of anti-CMV IgG levels compared to the pre-
transplantation titer. CMV infections in patients who were either seronegative or
seropositive before transplantation were designated as primary or secondary infections,
respectively. CMV disease was defined according to the criteria of Metselaar et al. (4): fever
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for at least 3 consecutive days, leukocytopenia. thrombocytopenia, liver abnormalities and
organ involvement, confirmed by concomitant positive cell culture and/or antigenemia
results.
If a patient showed signs of CMV disease, ganciclovir was given i.V. for at least 2 weeks
until two subsequent blood samples were negative for the antigenemia assay. The
perioperative protocol did not include routinely prophylactic anti-CMV therapy. 1 lowever,
patients with a primary infection (D+, R-) also received ganciclovir during rejection
therapy with antithymocyte globulin, even in the absence of clinical signs of CMV disease.
In addition, all patients with positive antigenemia assay adults during rejection also
received ganciclovir.
Heparinized whole blood and serum specimens were collected wecklv from the patients
during hospitalization. After discharge, specimens were collected either monthly or more
frequently, if the patient showed clinical symptoms of CMV infection. Specimens were
screened prospectively for the presence of CMV by routine cell cultua- and the ppf>5-
antigenemia assay. In addition, 1 ml of heparinized blood was added to 9 ml of NASHA
lysis buffer (4.7 M guanidinium thiocyanate; 46 mM Tris, pH 6.4; 20 mM hi>l A; 1.2'i w/v
Triton X-100) and stored at -70'C. A total of 489 blood specimens was collected from the
patients.
Cell culture (DEAFF and CPE), pp65 antigenemia, serology [anti-HCMV IgG and IgM
(Abbott Laboratories, Abbott Park, ID] and the pp67 NASBA assay were performed as
described previously (1). The IE NASBA procedure was carried out essentially as described
for the pp67 NASBA assay. Briefly, the assay was performed on a 1-ml aliquot of lysed
blood suspension (100 ul of whole blood added to 900 ul of NASBA lysis buffer). Nucleic
acids were isolated using the method described by Boom et al. (2). System control (SC)
RNA was added to the sample prior to isolation and subsequently served as a positive
control for isolation, amplification and detection. The SC RNA comprised part of the IH1
mRNA corresponding to the positions 171,797 to 172,050 of the HCMV (AD169) genome
(3). SC RNA could be distinguished from WT RNA by insertion of a fragment of 134
nucleotides between nucleotides 172,028 and 172,050. This fragment originates from the 5'
noncoding region of the human immunodeficiency virus-type 1 pv22 sequence (5). IE WT
and SC mRNA were amplified using a T7 promoter containing primer and a reverse primer.
Amplification products were detected by electrochemiluminescense, using capture probes
coupled to magnetic beads and WT and SC specific tris-[2,2-bipyridine]-ruthenium[ll|
complex-labeled oligonucleotide probes.
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RESULTS AND DISCUSSION
Early detection of CMV enables the clinician to take adequate measures to prevent CMV
disease. Figure 1 shows for each individual patient with CMV infection (see definition
described above) at which time-point after transplantation, CMV was detected for the first
time. This demonstrates that in each serogroup, IE NASBA detected CMV (median: 26 days
.»Her transplantation; range 11-^ 5 days) before the antigenemia (median: 35; range 28-69),
pp67 NASBA (median: 36; range 21-75) or cell culture assay (median: 65; range 27-103) was
also found positive. In meist cases, cell culture results were obtained several weeks after IE-,
pp67 NASBA and antigenemia were found positive for the first time, except in four patients
with a primary infection (patients 12,14, 16 and 17) and one with a secondary infection
(patient 5).
Table 1 shows the incidence of active CMV infection per serogroup. In addition, the
sensitivity and specificity for active CMV infection of cell culture, antigenemia assay, IE-
and ppf>7 NASBA an' indicated. CMV was not detected in the group of seronegative
patients who received a kidney (mm a seronegative donor (D-, R-). CMV infections were
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0%
-
Diagnostic
PP65
genemia
18%
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-
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most frequent (85%) in the serogroup in which both donor and recipient were seropositive
(D+, R+). The sensitivity value of IE NASBA for these infections was KM)'/, in contrast to
737c and 55% for cell culture and pp67 NASBA, respectively. The sensitivity of the
antigenemia assay was as low as 18%. For two patients (2 and 11), CMV infection was
detected by IE NASBA, whereas pp67 NASBA, antigenemia and cell culture assay results
were negative. However, in these two patients a significant rise of anti-CMV IgC titers and
seroconversion of anti-CMV IgM indicated CMV infection (results not shown). This
demonstrates that the IE NASBA positive results were specific. This can also be seen for the
detection of reactivating CMV by IE NASBA in the group of seropositive patients who
received a kidney from a seronegative donor (D-, R+). CMV infection occurred in 9 of the
13 patients (69%). The IE NASBA assay detected 78% of the CMV infections in this patient
group. Again serology confirmed CMV infection, whereas the antigenemia and pp67
NASBA assays were negative, except for patient 21. For two other patients of the same
serogroup, IE mRNA was detected in several subsequent samples, whereas all other assays
remained negative, including serology. For IE NASBA, this results in a specificity of 50% for
the detection of infections caused by reactivating endogenous virus, since the assays that
are considered as the gold standard (see definition of CMV infection) were negative.
One of the 20 patients with a secondary infection developed CMV disease. In contrast,
three of the six patients with a primary CMV infection suffered from CMV disease. Although
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the primary infections were detected by all CMV detection assays used in this study, IE
NASBA alwavs detected the onset of CMV infection first.
Figure 2 shows typical results for patients from two of the four patient groups. Patient 1
was seropositive before transplantation, whereas the kidney donor was seronegative. These
results are an example of CMV infection caused by reactivation of endogenous virus. It is
likely that the IE NASBA positive results for the subsequent samples from day 20 to 77,
represent true iwictivation of the virus, because anti-CMV IgG and IgM levels increased
during this period. The other patient (II) suffered from a primary infection that resulted in
the appearance of clinical symptoms of CMV disease at day 25. The onset of CMV infection
in this patient was first detected by IE NASBA at day 18, followed by pp67 NASBA at day
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26 and the antigenemia assay at day 28. The first cell culture positive sample WM taken
from the patient at day 26. However, this result was not known in the clinic before day 2&
because it took 2 days betöre the DEAFF procedure could be performed. Ganciclovir was
administered to the patient from day 27 to 47. During antiviral therapy all assays became
negative. Interestingly, IE NASBA results became positive again for patient II after the
therapy had stopped, at days 60 and S8. These results pmbably reflect residual viral activity
that was not cleared by the antiviral therapy but was controlled by improved immune
reactivity, reflected by an increase in antibody titers, preventing lytic virus replication.
The IE NASBA assay proved to be a highly sensitive method for the detection of both
primary and secondary CMV infections after kidney transplantation. IF. NASBA indicated
CMV infection significantly earlier than the other assays. This would enable the start of
effective antiviral therapy at an early state of infection for the prevention of CMV disease
in patients at risk, i.e. patients with a primary CMV infection and patients under rejection
therapy. Further research needs to be done to evaluate the diagnostic value of IE NASBA
for other organ transplant patients, such as bone marrow or liver transplant patients, in
which CMV infection often causes disease.
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CMV DETECTION IN LIVER TRANSPLANT PATIENTS BY NASBA
ABSTRACT
Nucleic acid sequence-based amplification (NASBA) was used for detection of the
human cytomegaiovirus (CMV) immediate early-1 (IE) and the late ppb7 mRNA in 353
blood samples collected from 34 liver transplant patients. The diagnostic value of these
assays was compared to that of the pp65 antigenemia assay. Overall, 95 and 42% of the
antigenemia-positive samples were IE NASBA and pp67 NASBA positive, respectively.
Although the results from pp67 NASBA and the antigenemia assay appeared to
correspond poorly, a clear correlation was seen between ppb7 NASBA-negative results
and low numbers of pp65 antigen-positive cells. Twenty patients (59'i) were treated
with ganciclovir after the diagnosis of symptomatic CMV infection. Before initiation of
the antiviral therapy, the antigenemia assay detected the onset of symptomatic infection
in all patients, whereas 95 and 60*>i of these patients were IE NASBA and ppfc7 NASBA
positive, respectively. Although the sensitivity of IE NASBA was very high, the positive
predictive value (PPV) of this assay for the onset of a symptomatic infection was only
63%. The PPV of the antigenemia assay as well as pp67 NASBA was considerably higher
(80 and 86%, respectively). Thus, the detection of IE mRNA using NASBA appears to be
particularly useful as a marker for early initiation of antiviral therapy in patients at high
risk for the development of a symptomatic infection. Also, IE NASBA was found to be
more sensitive than the antigenemia assay for monitoring CMV infection during
antiviral therapy. On the contrary, pp67 NASBA did not appear to have additional
diagnostic value compared to the antigenemia assay.
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INTRODUCTION
Although the majority of the adult human population is seropositive for
cytomcgalovirus (CMV), symptomatic infections are mostly restricted to
immunocompromised individuals, such as transplant recipients. Early detection of the
virus is necessary to start effective antiviral treatment for the prevention of severe
complications and death. The diagnostic value of monitoring the expression of viral
immediate early (IE) and late (L) mRNAs in blood as markers for active CMV infection and
disease has previously been evaluated in several studies using reverse transcriptase PCR
(RT-PCR) (1, 7, 13, 17, 18, 21, 23, 24, 27, 29, 31, 38). However, controversial results were
obtained regarding the clinical significance of the detection of IE and L mRNAs, most
probably due to varying sensitivities of the different RT-PCR assays. Alternatively, nucleic
add sequence-based amplification (NASBA) has been developed for specific amplification
of RNA (19). This technique has recently been adapted for the detection of CMV (2, 4, 5, 15)
as well as other microorganisms (8). In previous studies we evaluated the diagnostic value
of monitoring the expression of the CMV IE-1 and pp67 mRNA in peripheral blood of
kidney transplant patients using NASBA (4, 5). The IE-1 mRNA is expressed directfy after
entrance of the virus into the cell (34), whereas pp67 mRNA is expressed in the late phase
of the replication cycle in vitro (9, 10).
In this study, we present an evaluation of the diagnostic value of IE NASBA and pp67
NASBA for monitoring CMV infection in liver transplant patients. These patients are at
higher risk for symptomatic CMV infection than kidney transplant patients (28). Liver
transplant patients are usually in a critical clinical condition at the moment of
transplantation and frequently require antirejection treatment. As a consequence, these
patients are highly susceptible to infections with opportunistic pathogens, such as CMV. It
is therefore essential to have a sensitive diagnostic assay that can predict the onset of
symptomatic CMV infections at an early stage, such that antiviral therapy can be initiated
in a timely fashion.
MATERIALS AND METHODS
Patients. The patient population consisted of 26 adult patients who received a liver
allograft at the Helsinki University Hospital in the period from December 1996 to
November 1997 and another 10 adult patients who received transplants during the period
September to December 1998. The number of blood samples collected after transplantation
was used as a selection criterion. Patients from which a minimum of five blood samples
were obtained were included in this studv (» = 34).
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As basic immunosuppression, the patients received triple-drug therapv with various
combinations of steroids, azathiopnne, and oral cyclosporine or tacn>linuis. Acute
rejections were treated with a high dt>se of methylprednisolone, and steroid-ivsistant
rejections were treated with OKT3. Diagnosis of rejection was based on histologic.il
findings at biopsy (11). The patients were grouped according to the CMV scmstatus
(positive | + | or negative |-|) of the transplant donor (D) and recipient (R), which resulted in
the following serogroups: D+ R+ (H = 19), D+ R- (N = 4), D- R+ (»/ = 8), and l> K (»i 2).
There was one additional patient who was seropositive at the moment of transplantation,
while the serostatus of the donor was unknown. Thus, 82% (28 of 34) of the liver transplant
recipients were seropositive at the moment of transplantation.
Antiviral therapy. Symptomatic CMV infections were treated with ganciclovir
(intravenously, 5 mg/kg of body weight twice daily) for at least 2 weeks I lu> diagnosis of
symptomatic CMV infection was based on positive ppftS antigenemi.i .)ss,n usiilis ,\nd
clinical signs of CMV infection, mostly fever which could not be explained otherwise.
Symptomatic CMV infection was also diagnosed in case of pneumonia with a CMV-
positive finding from a bronchoalveolar lavage (BAD. Five patients with a relapse ol CMV
infection after former antiviral therapy were again treated with intravenous ganciclovir.
Furthermore, for five patients the antiviral therapy was switched to orally administered
ganciclovir, allowing the patients to be treated at home. In general, the patients received no
antiviral prophylaxis. However, eight patients received ganciclovir intravenously during
antirejection therapy in order to prevent CMV reactivation due to increased
immunosuppression.
Blood samples. A total of 353 whole-blood samples were prospectively collected from
34 liver transplant recipients, including samples which were obtained shortly before the
operation. Additional blood samples were collected at least once a week during
hospitalization directly after transplantation and on all occasions when viral infection was
suspected. Otherwise, blood samples were obtained monthly, or more frequently if the
patients were again hospitalized.
pp65 antigenemia. The CMV pp65 antigenemia assay was performed as described
previously (36, 37). Briefly, cytospot preparations were made with 1.5 x IIP dextran-isolated
leukocytes per spot. The cells were subsequently fixed with a mixture of formaldehyde and
NP-40. The pp65 antigen was stained by an indirect immunoperoxidase protocol using the
antibodies clO and ell (Biotest Pharma, Frankfurt, Germany). The results were expressed
as the number of positive cells per 50 x 10"* leukocytes.
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Shell vial culture. A modification of the rapid shell vial culture (16) was performed on
BAL specimens as described previously (22). The BAL samples were collected from the
patients when CMV pneumonia was suspected.
Serology. Patient sera were subjected to both the IMx CMV and AxSym CMV assays
(Abbott laboratories. North Chicago, HI.) in order to detect CMV-specific immunoglobulin M
(IgM) and IgC antibodies, respectively. The IgM titers were expressed as index values. Index
values 2<).5(X) were considered positive. IgG titers were expressed as numbers of antibody
units (AU) per milliliter. Sera with IgG levels of >15 AU/ml were considered positive. The
detection limit of 250 AU/ml could be obtained for sera with high levels of IgG.
NASBA. The isolation of nucleic acids from blood samples and the NASBA procedure for
amplification of the CMV IF and ppf>7 mRNA were carried out as described previously (4, 5).
Briefly, nucleic acids were isolated according to the method of Boom et al. (6). First, 1(X) ml of
whole FDTA-treated blood was added to 9(K) ml of NASBA lysis buffer, containing guanidine
thiocyanate (C)rganon Teknika B.V., Boxtel, The Netherlands). The nucleic acids were
subsequently bound to silica and washed with ethanol and acetone to remove residual cell
debris. The nucleic acids were eluted from the silica after drying and used as input in the NASBA
reaction. This isothermal amplification reaction (41 °C, 91) min) depends on the concerted action
of three enzymes: 17 KNA polymerase, avian myeloblastosis virus reverse transcriptase, and
RNase H. Different primer sets were used for the amplification of either IE mRNA (T7 primer,
5'-AATTCTAATACGACTCACTATAGGGAGACTTAATACAAGCCATCCACA-3'; primer
2, 5'-TAGATAAGGTTCATGAGCCT-3') or the pp67 mRNA (T7 primer, 5'-
A A T T C T A A T A C C ; A C T C A C T A T A G G G A G A G G G T C G A T T C A G A C T G A - 3 ' ; primer 2,
5'-CTGGAGATATATGTTGACCA-3'). The amplification products were detected using
specific ruthenium-labeled probes and electrochemiluminescence. The assays included an
internal control RNA, which served as a positive control for the isolation, amplification, and
detection procedures.
Statistical analysis. The Student t test was used for statistical analysis of the correlation
between NASBA results and the number of pp65 antigen-positive cells. The Wilcoxon
matched-pair signed-rank test was used to compare the assays with respect to detection of
CMV in time. P values of £0.05 were considered significant.
RESULTS
Interassay correlations. A total of 353 blood samples was prospectively collected from
34 liver transplant patients. The presence of CMV in these blood samples was routinely
tested using the antigenemia assay. Part of the blood sample was stored at -70°C in NASBA
lysis buffer (Organon Teknika B.V.). Retrospectively, we used NASBA for the detection of
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IE mRNA and pp67 mRNA in these samples. The antigenemia and NASBA results were
subsequently compared for each individual blood sample. Overall, the pp65 antigen was
detected in 74 samples (21%). IE mRNA and pp67 mRNA were detected in 175 and 42
samples (50 and 12%), respectively. It was found that 70 (95%) of the antigenemia-positive
samples were also IE NASBA positive. However, 105 (38%) of the IE NASBA-positive
samples were antigenemia negative. Only 31 (42%-) of the antigenemia-positive samples
were also pp67 NASBA positive. On the other hand, 11 (26%) of the pp67 NASBA-positive
samples were antigenemia negative. Negative pp67 NASBA results strongly correlated
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with low numbers of pp65 antigen-positive cells. This is demonstrated in Fig. 1 by the fact
that only 23% (11 of 47) of the samples with 1 to 10 pp65 antigen-positive cells per 50 x 1CP
leukocytes were pp67 NASBA positive. Of the samples with 11 to 50 pp65 antigen-positive
cells, 69% (11 of 16) were pp67 NASBA positive. A value of 82% (9 of 11) was found for the
group of samples with >50 ppf>5 antigen-positive cells. In contrast, 94% of the samples with
1 to 10 or 11 to 50 pp65 antigen-positive cells, was also IE NASBA positive (44 of 47 and 15
of 16, respectively). All samples with >50 pp65 antigen-positive cells (« = 11) were IE
NASBA positive. Together, the mean number of pp65 antigen-positive cells in samples that
were IH NASBA positive and pp67 NASBA negative (H = 135) was four. This was
significantly higher for samples that were both IE and pp67 NASBA positive (« = 40) (mean,
36 positive cells; P < O.(XX)l).
Assay results for ganciclovtr-treated infections. Of the 34 liver transplant patients, 20
(59%) developed a symptomatic CMV infection during the follow-up (four primary
infections and 16 reactivations). The patients with symptomatic infection were treated with
ganciclovir. Five of these patients were given ganciclovir more than once to treat a relapse
of CMV infection. In the evaluation of the NASBA and antigenemia results we focused on
the detection of CMV in the period prior to the first antiviral treatment. In 17 of the
symptomatic patients, the first antiviral treatment was initiated on the basis of positive
antigenemia results together with clinical signs of CMV infection. For the other three
patients, antiviral therapy was initiated after the diagnosis of pneumonia, with
concomitant detection of CMV in a BAL sample by the shell vial assay. CMV was also
present in the blood of these patients as determined by the antigenemia assay. Thus, all
symptomatic infections were detected by the antigenemia assay. However, the positive
predictive value (PPV) of antigenemia was 80% (20 of 25), indicating that 5 of 25
antigenemia-positive patients remained asymptomatic. IE NASBA- and pp67 NASBA-
positive results were obtained for 19 (95%) and 12 (60%) of the ganciclovir-treated patients
before initiation of the first antiviral therapy The PPV of IE NASBA was only 63% (19 of
30), whereas the PPV of pp67 NASBA was 869; (12 of 14). However, IE NASBA detected the
onset of CMV infection significantly earlier than both pp67 NASBA and the antigenemia
assay (P < 0.001). No significant difference was found between the latter assays with respect
to the detection of CMV in time (P > 0.05).
Monitoring of CMV during antiviral therapy. Blood samples were collected from
patients to monitor the CMV infection during antiviral therapy. In total, 37 samples were
obtained from 13 different patients (Fig. 2) during the first antiviral treatment after
transplantation. This first treatment was maintained for a minimum of 2 weeks. As shown
in Fig. 2, then» is a clear correlation between IE NASBA- and antigenemia-positive samples
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during the first week. Furthermore, 8 of the 12 samples that were both IE NASBA and
antigenemia positive were also pp67 NASBA positive. The number of antigenemia-positive
cells was much higher in these samples than in samples that were only IE NASBA- and
antigenemia-positive. In the second week, the number of samples that were antigenemia,
IE NASBA, or pp67 NASBA positive decreased. In the third week, only one sample was
pp67 NASBA positive, whereas in the fourth week only IE mRNA was detected in two
samples. After more than 4 weeks of treatment, two samples were either IE NASBA positive
or antigenemia positive. One sample was positive for both IE NASBA and the antigenemia
assay. The antigenemia-positive samples were obtained from patients that were treated
orally with ganciclovir. IE mRNA could be detected at a median of 10.5 days after the start
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of antiviral therapy (range, 0 to 63 days), whereas pp67 mRNA and pp65 antigen were
detected at a median of 9 and 3.5 days (range, 0 to 17 and 0 to 63 days), respectively.
Compared to the antigenemia assay, IE NASBA detected the presence of CMV significantly
longer (P < 0.05), whereas no significant difference was found between IE NASBA and pp67
NASBA. Furthermore, there also appeared to be no significant difference between pp67
NASBA and the antigenemia assay.
Patient examples. Figure 3 shows representative examples of assay results obtained for
three different liver transplant patients. Patient I suffered from a primary infection that was
first detected at day 20 by IE NASBA. The pp65 antigen was detected in the subsequent
sample at day 27. The pp67 NASBA test was not positive until day 38. At day 42,
symptomatic CMV infection was diagnosed and treatment with ganciclovir was initiated.
Ganciclovir was given intravenously until day 51. Subsequently, the treatment was
continued by oral administration until day 110, in order to prevent a recurrent CMV
inlection. However, during this period, positive results were again obtained for both IE
NASBA and the antigenemia assay, although only few cells (two to five) were pp65 antigen
positive. After antiviral therapy, IE mKN A was still detected in several samples, whereas all
other assays remained negative. In the early period after transplantation, i.e., from day 27
to day 57, CMV infection was indicated by a significant rise of IgG and seroconversion of
lgM. Patient 1 is an example of one of the four patients with a primary infection. However,
the majority of the CMV infections were reactivations. In fact, 82% of the 34 patients were
seropositive at the moment of transplantation. The results shown for patient II demonstrate
the results for a patient with reactivating CMV. Both donor and recipient were CMV
seropositive at the moment of transplantation. IE NASBA was the first assay to become
positive, at day 15, followed at day 29 by both the antigenemia assay and pp67 NASBA.
Then, antiviral therapy with ganciclovir was initiated and maintained for a standard pericxl
of approximately 14 days. Antiviral therapy was again initiated after the finding of an
nntigenemia-positive sample at day 75. However, at this time point, no blood samples were
taken that wen.' suitable tor performing NASBA assays. The antiviral treatment was
continued until day 106. At day 178, the antigenemia assay was found positive, albeit at a
low level. Because the patient showed no clinical symptoms of CMV infection, antiviral
therapy was not initiated. The overall serological results showed a significant rise of IgG
and seroconversion of lgM. Reactivation of CMV was also seen in patient III. Initially, the
patient received ganciclovir prophylaxis from day 9 to 22 in order to prevent symptomatic
CMV infection during antirejection therapy. Retrospectively, both IE mRNA and pp67
mRNA could be detected during that period, whereas the antigenemia assay became
positive at day 26. At days 48 and 50, an increase in the number of pp65 antigen-positive
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cells was found together with the onset of symptoms of CMV infection, which urged the
start of antiviral therapy at day 50. The pp67 NASBA test was also positive at day 50,
whereas IF. NASBA was positive in every subsequent sample until day 100. At day 123, the
patient developed recurrent CMV infection with positive antigenemia results.
Consequently, the patient was again treated with ganciclovir. NASBA results are not
available for this time point. The IgG titers soon reached the detection limit of the assay (250
AU/ml), and remained high in all subsequent samples. The fluctuation of the IgM titers
corresponded well with the course of infection, as indicated by the NASBA and
antigenemia results.
DISCUSSION
Severe symptomatic infection after organ transplantation can be prevented by an early
start of antiviral therapy with ganciclovir. The adverse effects of ganciclovir (33) and the
chance of development of drug-resistant virus strains (1, 20) do not favor prolonged
prophylactic use of this antiviral drug in every transplant recipient. Therefore, unnecessary
prophylaxis in patients who are not at risk for symptomatic CMV infection should be
avoided. Alternatively, preemptive therapy seems to be an effective approach to prevent
the onset of a symptomatic infection (32, 33). This approach strongly depends on the
availability of an assay which is sensitive enough to detect CMV infections before the actual
onset of symptoms. Moreover, the assay should have a high predictive value for the onset
of ,i symptomatic infection.
In this study, wo investigated the diagnostic value of monitoring the expression of the
CMV IE-1 and pp67 mRNA in whole-blood samples from liver transplant patients using
NASBA. The results of these NASBA assays were compared to the results of the pp65
antigenemia assay. This assay is widely used for detection of CMV infections in
imnumocomproniised patients. In general, the antigenemia assay is a sensitive assay.
However, for solid-organ transplant recipients, positive antigenemia results do not always
correlate with symptomatic infection (33). In this study, the initiation of antiviral therapy in
liver transplant patients was guided by both positive antigenemia results and clinical signs
of symptomatic CMV infection. In order to investigate the relevance of IE mRNA and pp67
mRNA detection as possible markers for early preemptive therapy, the evaluation of the
NASBA results was focused on the period prior to initiation of the first antiviral treatment
with ganciclovir.
Fifty-nine percent of the liver transplant patients received antiviral therapy with
ganciclovir to treat symptomatic CMV infection. IE NASBA detected the onset of
symptomatic CMV infection in all but one of these patients. Moreover, IE NASBA was
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positive significantly earlier than pp67 NASBA and the antigenemia assay. However, the
PPV for symptomatic infection of IE NASBA was only <vV'{. Similar findings were reported
for kidney transplant recipients (4). As suggested for those patients, early detection ot I'MV
with IE NASBA would be particularly useful for patients at high risk for a symptomatic
CMV infection, e.g., patients with a primary infection or undergoing antirejection
treatment. In these patients, the early detection of IE mRNA is likely to bo i onvl.n<\) with
the onset of a symptomatic infection and could possibly serve as an earlv marker lor
initiation of antiviral therapy. However, the majority of the studied population ot liver
transplant patients was CMV seropositive at the moment of transplantation. Therefore,
most CMV infections were reactivations rather than primary infections. In addition, some
of the seropositive patients were already IK NASBA positive at the moment of
transplantation. This is probably due to the critical condition ot most liver transplant
patients, which may be accompanied by a degree of immunosuppression that allows I'MV
to reactivate at an early phase. Furthermore, IE mRNA could be detected in some patients
after a period of antiviral treatment, although there was no relapse ol .1 symptomatic
infection (Fig. 3). Thus, the detection of IF. mRNA does not necessarily predul the onset of
a symptomatic infection. In contrast, it was recently reported that IE NASBA could serve as
a new parameter for preemptive therapy in allogeneic bone marrow transplant recipients
(14). These transplant patients are usually considered a distinct group, because mortality
rates due to CMV infections in this group are higher than in other transplant patients (39,
40). Graft-versus-host disease and severe impairment in the development of specific
antiviral immunity are important risk factors for development of symptomatic CMV
infection in these patients (25, 26). Instant initiation of antiviral therapy upon the first
detection of CMV after tranplantation is mandatory to prevent life-threatening disease.
Therefore, early detection of the presence of CMV by monitoring the expression of IE
mRNA is particularly relevant for allogeneic bone marrow transplant recipients. For kidney
and liver transplant recipients, however, IE NASBA results are not sufficient for evaluation
of the risk for the onset of a symptomatic infection, in particular for patients with a
reactivation.
In this study, it was found that 58% (43 of 74) of the antigenemia-positive samples were
pp67 NASBA negative. As a possible explanation for these discrepancies, we hypothesized
that samples that were collected during antiviral treatment with ganciclovir are more likely
to be positive by the antigenemia assay than by pp67 NASBA. Ganciclovir exerts its anti-
viral activity by inhibition of the viral DNA polymerase (35). This should result in a block
of the synthesis of viral late transcripts, such as the pp67 mRNA. Because, the pp65 protein
may be more stable than the pp67 mRNA, it may still be present in the blood at time points
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at which the pp67 mRNA has already been degraded. In addition, it is possible that pp65
protein is still synthesized during ganciclovir treatment. Unlike the pp67 mRNA, the pp65
mKNA is not a true late transcript (12). Its transcription is therefore not directly affected by
inhibitors of viral DNA synthesis. However, of the 43 samples that were antigenemia
positive and pp67 NASBA negative, only 7 were obtained during a period of antiviral
treatment with ganciclovir. In fact, for eight patients these discrepancies were found before
initiation of antiviral therapy. As a consequence, the sensitivity of pp67 NASBA for the
detection of a symptomatic CMV infection was low (60%). Nevertheless, for six of these
patients, the number of pp65 antigen-positive cells was low, ranging from 2 to 30. The other
two patients became pp67 NASBA positive several days after the start of antiviral
treatment.
Tin* low sensitivity of pp67 NASBA found in this study is in contrast with the previous
findings reported for kidney transplant recipients (5). In these patients, pp67 mRNA could
be detected in all patients with a symptomatic infection. A high sensitivity of pp67 NASBA
was also reported by Gerna et al. for heart and lung transplant recipients with a reactivated
CMV infection (lf>). A cutoff level of >100 ppfc5 antigen-positive cells/2 x HP leukocytes
was used for the initiation of preemptive antiviral therapy in these patients. The pp67
mRNA could be detected in all patients who were treated according to these criteria. In this
study, we also found a positive correlation between the number of pp65 antigen-positive
cells and the positivity of pp67 NASBA (Fig. 1). However, we did not use a cutoff level for
the antigenemia assay. Instead, an antigenemia-positive sample together with clinical
symptoms of CMV infection was an indication for the start of antiviral treatment of the
liver transplant patients. The discrepancy between the different studies with respect to the
sensitivity of pp67 NASBA is probably explained by the difference in timing of the start of
antiviral therapy with ganciclovir. As explained above, ganciclovir should inhibit the
synthesis of late mRNA. As a consequence, early onset of antiviral therapy could prevent
the detection ot ppt>7 mRNA. In fact, in studies in which patients were preemptively
treated with ganciclovir, based on the first antigenemia-positive samples after
transplantation, the sensitivity of pp67 NASBA for the detection of symptomatic CMV
infection was found to be lower than the sensitivity of the antigenemia assay (14, 15, 30). It
is difficult to investigate this hypothesis because delayed initiation of antiviral therapy
based on ppf>7 NASBA-positive results in these patients may increase the risk for the
development of symptomatic infection to an unacceptable level. Nevertheless, detection of
pp67 mRNA appears to have no additional diagnostic value compared to the antigenemia
assay as a marker for the early start of preemptive therapy in patients at high risk for the
onset of symptomatic CMV infection.
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In previous studies, no significant difference was found between the disappearance of
CMV from the blood during antiviral therapy as determined by pp<»7 NASHA and the
antigenemia assay (5, 14, 15). A similar result was found in this study. However, il should
be noted that for several patients the pp67 NASBA assay was negative before and during
antiviral therapy, whereas the antigenemia assay was found to be positive. In agreement
with the results described above, the pp67 NASBA-negative results obtained during
antiviral therapy corresponded with low levels of pph5 antigen-positive colls. lor 11:
NASBA, a clear correlation was found with the results of the antigenemia assay, in
particular during the first week of antiviral therapy. Thereafter, IE mRNA could still be
detected, whereas the antigenemia assay was negative. In addition, it was found that IE
mRNA could be detected after termination of therapy (Fig. 3). Similar findings were
reported for individual allogeneic bone marrow transplant recipients (14). Nevertheless, tor
most of these patients, the times to disappearance of CMV during antiviral therapy, as
demonstrated by IE NASBA, pp67 NASBA, and the antigenemia assay, were comparable.
It should be investigated in more detail whether prolonged IT mRNA detection has clinical
implications. As such, this could justify prolonged antiviral treatment with gam iilovir.
In conclusion, the detection of IE mRNA appears to be particularly useful as a marker
for early initiation of preemptive antiviral therapy in patients at high risk for the
development of a symptomatic infection. In contrast to IE NASBA, pp67 NASBA did not
appear to have additional diagnostic value compared to the antigenemia assay.
ACKNOWLEDGMENTS
We thank Bieke Vanherle, Martine Hulsbosch, Annick Hermans, and Magdalena Garcia
for their help with the NASBA tests and serological assays and Raisa Loginov, Kristina
Messina, and Kaarina Inkinen for performing the pp65 antigenemia assays and collecting
the samples for NASBA and serology. Finally, we thank Organon Teknika B.V. for providing
the NASBA reagents.
87
CHAPTER 4
REFERENCES
1. Alain, S., P. Honderlick, D. Crenel, M. Stern, C. Vadam, M. J. Sanson Le Pors, and M. C.
Mazernn. 1997. Failure of ganciclovir treatment associated with selection of a ganciclovir-
resislant cytomegalovirus strain in a lung transplant recipient. Transplantation 63:1533-1536.
2. Aono, T., K. Kondo, H. Miyoshi, K. Tanaka Taya, M. Kondo, Y. Osugi, J. Hara, S. Okada, and
K. Yamanishi. 1998. Monitoring of human cytomegalovirus infections in pediatric bone marrow
transpl.int recipients by nucleic acid sequence-based amplification. J. Infect. Dis. 178:1244-1249.
3. Bitsch, A., H. Kirchner, R. Dupke, and G. Bein. 1993. Cytomegalovirus transcripts in peripheral
blood leukocytes of actively infected transplant patients detected by reverse transcription-
polymerase chain rx'action. J. Infect. Dis. 167:740-743.
4. Blok, M. J., M. H. Christiaans, V. J. Coossens, J. P. van Hooff, P. Sillekens, j . M. Middeldorp,
and C. A. Bruggcman. 1999. Harly detection of human cytomegalovirus infection after kidney
transplantation by nucleic acid sequence-based amplification. Transplantation 67:1274-1277.
5. Blok, M. J., V. J. Goossens, S. J. V. Vanherle, B. Top, N. Tacken, J. M. Middeldorp, M. H. L.
Chrisli.ians, |. P. van Hooff, and C. A. Bruggeman. 1998. Diagnostic value of monitoring human
cytomegalovirus late pp67 mKNA expression in renal-allograft recipients by nucleic acid
sequence-based amplification. J. Clin. Microbiol. 36:1341-1346.
6. Boom, K., ( . ). A. Sol, M. M. M. Salimans, C. L. Jansen, P. M. E. Wertheim-van Dillen, and J.
van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin.
Microbiol. 28:495-503.
7. Buffone, G. J., E. Hine, and G. J. Demmler. 1990. Detection of mRNA from the immediate early
gene ol human cytomegalovirus in infected cells by in vitro amplification. Mol. Cell. Probes
4:143-151.
8. Chan, A. B., and J. D. Fox. 1999. NASBA and other transcription-based amplification methods
for research and diagnostic microbiology. Rev. Med. Microbiol. 10(4):185-196.
9. Davis, M. G., and E.-S. Huang. 1985. Nucleotide sequence of a human cytomegalovirus DNA
fragment encoding a 67-kilodalton phosphorylated viral protein. J. Virol. 56:7-11.
10. Davis, M. G., E.-C. Mar, Y.-M. Wu, and E.-S. Huang. 1984. Mapping and expression of a human
cytomegalovirus major viral protein. J. Virol. 52:129-135.
11. Demetris, J. A., K. P. Batts, A. P. Dhillon, L. Ferrell, J. Fung, S. A. Geller, J. Hart, P. Havry, W.
J. Hofman, S. Hubscher, J. Kemnitz, G. Koukoulis, R. G. Lee, K. J. Lewin, J. Ludwig, R. S.
Markin, L. M. Petrovic, M. |. Phillips, B. Portmann, J. Rakela, P. Randhawa, F. P. Reinholt, M.
Reynes, M. J. Robert, H. Schlitt, K. Solez, D. Snover, E. Taskinen, S. N. Thung, G. W. Tillery,
R. H. Wiesner, D. G. D. Wight, W. Williams, and H. Yamabe. 1997. Banff schema for grading
liver allogratt rejection: an international consensus document. Hepatology 25:658-663.
12. Depto, A. S., and R. M. Stenberg. 1989. Regulated expression of the human cytomegalovirus
pp65 gene: octamer sequence in the promoter is required for activation by viral gene products. J.
Virol. 63:1232-1238.
13. Gaeta, A., C. Nazzari, S. Angeletti, M. Lazzarini, E. Mazzei, and C. Mancini. 1997. Monitoring
for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and
late mRNA in peripheral blood leukocytes. |. Med. Virol. 53:189-195.
88
CMV DETECTION IN LIVER TRANSPLANT PATIENTS BY NASBA
14 Cfmi, C... F. Baldanti, D. Lilien, M. Pare«. E. Alessandrino, A. Pagani. F. Located!, f.
Middeldorp, and M. G. Revello. 2000. Human cvtomegalovirus immedi.tte-e.ulv mRNA
detection by nucleic acid sequence-based amplitication as a new parameter tor preemptive
therapy in N w numtw transplant recipients. |. Clin Microbiol .W:IS4^ 185.V
15. Gerna, G., F. Baldanli, ). M. Middeldorp, M. Furione, M. Zavattoni, Ü. Lilleri, and M. G.
Revello. 1*W. Clinical significance of expression ol human cytomegalovirus ppft7 late transcript
in heart, lung, and bone marrow trans-plant recipient* as determined by nucleic acid aei|iience-
based amplification. J. Clin. Micn>biol. 37:902-911.
16. Cleaves. C. A., T. F. Smith, E. A. Shusler, and G. R. Pearson. 1984. Rapid detection of
cytomegalovirus in MRC-5 cells inoculateil with urine specimens by using low-speed
centrifugation and monoclonal antibody to an early antigen | Clin. Microbiol. 19:**I7-»*W.
17 Gozlan, J., J. P. Laporte, S. Lesage. M. Labopin, A. Najman, N. C. Gorin. and J. C. Petit. l«*%.
Monitoring of cytomegalovirus infection and disease in bone marrow rvvipients by reverse
transcription-lVR and comparison with IVR and blood and urine cultua-s. ). Clin. Murobiol.
34:2085-2088.
18. Gozlan, ).,). M. Salord, C. Chouaid, C. Duvivier, O. Picard, M. C. Meyoha», and |. C. Petit.
1993. human cytomegalovirus (HCMV) late-mKNA detection in peripheral Hood ol AIDS
patients: diagnostic value for HCMV disease compared with tints»- of viral culture and I ICMV
DNA detection. J. Clin. Microbiol. 31:1943-1945.
19. Kievits, T., B. van Gemen, D. van Strijp, R. Schukkink, M. Dircks, H. Adriaanse, L. Malek, R.
Sooknanan, and P. Lens. 1991. NASBA isothermal enzymatic in vitro nucleic acid amplification
optimized for the diagnosis of HIV-1 infection. J. Virol. Methods 35:273-286.
20. Kniger, R. M., W. D. Shannon, M. Q. Arens, j . P. Lynch, G. A. Storch, and E. P. Trulock. 1999.
The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.
Transplantation 68:1272-1279.
21. Lam, K. M., N. Oldenburg, M. A. Khan, V. Gaylore, G. W. Mikhail, P. D. Strouhal, J. M.
Middeldorp, N. Banner, and M. Yacoub. 1998. Significance of reverse transcription polymerase
chain reaction in the detection of human cytomegalovirus gene transcripts in thoracic organ
transplant recipients, j . Heart Lung Transplant 17:555-565.
22. Lautenschlager, I., j . Suni, J. Ahonen, C. Gronhagen Riska, P. Ruutu, T. Ruutu, and P.
Tukiainen. 1989. Detection of cytomegalovirus by the early-antigen immunofluorescence test
versus conventional tissue culture. Eur. J. Clin. Microbiol. Infect. Dis. 8:610-613.
23. Meyer, T., U. Reischl, H. Wolf, C. Schuller, and R. Arndt. 1994. Identification of active
cytomegalovirus infection by analysis of immediate-early, early and late transcripts in peripheral
blood cells of immunodeficient patients. Mol. Cell. Probes 8:261-271.
24. Meyer-König, U., A. Serr, D. von Laer, G. Kirste, C. Wolff, O. Haller, D. Neumann Haefelin,
and F. T. Hufert. 1995. Human cytomegalovirus immediate early and late transcripts in
peripheral blood leukocytes: diagnostic value in renal transplant recipients. J. Infect. Dis.
171:705-709.
25. Meyers, J. D., N. Flournoy, and E. D. Thomas. 1986. Risk factors for cytomegalovirus infection
after human marrow transplantation. J. Infect. Dis. 153:478-488.
89
CHAPTER 4
26. Muller, C. A., H. Hebart, A. Roos, H. Roos, M. Steidle, and H. Einsele. 1995. Correlation of
interstitial pneumonia with human cytomegalovirus-induced lung infection and graft-versus-
host disease after bone marrow transplantation. Med. Microbiol. Immunol. Berl. 184:115-121.
27. Nelson, P. N., B. K. Rawal, Y. S. Boriskin, K. E. Mathers, R. L. Powles, H. M. Steel, Y. S.
Tryhorn, P. D. Butcher, and J. C. Booth. 1996. A polymerase chain reaction to detect a spliced late
transcript of human cytomegalovirus in the blood of bone marrow transplant recipients. J. Virol.
Methods 56:119-14«.
28. Patel, R., and C. V. Paya. 1997. Infections in solid-organ transplant recipients. Clin. Microbiol.
Rev. 10:86-124.
29. Paid, R., T. F. Smith, M. Espy, D. Portela, R. H. Wiesner, R. A. Krom, and C. V. Paya. 1995. A
prospective comparison of molecular diagnostic techniques for the early detection of
cytomegalovirus in liver transplant recipients. J. Infect. Dis. 171:1010-1014.
30. Pellegrin, I., I. Garrigue, D. Kkouevi, L. Couzi, P. Merville, P. Merel, G. Chene, M. H. Schrive,
P. Trimuulct, M. L. Lafon, and H. Fleury. 2(XX). New molecular assays to predict occurrence of
cytomegnlovirus disease in renal transplant recipients. J. Infect. Dis. 182:36-42.
31. Randhawa, P. S., R. Manez, B. Frye, and G. D. Ehrlich. 1994. Circulating immediate-early
mKNA in patients with cytomegalovirus infections after solid organ transplantation. J. Infect.
Dis. 170:12h4-l 267.
32. Rubin, R. H. 1991. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med.
324:1057-1059.
33. Sia, I. G., and R. Patel. 2000. New strategies for prevention and therapy of cytomegalovirus
infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13:83-121.
34. Stenberg, R. M., D. R. Thomsen, and M. F. Stinski. 1984. Structural analysis of the major
immediate early gene of human cytomegalovirus. J. Virol. 49:190-199.
35. Swierkosz, E. M., and R. L. Hodinka. 1999. Antiviral agents and susceptibility tests, p.
Ih24-1639. In I' R. Murray, K. J. Baron, M. A. I'faller, F. C. Tenover, and R. H. Yolken (ed.), Manual
of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
36. The, T. H., A. P. van den Berg, M. C. Harmsen, W. Van der Bij, and W. J. van Son. 1995. The
cytomegalovirus antigenemia assay: a plea for standardization. Scand. J. Infect. Dis.
99(Suppl.):25-29.
37. Van der Bij, W., J. Schirm, R. Torensma, W. J. van Son, A. M. Tegzess, and T. H. The. 1988.
Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J. Clin.
Microbiol. 26:2531-2535.
38. Velzing, J., P. H. Rothbarth, A. C. Kroes, and W. G. Quint. 1994. Detection of cytomegalovirus
mKNA and DNA encoding the immediate early gene in peripheral blood leukocytes from
immunocompromised patients. |. Med. Virol. 42:164-169.
39. Wingard, J. R., S. Piantadosi, W. H. Burns, M. L. Zahurak, G. W. Santos, and R. Saral. 1990.
Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive
therapy. Rev. Infect. Dis. l2(Suppl. 7):S793-804.
40. Winston, D. J., W. G. Ho, and R. E. Champlin. 199(1. Cytomegalovirus infections after allogeneic
Nine marrow transplantation. Rev. Infect. Dis. 12 (Suppl. 7):S776-792.
90
~ CHAPTER 5 ~
Immediate Early-1 mRNA Expression and
Virus Production are Restricted During the
Acute Phase of Rat Cytomogalovirus
Infection in Immunocompetont Rats
MARINUS |. BLOK, KIM G. M. SAVELKOULS, GERT E. L. M.
GRAULS, CATHRIEN A. BRUGGEMAN AND CORNEL1S VINK
DiywrfH/i'H/ o/Mi'rf/cfl/ M/cro/'io/o^i/, Cnn/iornst-H/flr Rt'scnrr/» /;/s//7///f
rs/7i/, 6202 /4Z
A modified version of this chapter is submitted to Virology
91
CHAPTER 5
RCMV INFECTION OF IMMl MX OMl'HTENT RATS
ABSTRACT
We characterized the dissemination of rat cytomegalovirus (RCMV) after primary
infection of immunocompetent rats. The presence of infectious virus, viral DNA and
mRNA (immediate-early R123 |IE-1|, early R44 and late R32 transcripts) in different
organs was determined at defined time-points post infection (pi). During the Unit week
pi, RCMV DNA could be detected in virtually every organ. In addition, late and/or early
mRNA was found in several organs and tissues, such as salivary glands, spleen, liver,
lungs, heart, brain, bone marrow and blood leukocytes. However, infectious virus and
IE-1 mRNA were rarely detected. Together, these results indicated that the replicition of
RCMV in immunocompetent rats is severely restricted compared to that in
immunocompromised rats during the first week pi. At 4 months pi, infectious virus,
viral DNA and each of the three viral transcripts were detected in the salivary glands of
the majority of the rats. In the other organs, RCMV DNA was found ouasionallv, but
neither infectious virus nor any of the viral transcripts were detected in those organs.
Interestingly, we identified two novel antisense transcripts from the major II region that
are partly complementary to the IE-1 transcript. These antisense transcripts, IE-AS 1 and
IE-AS2, were detected in blood leukocytes in the absence of IE-1 mRNA expression.
However, IE-1 and IE-AS mRNA were found to be expressed simultaneously in the
salivary glands and in RCMV-infected fibroblasts in vitro. Although the function of the
RCMV IE-AS transcripts is still enigmatic, their expression adds yet another intriguing
feature to the compact and complex pattern of herpesviral gene expression.
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INTRODUCTION
Human cytomegalovirus (HCMV) is an important cause of morbidity and mortality in
immunocompromised patients, such as organ transplant recipients and individuals with
AIDS (.30, 47). In our laboratory, rat cytomegalovirus (RCMV) is being studied as a model
for HCMV. Like HCMV infections, RCMV infections of immunocompetent hosts are
usually not life-threatening even when a high dose of virus is used (10,11, 55). In contrast,
RCMV infection of immunocompromised rats results in severe complications and high
mortality rates (55). During the first week after primary infection of immunocompetent rats
with RCMV, infectious virus can be isolated from several organs, except the salivary glands
(11, 55). In general, infectious virus cannot be isolated from the salivary glands within 10
days post infection (pi), although RCMV DNA can be detected in these glands as early as 3
days pi (7). Up to 28 days pi, virus titers increase in the salivary glands, whereas infectious
virus cm no longer be detected in other organs. However, it is likely that RCMV is still
present in these organs in a latent form, since studies in which latently infected renal
allograftn were transplanted to seronegative rats indicated that virus could reactivate
although infectious virus could not be isolated from this organ (13, 15). Similar findings
were reported with cardiac allografts, although virus reactivated less frequently from these
allografts than from renal allografts (13). RCMV could also be isolated from latently
infected spleens by long-term cocultivation with rat embryonic fibroblasts (REF) (10). In
contrast, transfer of latent virus could not be accomplished by means of syngeneic or
allogeneic transfusion of peripheral blood leukocytes (PBL) or thoracic duct cells into
immunocompromised hosts (13).
In the majority of the previous studies on RCMV infections in vivo, rats were subjected
to immune suppression prior to virus administration. This allowed the virus to replicate
efficiently and induce a full-blown, severe infection (55). Nevertheless, natural CMV
infections generally occur in immunocompetent hosts, which usually do not suffer from
serious complications due to the infection. Despite the stringent control of the infection,
however, the virus is still able to establish a life-long, latent infection in these hosts.
In order to study the pathogenesis of RCMV infection, virus dissemination as well as
viral gene expression under 'natural' conditions in vivo, we set out to monitor the course
of RCMV infection of immunocompetent rats at various time points pi. To this end, organs
and tissues of rats were subjected to different (RT-) PCR assays, which allow the highly
sensitive detection of RCMV genomic DNA as well as transcripts. Previously, we
developed a nested IXTR that enables the reliable detection of approximately 10 copies of
viral DNA (b). Here, we describe the generation of three novel RT-PCR assays that monitor
the expression of genes that are transcribed during different phases of RCMV infection in
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vitro. These genes include R32, a late gene that encodes tho homolog of tho HCMV major
tegument protein (8, 61), R44, an early-late gene that encodes the homolog of the HCMV
DNA polymerase accessory protein (31, bl), and R123, an immediate early (110 gene
encoding the homolog of the HCMV major IE-1 protein (5). By using the IVR and RT-PCR
assays, we demonstrate that RCMV DNA is present in many organs during the acute phase
of infection in immunocompetont rats. Although early and late mRNA won' found in
several of these organs at 7 days pi, infectious virus was not detected at that tinu-point.
Interestingly, expression of IE-1 mRNA was only rarely observed. After 4 months,
infectious virus, viral DNA and mRN As were found to be present in the salivary glands. In
the other organs, RCMV DNA was occasionally detected, but not viral mRNA or infectious
virus. Finally, we describe the identification of two novel, antisense transcripts from the
RCMV major IE (MIE) region. These mRNAs could be detected m PBI. and salivary glands
at 7 days pi, in salivary glands at 120 days pi, and in vitro, in productively infected REF.
MATERIALS AND METHODS
Rats and virus. Three-week-old male specific-pathogen-free Wistar Kyoto rats (Central
Animal Facility, Maastricht University, Maastricht, the Netherlands) were infected with 1 x
10^ PFU of RCMV (Maastricht strain). In an initial experiment (experiment I), 30 rats were
infected of which 5 were sacrificed at either 3, 5, 7, 14, 31 or 120 days pi. Salivary glands,
spleen, kidney, liver, lungs, heart, thymus, pancreas, brain, aorta, left carotid artery, PliL,
blood plasma, and bone marrow were collected and stored immediately at -70°C until
nucleic acid isolation or plaque assay analysis. In this experiment, nucleic acid isolates of
the organs were analyzed for the presence of RCMV DNA using PCR (see below). The
plaque assay was performed as described previously (12). Virus titers were expressed as
PFU per ml of a 10% w/v organ suspension.
In a second experiment (experiment II), a group of 10 three-week-old rats were infected
with 1 x 10"' PFU of RCMV. Five rats were sacrificed at either 7 or 120 days pi, respectively,
and a similar set of organs and tissues as described above was collected from these animals.
From these organs, nucleic acids were isolated and analyzed for the presence of both
genomic RCMV DNA and mRNA using PCR and RT-PCR, respectively (see below). In
addition, plaque assay was performed for salivary glands, spleen and liver.
In vitro RCMV infection of REF cells. REF cells were grown in EMEM supplemented
with 10% NCS until confluency. The cells were subsequently incubated with RCMV at a
multiplicity of infection of 1 in EMEM supplemented with 2% NCS for 1 hour. Thereafter,
the medium was replaced with fresh EMEM supplemented with 2% NCS. After 48 hours,
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the cells were collected using a cell-scraper and centrifuged at 725 x g for 10 min at 4°C. A
total of 3 x 10*" cells was used for isolation of total nucleic acids.
Blood plasma preparation and isolation of PBL. EDTA-blood was collected from the
rats by puncture of the abdominal aorta. The blood samples were centrifuged at 1,250 x g
for 10 min at 4°C. Hundred ul of plasma was collected and stored at -70°C until nucleic acid
isolation. The layer of buffy coat cells was subsequently aspirated and transferred to a new
tube. Contaminating erythrocytes were lysed for 10 min at 4°C in a buffer containing 0.155
M Nl I4CI, 0.01 M KHCO3 and 0.1 mM EDTA. The leukocytes were centrifuged at 725 x g
for 10 min at 4"C and washed three times with PBS. After the final wash step, 0.5 x lO'' to
1.0 x lO^cells were stored at -70°C until nucleic acid isolation. In addition, 0.5 x 10^  to
1.0 x 10* cells were resuspended in 1 ml of EMEM supplemented with 2% NCS and kept at
-70 C until plaque titration.
Preparation of bone marrow samples. Bone marrow cells were extracted from both
femurs of a rat and subsequently washed three times with PBS. A total of 1.5 x 10^ cells was
resuspended in I ml EMEM supplemented with 2% NCS for plaque titration. In addition,
1 x 10'cells were UMAI lor isolation of nucleic acids.
Isolation of DNA and RNA. The XTKAX DNA isolation kit (Gull Laboratories, Salt Lake
City, Utah) was used for the isolation of total cellular DNA. Extractions were performed
according to the manufacturer with some technical modifications. Briefly, various tissue
samples (50 - 200 mg), bone marrow, blood cells and plasma were resuspended in 1 ml of
lysis buffer and lysed during rotation for at least 3 hours. A water sample was included
after every ninth organ sample to serve as a negative control for cross-contamination
during the isolation procedure. The samples were centrifuged at 20,000 x g for 1 min and
800 pi of the supernatant was transferred to a new reaction tube. Proteins were
subsequently denatured by heating the samples to 95°C for 5 min, followed by cooling at
room temperature. After another round of heating and cooling, the samples were
centrituged for 2 min at 20,000 x g. Five hundred ul of the supernatant was transferred to a
new reaction tube and an equal volume of isopropanol was added. The nucleic acids were
precipitated during 5 min at room temperature. After centrifugation at 20,000 x g for 2 min,
the pellet was washed with 70'! EtOH, air-dried and dissolved in 35 ul of H^O. The nucleic
acid concentration was determined by measuring the optical density (OD) at 260 nm in a
spectrophotometer.
In experiments in which the presence of both RCMV DNA and mRNA in tissue samples
or RCMV-infected REE cells was evaluated, the Wizard genomic DNA purification kit
(Promega. Leiden, the Netherlands) was used. The isolation was performed essentially as
prescribed by the manufacturers, with some modifications. Briefly, cells or small tissue
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samples (± 25 mg) were added to 300 ul of the Nuclei Lysis Solution containing M> ug of
proteinase K (Roche molecular diagnostics, Mannheim, (iermanv) and incubated at 5f»°C
for 1 to 2 hours until complete lysis. A water sample was included after every ninth tissue
sample to serve as a negative control for cross-contamination during the isolation
procedure. The subsequent RNase step in the standard protocol was omitted to allow the
isolation of both total cellular DNA and RN A. Instead, the samples wen," direct I v incubated
for 5 min at 4"C after 100 ul of the Protein IVecipitation Solution was added. I'he samples
were subsequently centrifuged at 20,000 x g for 20 min. The supernatant was transferred to
a new reaction tube which contained 1 volume of isopropanol and 1 ug of glycogen. After
incubation for 10 min at room temperature and subsequent centrifugation at 20,0(X) x g for
10 min, the pellet was washed with 7O'<! HtOH and air-dried for 30 min at nxtm
temperature. The pellet was dissolved in 50 ul of HiO by incubation tor I hour at o5"l'. The
total nucleic acid concentration was determined by measuring the OD at 260 nm. I'art of
this total nucleic acid preparation was used to perform a single-tube nested IVR reaction
for the detection of RCMV DNA. The remaining DNA and RNA was treated with 20 units
of DNase 1 (Amersham Pharmacia Biotech, Roosendaal, the Netherlands), in the presence
of 10 mM MgCl2, 1 mM DTT, 10 units of RNAguard (Amersham Pharmacia Biotech), and
10 mM Tris pH 7.5 in a total volume of 100 ul for 1 hour at 37°C. Thereafter, the DNasel was
inactivated at 70°C for 10 min. The RNA was directly precipitated by adding 1 volume of
isopropanol and incubation of the samples at -70°C for at least one hour. After
centrifugation at 20,000 x g for 10 min, the pellet was washed with 70% EtOH, air-dried at
room temperature for 30 min and dissolved in 50 pi of H2O. The RNA concentration was
determined by measuring the OD at 260 nm. For the majority of samples from the salivary
glands, it was found that RT-PCR was frequently inhibited. Therefore, isolation of RNA
from salivary gland tissues was repeated using an alternative method for the direct
isolation of total RNA by guanidine thiocyanate, essentially as described by Chomczynski
and Sacchi (20).
Plasmid constructs. The single-tube nested PCR reaction was optimized in vitro using a
plasmid that contains the target DNA sequence. This plasmid was also used to spike PCR
reactions in order monitor the presence of PCR inhibitors. The PCR control DNA was
constructed by cloning part of the RCMV genomic sequence (61), corresponding to position
172,719 to 173,428 (GenBank accession number AF232689), cloned into the Hindi site of
pLJC119. An additional EcoRI fragment of 129 bp, corresponding to position 215,968 to
216,096 of the RCMV genomic sequence, was cloned into the fccoRI site of the insert at
position 173,042. As a result of this insertion, the fragment generated by PCR from this
control plasmid is 123 bp larger than the PCR fragment that is generated from RCMV
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genomic DNA (369 bp versus 246 bp). These fragments can easily be distinguished by
agarose gel electrophoresis.
The control KNA that was used in the different RT-PCR assays was generated in vitro
from plasmids that contain a T7 RNA polymerase promoter directly upstream of the
inserted cDNA. The control KNA was used to optimize the different RT-IXTR reactions in
vitro and was also used as a spike to monitor the presence of RT-PCR inhibitors. The IE-1
and ß-actin proteins are encoded by spliced transcripts (5, 46). The cDNA of these
transcripts was obtained by the isolation of poly(A) mRNA from RCMV-infected REF cells,
using the Quickprep Micro mRNA purification kit (Amersham I'harmacia Biotech). First-
strand cDNA was subsequently generated by reverse transcription using an oligo-dT
primer (.YRACE-1; 5 ' -GTACGATTCGGACACCCTGCAG(T) ,T-3 ' ) and Superscript II RT, as
described by the manufacturer. For cloning part of the cDNA encoding IE-1, the primers
KC MVMIH-2a (5-ATGGAACTCAGCAACCCCAGG-3'; corresponding to the complement
of position 173,715 to 173,735 of the RCMV genomic sequence) and RCMVMIE-3b (5'-
GTTGTAGGACCTTAGCGATGATGTTC-3'; corresponding to position 172,719 to 172,744
of the KCMV genomic sequence) were used. The amplified cDNA fragment contained part
of exon 3 and 4 of the IF.-l mRNA (5). The PCR fragments were treated with T4 DNA
polymerase to generate blunt ends, 5'-phosphorylated using polynucleotide kinase and
cloned into the H/iicIl site of vector pBluescriptSK(+) (Stratagene, Heidelberg, Germany),
which was dephosphorylated before ligation. The cDN A for the ß-actin gene was generated
using primers RT-ACT-B (5'-CiGTCiGGTATGGGTCAGAAGG-3'; corresponding to position
1,462 to 1,481 of the DNA sequence with Genbank accession no. J00691) and RT-ACT-F (5'-
TGCCGATAGTGATGACCTGA-3'; corresponding to the complement of the DNA
sequence from position 2,529 to 2,548). The PCR fragments were treated with T4 DNA
polymerase, 5'-phosphorylated, and cloned into vector pGEM3z (Promega), which was
restricted with / coRl, treated with Klenow enzyme, and dephosphorylated before ligation.
This vector was also used for cloning of the R32 and R44 cDNA fragments. In contrast to
IE-1 and iS-actin, the mRNAs that are transcribed from these genes are not spliced (8, 31).
The cDNA of these genes was directly subcloned from genomic RCMV DNA. For the R44
gene, a Nurl-Nrol restriction fragment was cloned, corresponding to position 41,295 to
42,300 of the RCMV genomic sequence. The fragment was tre<»ed with Klenow before
ligation. For the R32 gene, a SM/WI-SIK I restriction fragment was cloned, corresponding to
position 25,458 to 26,011 of the RCMV genomic sequence. The fragment was treated with
T4 DNA polymerase to generate blunt ends before ligation. The DNA sequence of all inserts
was determined to check the orientation of the insert and to confirm the absence of
mutations.
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In vitro synthesis of RNA. T7 RNA polymeraso was used to synthesize RNA in vitro
from PCR fragments. These IXTR fragments were generated from pC.F.M3/ or pHluescript
plasnnids that contain IE-1, R44 or R32 cDNA. using the univers.il pUC/MI3 torw.ml and
reverse primers. The T7 RNA polymerase (Roche molecular diagnostics) was imiikUod
with 100 to 2(X) ng of purified PCR fragment for 2 hours at 37°C in a total volume ot 20 ul
using reaction conditions as described by the manufacturer. Thereafter, 10 units ot DNasel
(Amersham Pharmacia Biotech) were added to the reaction mixture, which was
subsequently incubated for another 30 min at 37'C. Alter addition ot 2 ul of 0.2 M FDTA
(pH 8.0), the RNA was precipitated by adding 2.5 pi of 4 M LiCI and 75 ul of prechilled
(-20°C) EtOH, and incubation at -70°C for at least 1 hour. The RNA was pelleted by
centrifugation at 20,000 x g, and subsequently washed with ice-cold 70'-i F.tOH. The pellet
was dissolved in 100 ul HiO and the concentration ot RNA was determined by measuring
the OD at 260 nm. The RNA was aliquoted in portions of 1 x 10" copies/ul and store«.! at
-70°C. For each new RT-IXJR run, an aliquot was thawed and used to make fresh dilutions.
PCR. For the detection of genomic RCMV DNA, we used a single-tube nested I'CR with
primers which are located within exon 4 of the lli-l gene, as described previously (f»),
except that the MgCh concentration was 2.0 mM in stead of 1.5 mM. This PCR results in
the amplification of a 246-bp DNA fragment. In experiment 1, 1 ug of the isolated nucleic
acids was added to the PCR reactions. However, for blood plasma, PBL, aorta and left
carotid artery the yield of isolated nucleic acids was relatively low. Therefore, it was not
always possible to include 1 ug of nucleic acids in the PCR reaction. To dilute potential PCR
inhibitors, reactions were also performed with 0.1 or 0.01 ug of nucleic acids. In experiment
II, PCR reactions were performed using an input of 1 or 0.1 pg. To determine the presence
of potential PCR inhibitors in this experiment, each of the reactions was performed in
duplicate, either in the presence or absence of 10 copies of the PCR control DNA. A PCR
result was considered as invalid if the PCR control DNA could not be detected. Again, the
yield of isolated nucleic acids from PBL, aorta, left carotid artery and, in particular, blood
plasma, was not always sufficient to include 1 ug of nucleic acids in the PCR reaction.
However, this occurred less frequently in experiment II than in experiment I. In both
experiments, the sensitivity of the single-tube nested PCR was monitored during every run
by testing dilutions of the PCR control DNA in water. Furthermore, PCR reactions with
water instead of nucleic acids were included as negative controls. After amplification, PCR
products were analyzed by agarose gel electrophoresis and ethidium bromide-staining.
RT-PCR. The synthesis of cDNA and its subsequent amplification by PCR was
performed in a single tube. Improved sensitivity for the detection of IE-1, R32 and R44
mRNA was obtained by performing an additional nested PCR. The reaction mixtures for
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RT-PCR were prepared on ice and contained 1 ug of total RNA isolate, 2 ug of brewer's
yeast tRNA (Roche molecular diagnostics), 0.2 mM dNTPs, 5 mM DTT, 0.2 uM of each
primer (for RCMV RT-PCR primers, see Table 1), 10 units of RNAguard (Amersham
Pharmacia Biotech), 1.25 units of HotstarTaq DNA polymerase (Qiagen, Leusden, the
Netherlands), 10 units of Superscript II RT (Gibco BRL Life technologies, Breda, the
Netherlands), and 1 x HotstarTaq reaction buffer, containing 1.5 mM MgCb (Qiagen). For
the detection of IE-1 mRNA by RT-PCR, the reaction was supplemented with 0.5 mM
MgC I2 (Qiagen). As a positive control, we also performed RT-PCR on cellular ß-actin
111RN A using the primers RT-ACT-13 and RT-ACT-F (see plasmid constructs section above).
KT-PCR using these primers results in the amplification of a fragment of 622 bp. Since the
primers flank an intron in the tf-actin gene, the RT-PCR prcxiuct is 464 bp smaller than the
PCR product that would be generated on genomic DNA (46).
The total KN A isolates were used as input for each RT-PCR. For each measurement three
control reactions were included. One of these reactions contained only the total RNA
isolate, and amplification was performed without RT. The other two reactions contained the
total RNA isolate, and were spiked with in vitro synthesized control RNA. The
amplification of these samples was also performed either with or without RT. The spiked
samples served to monitor the presence of potential PCR inhibitors. An RT-PCR result was
considered as invalid if the control RNA could not be detected. As a spike, 10 copies of both
IE-1 and R44 control RNA were used, whereas 50 and 5 x 10^ copies of R32 and ß-actin
control KNA were used, respectively. The reactions with and without RT were used to
demonstrate the specific amplification of mRNA instead of genomic DNA. Furthermore,
7/4BLE /. /'ri/m-rs used /or SI'HJJWufo- RT-PCR, /u//tmvd fry fliMir/oiw/ m-s/ed PCR.
Primer Sequence (S'-.T) Position in RCMV
genomic sequence •'
Function Size of
PCR product |bp]
RT-IEI-F2 CrCTCTGTGCGGCTTC
Rl -IE 1-B2 AACCCAGACCACCGAAC
IF. I -N RTF TTCTA ACCC ATCCAG A ACC A
IE1-NRTK (ICGAATCTCATCACCATTTC
R1-K44-FI GAGlTGGCCrGGTAGnGGA
RT-R-W-IU CCCGACT1X AACATGCACTT
R44 -NRT-H2 AACACCGAGGTCCACTTCAC
R44NRT-F2 CCKJAGGAAGnXTCGATGG
RT-R32-F.1 CG 1 AlX.AGCrrGAGGCGAT
RT-R3MW CVARIGCTCCGCTACTACGA
R32-NRT-H2 AACTrraXXXTACTTC
IO2-NRT-A2 rAGGTC.TGGACXnTATC
172.857 - 172,872 1*' strand cDNA synthesis
173.497-173,513^ 2"^ strand cDNA synthesis 559
173,447 - 173,4hh'' nested PCR lonvord primer
173,174 - 173.193 nested PCR reverse primer 195
41,391 - 41,410 P ' strand cDNA synthesis
41.SW-41,914'' 2"^ strand cDNA synthesis 523
41 .f>55 • 41 ,h74^ m>sti\1 PCR fonvan.1 primer
4I.4O2-41.481 nested It 'R reverse primer 212
25,5(15 - 25.523 I"' strand cDNA synthesis
25,98« • 2t\007'' 2^' strand cDNA synthesis 502
Z\87h - 25,892^ nested PCR forward primer
25,d55 - 25*71 nested PCR reverse primer 237
(i OonKink s»\]vience accession no. AF232r>89 (f>l).
<• Primer sequence is cv>mplenientar\ to RCMV genomic sequence.
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the sensitivity of the RT-PCR assay was monitorvd during every single run bv testing
dilutions of control RNA in a background of 2 ug of brewer's veast tRNA. Negative
contmis consisted of RT-PCR reactions on water instead of nucleic acids.
Total RNA was first incubated at 65°C for 5 min and subsequently cooled on ice for
5 min, before it was added to the RT-PCR reaction mixtures. The reaction tube* wen*
transferred from the ice to the thermal cycler once they had reached the appropriate
tempera tu a* for reverse transcription. The RT-1VR reactions wen» performed on .» I' I ( 2lX)
thermal cycler (MJ Research Inc., Watertown, Massachussets), which was progi.immcd to
perform an initial incubation step of 20 min at the temperatun» for reverse transcription
(Trt; see below), followed by 15 min at 95X, 40 cycles (for IE-1, R44 and R32 RT-PCR) or
50 cycles (for ß-actin RT-PCR) of 30 s at 95X, 30 s at melting temperature (Tm; siv M O W )
and 30 s at 72°C, concluded with 5 min at 72"C. For the detection of IF and ti-actm inRNA,
Trt was 55°C, and Tm was 58.5 or 65°C, respectively. For the detection of R32 and R44
mRNA, Trt was 50°C and Tm was 63"C or 60°C, respectively. For nested K'R, 5 pi of the
RT-I*CR reaction was transferred to a reaction mixture containing 0.2 uM of each of the
nested primers (seeTable 1), 0.1 mM dNTPs, 1 x HotstarTaq 1*CR buffer, containing 1.5 mM
MgCl2, and 1.25 units of HotstarTaq in a total volume of 50 ul. The PCR reaction was
performed by incubation for 15 min at 95°C, 35 cycli of 30 s at 94°C, 30 s at Tm, 30 s at 72°C,
and a final incubation step of 5 min at 72°C. The Tm for the nested amplification of cDNA
from IE-1, R32, and R44 mRNA was 60, 58 and 65°C, respectively. The PCR products were
analyzed by agarose gel electrophoresis and ethidium bromide-staining.
Rapid amplification of cDNA ends (RACE). The 5'RACE System Version 2.0 (Gibco
BRL Life technologies) was used for determination of the 5' ends of the antisense transcripts
as described previously (5). First, poly(A) mRNA was isolated from RCMV-infected REF
cells at 48 hours after infection, using the QuickPrep Micro mRNA Purification kit. First-
strand cDNA was generated using primer RT-IE1-B2 (for primer sequences see Fig. 9). After
tailing the cDNA with dCTP and terminal deoxynucleotidyl transferase, PCR was
performed using the "5'RACE Abridged Anchor Primer" (AAP, Gibco BRL Life
technologies) and the internal gene-specific primer IE1-NRT-F. A second, semi-nested PCR
was subsequently performed using the "Abridged Universal Amplification Primer"
(AUAP, Gibco BRL Life technologies) and the gene-specific primer 3F2.
To amplify the 3'end of the antisense transcripts, 3'RACE was performed using poly(A)
mRNA from RCMV-infected REF. The primer 3'RACE-RL-l was used to generate cDNA
using Superscript II RT under conditions as described by the manufacturer. A first round of
PCR was subsequently performed with primer 3'RACE-N1 and the gene-specific primer p-
lnt3IE. A second, nested PCR was performed with primer 3'RACE-N2 and the gene-specific
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primer p-Int3IEnes. PCR mixtures contained 0.4 uM of each primer, 0.1 mM of each dNTP,
1.25 units of HotstarTaq DNA polymerase, 1 x HotstarTaq polymerase buffer, and 5 pi of
cDNA or 100 x diluted first-round PCR product, in a total volume of 50 ul. Amplification
(15 min at 95X", 35 cycles of subsequently 1 min at 94°C, 1 min at 55'C, and 1 min at 72°C,
and a final incubation of 5 min at 72°C) was performed in a PTC-200 thermal cycler. The
resulting RACE fragments were T-A cloned using the pGemTeasy vector (Promega) and
sequenced.
RESULTS
Dissemination of RCMV in immunocompetent rats. In an initial experiment, which
will be further referred to as experiment I, 30 immunocompetent rats were infected with
RCMV. live rats were subsequently sacrificed at either day 3, 5, 7, 14, 31 or 120 pi. Organs
were collected from these rats and analyzed for the presence of infectious virus using the
plaque titration assay. In addition, total nucleic acids were isolated and used for the
detection of RCMV DNA by a PCR assay. As shown in Fig. 1 (lane 4), this assay is able to
reproducibly detect at least 10 copies of PCR control DNA. The number of DNA-positive
organs in each group of 5 rats at the different time-points after infection was determined
(Fig. 2). RCMV DNA could first be detected in spleen, liver, lungs, heart, pancreas, thymus
and aorta, at day 3. However, within the first week pi, RCMV DNA was also detected in the
other tissues and organs, except in blood plasma. The inability to detect RCMV DNA in
No. of copies control DNA
MW 10' 10' 10' 10
1 2 3 4 5 6
F/G. J. SfMsifi't'ify of "»' soiy/c-MiN'. m*s/<if RCMV PCR. Tni-faM difMfions of PCR iwifn>/ D/VM MOT
fn>m / \ /(>' ay /e s I/IUCH h> I cc>/>y <im/ ri-s/e*«/ />y /'CR (/<»!«• 2, 3, -I. 5). W<I/«T HWS <J/*> us«/ as in/>Mf in f/it'
/VK IHN/ SITJVI/ us (i Mi\\jijf/«v ivnfn»/ (/imr (•>). M<>/ivn/<ir aviy/if (MWI »writrr siais an* iiniira/tif on f/u- /tff
). T/ir«'v/vvfri/ si;r fi>r f//<-iim/>///iV(if/<vi ;>n\/nif cf PCR iwifno/ PN,4 is 369 h;». 77iis is 723
/ \ r(iv,v»i("ii/ f/id/ rci>»/(/ /v \v»tTi;fc</ fn>»i RCMV ^I'mwiic PNM fstii' Mufi*rw/s arri/ M«*f/«x/s).
JVit' (ii/i/i/ii'/Ki/ DN,'\ fhi,\'«it'iifs tt'if/i silt's ymi/iT f/mn 369 <>;' <in* //if rrsu/f o/' um^/i/icdMon mfrfiatai hy
HI HIT mil/ I>U/CT ;»rmiiT ;wir a>m/>iiwfii>ns.
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Day* pi
o
i i i t 1 • i
RCMV f/ssm-s nf iwnous
um/
77ir
F/G. 2.
/>(MMf. 5 rdfs uvrr
m/mfrcr of ra/s f/wf (
<!ssuy-fi>sifii¥ (irj^ iiHS. d, 4 [»/iJifuc iiSNiy-fHMfii'i' ru/s, mci/iiiii ciriis /i/i-r / J x /(>' /'/'(y/wi/; /'. '> ;>/III/I/C n>Niy
;)()s;7/z'f rafs, mt'rfw« t'/ri/s //7er 2.6 x 70*" PFU/;;//; c, 5 ^/(«/«f flssm/-/ws/7/w rnfs, m«/w« i>/n/s //7cr 5.7 x Itf*
PFU/»;/; rf, J /'/niyi/c flssfly-;ws/f/iv raf, 770 PFt//»//; c, 7 />//KJI/C (jssny-/»os;7;i'f ro/, 67 / '/1///I//; f, 7 /»/i/i/i/c
(jss<7i/-;ws;7;z't' rnf, 767
blood plasma indicates that the virus is predominantly cell-associated. For most organs, the
highest number of RCMV DNA-positive samples was seen within the first week pi.
However, the highest number of positive samples from salivary glands, lungs, brain and
left carotid artery was found at later time-points, namely at day 14 (lungs) or day 31
(salivary glands, brain and left carotid artery). In one of the rats that was sacrificed at day
7, RCMV DNA was not detected in any organ. Therefore, it is likely that this animal had not
been successfully infected with RCMV.
At 120 days pi, the salivary glands of all rats contained RCMV DNA, whereas in the
other organs RCMV DNA could be detected in the heart, brain, aorta and left carotid artery
for a maximum of two rats. However, detection appeared to be random and was not
restricted to the same rat(s) within the group of 5 (data not shown).
Although RCMV DNA could be detected at least once in most organs from 3 to 120 days
pi, infectious virus was only detected in three organs in that period (bone marrow at day 3,
spleen and kidney at day 5), obtained from three different rats. Moreover, the virus titers in
these organs were low: 167, 110 and 67 PFU/ml of a 10% w/v organ suspension for bone
marrow, spleen and kidney, respectively. Surprisingly, RCMV DNA was not detected by
PCR in the plaque assay-positive bone marrow. Most likely, this was due to the presence of
PCR inhibitors in the nucleic acid isolate. In contrast to the limited number of plaque assay-
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positive results for most organs, infectious virus could be detected in the salivary glands of
80% of the rats (4/5) at day 14, and in 100% of the rats (5/5) at both day 31 and day 120.
The median virus titer at day 14, 31 and 120 was 1.3 x 10*\ 2.6 x 10*, and 5.7 x Iff* PFU/ml,
respectively. Thus, in striking contrast to RCMV infection in immunocompromised rats
(55), viral replication is severely restricted in most organs during RCMV infection of
immunocompetent rats, except in the salivary gland.
Viral mRNA expression in vitro. To characterize the viral activity during the acute and
l.itrnt ph.ise of KCMV infection in more detail, we designed RT-PCR assays for the
detection of three different RCMV transcripts. These transcripts, derived from the R123 (IE-
1), R44 and R32 genes, are representatives of each of the kinetic classes of viral gene
expression in vitro, namely IE, early and late, respectively. Each RT-PCR was performed in
.i single tube, followed by a separate nested PCR for increased sensitivity. The assays are
able to detect at least 10 copies of in vitro generated control RNA (Fig. 3A, lane 6; Fig. 3B,
No. of copies
IE-1 control RNA
0' 10' 10' 10° H2O
B
No. of copies
R44 control RNA
10' 10' 10' 10° H2O
03
0.1
C
1
1
D
2
"10'
E
3 4 5 6 7 8
No. of copies
R32 control RNA
10' 5x10' 10'
•
9
10°
•
10 11
H2O
1 2 3 4 5 6 7 8 9 10 11
No. of copies
Q fl-actin control RNA
10* 10' 5x10' 10' H2O
kb MW^+ T"^ 7""+ .'""+ T%T_% - ' RJ kb M W T
04 |^^HHHH2^^^^^HHBjj^^H 1.0
02 ^ ^ D ^ ^ l 0.6
1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11
/•/(•;..•?. 77n- sfiisi/i'i'f/y .>/ siiiy/f/ii/v (iies/e</) RT-PCR for f/if ife/fi/iori of RCMV / £ - / , R-W am/ RJ2 ion/ro/
KN.4 urn/ //n- ir//i«/iir /.»'-IU/IM uxi/rn/ RAM. 7Wi-/oM </i/u/ioiis of / £ - ! M) . R44 (B) unJ R32 ( O coii/ro/ RAM
!C«7i' »iu«tV fn>m / \ /(>' iv/'iVs i t a i i /(> I ii>;»y, UM«/ /Vs/fi/ />v RT-PCR HI //it' ;>rfsfii«-f ("+) or afrsfiirf (-) 0/
mvrsf fniMSiri/'/iise (RT) us IMC/IVU/CI/ iih>iv (iJi"/i ;K»I«"/. W«/«T HWS II/SO i/s«"i/ as inpi/f /n Z/ir RT-PCR ÄIK/
SIT!«("I/ us ii m\v;ii/iiv ii)ii/ri>/ f//•>()). Mc/ivit/iir «viy/i/ (MW) »KIrHvr si;«-s an' im/icii/e'd 0» f/ic /if/ siA' of rtJf/i
;wnc/ (/due /). 7/ic cv/H-i/<•</ s e c 0/ //ie m-s/iv/ /'CR rrrtv;nicn/s iiffcr nm;>/if>V<ifton of t D N A is 195 ty> for / £ - ! ,
212 />/» /or R-M um/ 2J7 /'/»/or R32 RN.4 (s»v T<i/'/c 1). For R.?2 RT-PCR, 50 co/m-s 0/ coii/ro/ RAM urn- a/so
fcs/ii/ (/nut* f u»n/ 7). (P) Di/i/fiOMS 0//.J-ÜC/IM a)M/n>/ RN,4 nvrv »Wiif/rom 1 x lO^ A w n /o 1 x 10^
<III</ fi-s/ci/ /'y RT-PCR in //if ;>resfmv f +) or «ifisfiKr (-) of RTus nii/iai/fi/ uhnv fht* ;«MW. Wa/cr HWS
ns 11 M<yu/i'»v it>n/ii>/ (/iiiif 10 iiiii/ / / ) . T/if f.v^vJ«"«/ si:«* f«v PCR fniym«'»r/s is 622 h/'.
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lane 6; Fig. 3C, lane 8). Incidentally, also 1 copy of the IE-1 (data not shown) and R44 control
RNA could be detected (Fig. 3B, lane 8). The observed fragments with a si/o larger than that
of the nested PCR fragments are the result of amplification mediated by inner and outer
primer pair combinations. We also designed an RT-lfR assay for the detection of
transcripts from the cellular ß-actin gene to serve as a positive control. In this assay, the
single-tube RT-PCR was not followed by a nested PCR. The detection limit of this assay is
I x 10* copies of control RNA (Fig. 3D, lane 8).
It should be noted that the amplified IE-1 cDNA has a size of W5 bp (Fig. 3A), which is
97-bp smaller than amplified genomic DNA, since primers were used that flank intron 3 of
R123. The primers that were used to amplify ß-actin mRNA also flank an intron. As a
consequence, amplified ß-actin cDNA has a size of h22 bp (Fig. 3D), whereas amplified
cellular DNA has a size of 1086 bp (data not shown). In contrast, the R32 and R44 genes are
not spliced. Therefore, it is not possible to discriminate between RT-IVR products derived
from either genomic DNA or cDNA. Nevertheless, the RT-lXTRs that were performed for
the analysis of viral mRNA expression in rat organs were always accompanied by •> control
reaction from which RT was omitted. Thus, possible amplification of residual genomic
DNA could always be excluded.
For the combined isolation of DNA and RNA from the same sample, we used a different
isolation method than that used in experiment I (see Materials and Methods). The complete
procedure, from total nucleic acid isolation to PCR and RT-PCR, was tested on RCMV-
infected REF (Fig. 4). At 48 hours after infection, total nucleic acids were isolated and used
as input in the single-tube nested PCR. Ten-fold dilutions of the total nucleic acids were
tested from 10 ng to 10 fg. The lowest amount of total nucleic acids in which RCMV DNA
could still be detected was 0.1 pg (Fig. 4A, lane 7). Subsequently, total nucleic acid samples
were treated with DNasel, and the remaining total RNA was used as input for the different
RT-PCRs. Again, ten-fold dilutions of total RNA were tested, from 0.1 pg to 0.1 pg, both with
or without addition of RT to the reaction mixtures. The lowest amount of total RNA in which
R44, R32 and ß-actin mRNA could still be detected was 1 pg (Fig. 4C, 4D and 4E, lane 12),
whereas for IE-1 mRNA this was 10 pg (Fig 4B, lane 10). For IE-1, R44 and R32 RT-PCR
results, fragments were observed with a size larger than that of the nested PCR fragments,
in particular with higher RNA input concentrations. Again, these are the result of
amplification mediated by inner and outer primer pair combinations. In addition,
amplification occurred in the minus RT reaction for IE-1 (Fig. 4B, lane 3 and 5), R44 (Fig. 4C,
lane 3), and R32 (Fig. 4D, lane 3 and 5), with a high input of total RNA. These results
demonstrate that only at high input concentrations, residual DNA can be amplified.
Nevertheless, as mentioned above, the possible amplification of residual DNA in our RT-
PCR assays is controlled for by performing reactions both in the presence and absence of RT.
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o F7C. 4. Drt<rfion t»f RCMV PAM umf mRN.4 in RCMV inftvfn/ Rf.f .if -IS /tours ;>i M> Trn f
of MM/ nuWi-u- doJ tsufatVs t a w muii- fn>m JO ny M JO ft um/ fcshi/ />y siriy/e-fiilv. m-sto/ /VR. VMifiY t<ws
a/so us«iZ as iri;m/ in f/i«- PCR ami s m w i as a wynfitr ion/n>/ (/mir 9). Mo/ivx/nr uvi£/if (MWI sirf »KjrUvrs
an- imiuafrti on f/tr /«•// of f/u- ;*»««•/ f/<in«* J) 77ic «•.vfw/m/ sia- fi>r //ir iim/i/ifiuifion ;>iu/m-f of yrnnnur RCMV
DIVM is 24* ty>. 77ii- <i<i<Zifionu/ /«iryfr P f M /rnyrwnfs nr>- ffc«* n-s«/f o/ nm;>/ifi(-iifiivi mi\/nifii
ami ouftr ;»rim«T ;wir awiMnafions. for »fcf </rfev/ion of mRN.4. f«-M-fo/i/ i/i/wfions of MM/
nwi 0.1 ;<^ ' M 0.J /iy ami f.-sftii ^y " v / £ - ! (Bi. R44 (C), R.12 (£». mi«/ (»'-m-»i»i (/.") K7 I \ K .issny. in f/n-
v f • ) or «i/js«7icr (-) uf mvrs«" frnnscripMsc (RT) as iruiicnriii ahi>tv itrdi ;*nic/ VVlifrr *Tivi/ its n »r\iifitv
ron/r»>/ f/oiu' J7). MW s o - »MHUTS «in* in<iio>rii/ on f/i«' Zi'fV s«i<' <>f ctji7i ;»inr/. T/ir i'v/»vfrti si:(' of f/i«' u<-sf»"ii
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i45 a (.-onsti/urNiv. f/ir PCR ;»rorfiu7 ^rrii-ra(ni fn>»n /£• J ycmimii- R/23 DNyA is /flryi-r f/wn //KI/ ,\;rii«*nifii/ fn>m
/£- / rDNv4 C292 {7» tvrsus 795 f>;>). Sinic f/ir R44 miii R.12 y«vii-s 1/0 nc>/ conMiii m/nm X'I/KI'MI^, it
a;7»mm/i M liisonmifwff /vfuwn mn;»/ifirti >^fnt>mic' DN/^ ami < D/\M is «of
In conclusion, the combined isolation of DNA and RNA from RCMV-inkvted RF.F
enabled efficient amplification of RCMV DNA as well as mRNAs. Furthermore, the
expression of IE-1 mRNA at 48 hours pi appears to be 10-fold lower than that of both R44
and R32 mRNA. This is in concordance with previous reports, which demonstrated that
R44 and R32 mRNA are detected by Northern blot analysis during the late phase of
infection in vitro (8, 31), whereas IE-1 mRNA is not (5).
In vivo RCMV mRNA expression at day 7 and 120 after infection. After optimization
of the different RT-PCR assays as well as the protocol for combined isolation of DNA and
RNA, we set out to analyze viral mRNA expression in vivo. Since the DNA isolates from
experiment I were not suitable for mRNA analysis and the amount of residual organ and
tissue material was not sufficient for the extraction of both DNA and RNA, we performed
a second infection experiment. In this experiment (experiment II) a group of 10 rats was
infected with an equal amount of virus from the same virus pool as used in experiment I.
The rats were sacrificed at either day 7 (n=5) or day 120 pi (n=5). These time-points were
chosen since they are representative for acute and persistent/latent RCMV infection,
respectively. Both DNA and RNA were isolated from a similar set of organs as described for
experiment I. The detection of infectious virus by plaque assay was restricted to the salivary
glands, spleen and liver. Since infectious virus is generally not detected in the salivary
glands before day 10 (11), the plaque assay was carried out exclusively on salivary gland
samples obtained at day 120 pi.
As shown in Fig. 5 and 6, the number of RCMV DNA-positive organs and the number of
positive rats per organ was found to be somewhat higher in experiment II than in experiment
I, both at day 7 and 120. This difference between experiment I and experiment II can be
explained by the use of different nucleic acid isolation procedures in these experiments.
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experiment 1 0 experiment 2 day 7 pi.
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()/>/»i'iiri/ i/iir fc //i(' i'ii<if>i7i7i/ (<> diii/'/i/i/ f/ie s/'/Xc D/ani /ru / O N / \ »i/i/ci/ /i> f/ic / 'CR n'rtcfioi/.
RCMV DNA could be detected in all organs at day 7 (Fig. 5), including thymus, blood
plasma and bone marrow, which were DNA-negative in experiment 1. Further analysis of
the viral mRNA expression at day 7 was performed for 2 of the 5 rats (Fig. 7). The PCR
results from these selected rats were representative for those of the whole group. As a result
of the combined isolation of DNA and RN A, the results for PCR and RT-PCR can be directly
related to the same isolate from the same sample. As a positive control, RT-PCR was
performed on cellular tf-actin mRNA. This mRNAcould be detected in all organs, except in
the pancreas and blood plasma, which is a cell-free fraction. The inability to detect ß-actin
mRNA in pancreas tissue may be caused by either low expression of this mRNA or
unsuccessful isolation of RNA due to a high concentration of RNases in this organ.
The expression of early R44 as well as late R32 mRNA was detected in the salivary
glands, spleen, lungs and PBL at day 7 pi (Fig. 7). In addition, R44 mRNA was found in
liver, heart, brain and bone marrow. Nevertheless, infectious virus was not isolated from
any of these organs at 7 days pi, either in experiment II or I (Fig. 2). Interestingly, IE-1
mRNA could not be detected in all organs that were positive for R32 and/or R44 mRNA.
Mon> specifically, the detection of 1F-1 mRNA was limited to the salivary glands and lungs.
Since infectious virus is usually isolated from the salivary glands from day 10 pi (11), the
detection of IE-1 mRNA early after primary infection of immunocompetent rats appears to
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have a higher positive predictive value for the onset of a productive infection than the
detection of R44 or R32 mRNA.
At 120 days pi in experiment II, viral DNA was found in the salivary glands, spleen,
liver, lungs, pancreas, blood plasma, PBL, brain and left carotid artery (Fig. ri). For most of
these organs, only one of the five rats was RCMV DNA-positive. Only two organs were
found positive in at least two rats. Furthermore, each infected rat contained .it least one
RCMV DNA-positive organ, with a maximum of five (data not shown). The salivary glands
appeared to be the site of persistent infection, since it was found to contain RCMV DNA
and infectious virus in 5 out of 5 and 4 out of 5 rats in experiment I and II, respectively (Fig.
6). The presence of DNA in the salivary glands of one animal could not be determined due
to the presence of PCR inhibitors. However, viral DNA was also undelectable in other
organs of this rat. Moa-over, infectious virus could not be isolated trom the salivary glands
of this rat, whereas for the other rats these glands wen» found to contain relatively high
titers of virus (median = 6.8 x 1(P PFU/ml). Therefore, it is mi>st likely that the viral DNA-
negative rat had not been successfully infected with RCMV.
AH tissues and organs obtained from 2 selected rats at day 120 pi were subjected to the
different RT-PCR assays. IE-1, R32 as well as R44 mRNA were found in the salivary glands,
but not in any other organ (data not shown). Identical results were obtained after further
experiment 1 experiment 2
%; ^ %, %. ^
\
^
\
day 120 p.i.
F/G. 6. RCMV DN/4 detecfion by PCR i/r rarious raf organs and f/ssues of 120 days pi, in «rperimen/ / and //.
77ie iiumfrrr of rnfs f/wf <em' RCMV DN/4-posifiz>e /or o w specific or#a/i is iH</ioifft/ fry fr/acJt «»id /uifc/W
bars, ri*pri's«?HfiH£ eArpt*ri»»ieiif / a»id //, »vspecf izv/y. a a»(/ fr irirficaff Ma/ /or one «iMip/i' a/i iniw/it/ PCR r « « / /
fo f/ie i>»ifri/ifi/ fo nmp/ify f/;e spiJte o/confro/ DN/4 arfrferf /o r/;e PCR rent-f/7m.
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analysis of viral mRNA expression in viral DNA-positive organs from the other 3 animals.
Taken together, our data show that, in contrast to other organs and tissues, the salivary
glands contain a high load of replicating virus at 120 days pi. This situation is similar to that
in immunoeompromised, KCMV-infected rats at several months pi (13, 14). Apparantly,
differences in the course of RCMV infection between immunocompetent and
immunoeompromised rats exist mainly during the first weeks after infection. This can be
explained by the fact that rats aa> immunosuppressed by a single treatment with gamma
irradiation before infection. After infection with a sublethal dose of RCMV, the
immunoeompromised rats will usually recover and develop a similar antiviral immune
response as do immunocompetent rats (60). Thus the status of the infection may be similar
in imnuinocompetent and irradiated rats, after the immune system of the irradiated rats
has fully recovered.
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Detection of an antisense transcript of the RCMV major IE region. In RCMV-infected
rats, IE-1 mRNA was not frequently detected and its expression appears lo Iv mainly
restricted to organs in which infectious virus can also be detected, in particular the salivary
glands. Interestingly, the IE-1 RT-IX. R on total RNA from PBL, harvested 7days pi, resulted
in the amplification of a fragment of which the length, 2^2 bp, corresponds with that of.»
fragment that would be generated by amplification of either genomic RCMV DNA or
unspliced IE-1 mRNA (Fig. 8, lane 2). Since the amplification of this fragment was
dependent on the use of RT, it is not likely that it was generated by amplification of
genomic DNA. Similar fragments were observed in the salivary glands of rats sacrificed at
7 and 120 days pi, and also in vitro, in RCMV-infected REF at 4« hours pi. (Fig. 8, lane 8 and
14, respectively). We further investigated the structure of this transcript by performing
strand-specific RT-PCR reactions in order to determine the sense or antisense orientation ol
the mRNA. To this purpose, one of the primers of the RT-PCR primer set was omitted I mm
the reaction during the conversion of mRNA to cDNA. The omitted primer wa»
subsequently added after the inactivation of RT and activation of the HotstarTaq
polymerase for 15 min at 95°C. Using this procedure, reverse transcription in the presence
of primer RT-IE1-F2, resulted for salivary glands and REF in the amplification of a 195-bp
fragment that was derived from the spliced, sense IE-1 transcript (Fig. 8, lane 12 and 18).
Reverse transcription in the presence of RT-IE1-B2, resulted for PBL, salivary glands and
REF in the amplification of a 292-bp product that was derived from an antisense, unspliced
mRNA (Fig. 8, lane 4, 10 and 16). The observed fragments with a size other than 195-bp or
292-bp, are the result of amplification mediated by outer and inner primer pair
combinations. From these results we conclude that the 292-bp fragment is derived from an
unspliced antisense transcript of the MIE region. This antisense, unspliced mRNA will be
further referred to as IE-AS. Interestingly, IE-AS was detected in blood leukocytes in the
absence of IE-1 mRNA (Fig. 8, compare lane 4 to lane 6). This suggested that the expression
of IE-AS may be involved in downregulation of IE-1 synthesis. On the other hand, in the
salivary glands and in REF, IE-AS and IE-1 could be detected simultaneously. Furthermore,
IE-AS expression was not found in all tissues and organs in which IE-1 mRNA expression
appeared to be absent.
By Northern blot analysis, IE-AS could not be detected in RCMV-infected REF at either
IE, early or late times of infection (data not shown). We therefore conclude that IE-AS is
only expressed at low levels. As an alternative to Northern analysis, limited dilution RT-
PCR was performed on IE-AS, using total RNA isolates from RCMV-infected REF at IE,
early or late times of infection. Surprisingly, IE-AS was found in each phase of infection at
approximately similar levels (data not shown). Thus, in contrast to IE-1, which was
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exclusively detected during the IF phase of infection (5), expression of IE-AS does not seem
to be restricted to either the Hi, early or late phase of infection in vitro.
The structure of the RCMV IE-AS transcript. In order to elucidate the structure of the
novel IE-AS transcript, we amplified its 5' and 3' ends by RACE. Two major fragments of
approximately I,UK) and 570 bp wen* amplified by 5' RACE (data not shown). These
fragments were cloned and sequenced. For the largest 5' RACE product 4 independent
clones were obtained with identical 5' ends (5'-GGGGCCGTGAGGGTGACC-3'; in which
the 5' terminal G residue corresponds to position 172,229 of the RCMV genomic sequence).
This transcription start site is localized within exon 4 of the MIE region (Fig. 9). The exact
S'-terminal nucleotide could not be determined since a stretch of C-residues was added to
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the first strand cDNA in the 5' RACE procedure. As a consequence, each of the nucleotides
in italics may represent the actual 5' end of the IE-AS mRNA. For «he smaller 5'
RACE product, 3 independent clones were obtained with identical 5' ends (5'-
ACCTGATCCTGl IlCCACC-3'; in which the 5'-torminal A residue corresponds to
position 172,772 of the RCMV gonomic sequence). This 5' end is also located within exon 4
of the MIE region, 543 bp downstream of the first transcription start site.
To determine the 3' end of the IE-AS transcripts, 3' RACK was porfomu«d. The primers that
were selected for the 3' RACE would result in a IX. R fragment that partially overlaps the 5'
RACE products. Amplification using these primers generate«.! one major fragment of
approximately 400 bp (data not shown), which was cloned. Two independent clones were
sequenced and found to differ only 8 nuclcotides in length. Both 3'-termin.\l sequences, ,V-
AAAATAAAAATGTCCCACCTM/M-3' and 5-AAAATAAAAATGTCCC AC XTTTTTA-
TGTTAA/KV, contain a consensus polyadenylation site (underlined) and a polyA stretch
(in italics). The 3'- terminal T residues of the transcripts correspond to position 17.1,622 and
173,630, respectively, of the RCMV genomic sequence, and are both localized within intron
2 of the MIE region (Fig. 9). Thus, it can be concluded that at least two dillerent major Ili-
AS transcripts exist, IE-AS1 and IE-AS2, with a length of approximately 0.8ft kb and 1.4 kb,
respectively.
The transcription of antisense mRNA from the MIE region has also been reported for
HCMV in granulocyte-macrophage progenitor cells and in the bone marrow of healthy
seropositive individuals (34). The transcription start site of the HCMV antisense transcript
was found to be situated within exon 4 of the IE-1 transcript, at a position that corresponds
with the start site of RCMV IE-AS2 (Fig. 9). A second, downstream start site for the HCMV
antisense transcript has not been reported. In analogy to what has been described for the
HCMV antisense transcript, sequence analysis of the region upstream of the two start sites
of the RCMV IE-AS1 and IE-AS2 transcripts showed that a consensus TATA element is
lacking. Thus, the sequence upstream of the IE-AS transcription start sites is likely to
possess alternative signals governing transcription initiation.
Sequence analysis of the HCMV antisense transcript revealed the presence of six open
reading frames (ORFs) greater than 30 codons (Fig. 9). The RCMV IE-AS1 and IE-AS2 were
found to harbor only one and two of such ORFs, respectively. These ORFs, ORF58 and
ORF45, have the potential to encode small proteins with a predicted molecular mass of 6.4
and 5.0 kDa, respectively. Interestingly, the 3' end of the HCMV antisense trancript was
found to be localized in intron 1 of the IE-1 transcript, whereas the RCMV IE-AS transcripts
both terminated within intron 2. As a consequence, the RCMV IE-AS transcripts do not
encode putative homologs of the proteins encoded by HCMV ORF152, ORF35 and ORF50.
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Based on position and size, the RCMV ORF58 and HCMV ORF59, as well as the RCMV
ORF45 and HCMV ORF44 appear to bo conserved. However, the sequence homology
between the proteins predicted to bo encoded by the corresponding I K'MV and RCMV
ORFs is very low (data not shown). Further studios on the expression ol the Ili-AS
transcripts and their putative gone products may load to a bettor understanding of the
regulation of RCMV MIE gene expression.
DISCUSSION
We investigated the dissemination of RCMV after primary infection of
immunocompetent Wistar rats, using PCR and RT-PCR assays for the sensitive detection of
RCMV DNA and mRNA, respectively. In addition, the production of infectious virus was
determined by plaque assay. We found that RCMV DNA was readily detected in most
organs during the first week pi. However, the presence of infectious virus in this period was
limited to the bone marrow, spleen and kidney. In a previous study with
immunocompetent Brown Norway (BN) rats, infectious RCMV was not only detected in
these organs in the first week pi, but also in heart, thymus, and PBL, albeit at low titers (11).
It is highly likely that the differences between these data and the results from the present
study are the consequence of using different rat strains. In analogy, it was found for murine
CMV (MCMV) that the susceptibility for infection can vary considerably between different
strains of mice (2, 21, 42, 52).
The inability to detect infectious RCMV in the majority of organs or blood cells during
acute infection, indicated either that infectious virus was not produced at all or that the
amount of infectious virus was below the detection level of the plaque assay. Nevertheless,
the findings from this study on RCMV infection of immunocompetent rats are in striking
contrast with previous studies in immunocompromised rats. Infections in those rats with
similar doses of RCMV as used in this study usually result in high titers of infectious virus
(48, 55). Therefore, this study emphasizes once again the crucial role of a fully functional
immune system in controlling CMV infections.
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Analysis of IE, early and late mRNA expression was performed to investigate the viral
activity at 7 days pi in more detail. Late R32 mRNA could be detected in blood cells,
salivary glands, spleen, and lungs at 7 days pi, although infectious virus was not isolated
from any of these organs. This showed that the presence of late RCMV mRNA is not
necessarily correlated with the production of detectable amounts of infectious virus. In
liver, heart, bone marrow and brain, early R44 mRNA was detected in the absence of both
late mRNA expression and production of infectious virus. Thus, full replication of RCMV
leading to production of infectious virus may be arrested after either early or late mRNA
expression. This notion is supported by recent studies on MCMV infections, in which it was
found that the viral replication cycle can be blocked at several checkpoints on the way from
latency to complete reactivation (36, 37).
With respect to the possible existence of checkpoints in the replication cycle of RCMV,
I he general absence of RCMV IE-1 mRNA at 7 days pi, in particular in those organs in
which early and late mRNA are detected, is intriguing. In contrast to RCMV IE-1
Iranscripts, MCMV IE-1 mRNA can be detected in various organs during primary infection
of mice (4, 33, 64). However, there are clear differences between MCMV infections and
RCMV infections in vivo. In contrast to RCMV infections of immunocompetent rats,
infection of immunocompetent mice with MCMV leads to replication of virus to high titers
in various tissues and blood (2, 43, 56, 65). Moreover, a high dose of virus inocculated in
susceptible strains of immunocompetent mice can be lethal (1, 24), whereas RCMV
infections in immunocompetent rats is not lethal, even when a high dose of virus is used
(10, II, 55). Similarly, HCMV infections in healthy individuals usually remain
asymptomatic. Unfortunately, due to the limited availability of human tissue or blood
samples, little is known about the production of infectious HCMV and viral mRNA during
the acute phase of primary infections in healthy individuals.
In addition to the general absence of RCMV IE-1 mRNA expression at 7 days pi, this
transcript was also undetectable in all organs at 120 days pi, except in the salivary glands.
Also, early and late mRNA as well as infectious virus could only be detected in the salivary
glands at 120 days pi. Thus, infection of the salivary glands can be characterized as a
persistent infection rather than a latent infection at this time-point.
The inability to detect IE-1 mRNA in organs other than the salivary glands at 120 days
pi is in agreement with data from previous studies which reported that the expression of
the MCMV IE-1 gene could not be detected during latent MCMV infection in various
organs, including spleen, lungs and blood (9, 33, 45, 65). Expression of HCMV IE-1 mRNA
was also not found in blood cells during latent infection in healthy seropositive individuals
(25, 59). On the contrary, several authors reported the detection of MCMV IE-1 mRNA in
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latently infected spleen and lungs (29, 36, 64, 65). it was proposed that during latent
infection of the lungs, MCMV IH-1 transcripts are produced in a random, final fashion, but
this expression does not necessarily lead to the production ol infectious virus (2(>, 3d, 37).
RCMV IE-1 mRNA expression was found to be strongly correlated with production of
infectious virus, since it was mainly detected during persistent infection in the salivary
glands at 120 days pi, and during productive in vitro infection of REK IE-1 mRNA was also
detected in the salivary glands and lungs at 7 davs pi in the absence of infectious virus.
However, previous studies have shown that RCMV can be isolated from salivary glands as
early as 10 days pi (11). Thus, the expression of RCMV IE-1 has a high positive predictive
value for the onset of production of infectious virus. The absence of detectable levels of »he
RCVM IE-1 transcript during acute and latent infection in most organs suggests that the 1E-
1 expression is significantly «»presset! in immunoconipetent rats.
At 120 days pi, infectious virus was only detected in the salivary glands. This is in
agreement with previous studies with BN and Lewis rats (11, 12). In addition, similar
findings were reported for MCMV infection in mice (3, 53). It has previously been shown
that the rat salivary glands are not subject to natural killer cell surveillance ((>()).
Consequently, RCMV may persist in this organ for at least several months. Nevertheless,
the salivary glands are not the only organs that harbour RCMV at 120 days pi, as indicated
by the occasional presence of RCMV DNA in other organs.
It was reported for both HCMV and MCMV, that blood monocytcs are a predominant
site for latent infection (33, 49, 57, 58). Moreover, it was suggested that the bone marrow,
which harbors the progenitor cells of monocytes, acts as a reservoir from which CMV can
be transmitted (40,44,65,66). However, RCMV DNA was not detected in bone marrow 120
days after infection, and detection of RCMV DNA in blood was restricted to a single rat at
that time-point. In agreement with these data, it was previously shown that blood
leukocytes from latently infected donor rats were not capable of transferring RCMV to a
seronegative immunocompromised recipient (13). Therefore, bone marrow and blood cells
do not appear to be a major site of latent RCMV infection. Similarly, MCMV was found to
be cleared from bone marrow and blood several months after infection (3, 4, 21).
Conversely/ latent MCMV DNA was detected in various other organs of mice (19, 21, 32,43,
63). The preferred sites for latent MCMV infection were reported to be spleen and, in
particular, lungs (4, 43, 50). The lungs were found to contain a 10-fold higher viral DNA
load than the spleen during latency (4). In the present study, RCMV DNA was detected in
spleen and lungs, as well as in other organs at 120 days pi. The presence of RCMV in
various organs during latent infection is probably explained by the fact that the virus is
present in similar cell types in different organs. This theory is supported by the fact that
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latent HCMV and MCMV have been detected in vascular cells and tissue macrophages of
various organs (23, 28, 32, 33, 50). In conclusion, RCMV can reside in many different rat
organs during latent infection. It is important to note, however, that at 120 days pi, virus is
still produced in the salivary glands. Thus, although RCMV latency may have been
established locally at various sites within the infected rats, viral latency at the level of the
whole organism has not yet been set in at 120 days pi. In fact, it was previously found that
infectious virus can be detected in salivary glands for up to 7 months pi in BN rats, whereas
for Lewis rats this can be up to at least 1 year pi (10).
An interesting aspect with regard to the regulation of RCMV gene expression is the
identification of novel unspliced transcripts that are derived from the RCMV MIE region
and that are complementary to part of the IE-1 transcript. These antisense transcripts (IE-
ASI and IH-AS2) were initially detected at 7 days pi in PBL in the absence of IE-1 mRNA
expression. This suggested that the antisense transcripts might be involved in
downregulation of IE-1 transcription. However, in the salivary glands and during in vitro
infection, 11*-1 and IF.-AS transcripts could be detected simultaneously. Furthermore, the IE-
AS transcripts could not be detected in every organ in which IE-1 mRNA was absent.
For HCMV, transcription of a similar antisense transcript from the MIE region was
detected in granulocyte-macrophage progenitor cells and in bone marrow of healthy
seropositive individuals in the absence of transcripts that are generated during productive
infection. Therefore, the antisense transcript was designated as a CMV latency-associated
Iranscript ((.IT, 34). In addition, sense CLTs were found with transcription start sites in the
1ICMV Mlli promoter-enhancer region, upstream of the start site from which IE-1 and IE-
2 mRNA are transcribed. Nevertheless, the sense CLTs were recently also shown to be
expressed in a variety of HCMV-infected cell types, including human fibroblasts, during
productive infection in vitro (39). Similar findings for the HCMV antisense CLT have
hitherto not been reported.
The HCMV antisense CLT was found to contain six ORFs greater than 30 codons (Fig.
9). The function of the HCMV CLTs and /or their encoded proteins is still unclear (62).
Nevertheless, putative homologs of the largest proteins encoded by the HCMV antisense
Cl.T, ORF 154 and ORFI52, are not encoded by the RCMV IE-AS transcripts. Instead, two
small ORFs, OKF5S and ORF45, were found to have a similar position as well as orientation
as HCMV ORF54 and ORF44, respectively (Fig. 9). The corresponding HCMV and RCMV
proteins encoded by these ORFs, however, show only limited similarity (data not shown).
Antibodies directed against HCMV antisense CLT-encoded proteins ORF59, ORF154 as
well as ORF152 werv found in the serum of healthy sempositive individuals and patients
with active CMV infection, which indicates that these proteins are expressed in vivo
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(34, 38). Since similar analysis for the HCMV antisense CLT-encoded protein ORF44 WM
not performed, it is still unknown whether this protein is expressed in vivo.
Although the RCMV 1E-AS transcripts may indeed encode functional proteins, it is also
possible that they play a role in the regulation of gene expression by the formation of
double stranded (ds) RNA with the complementary, sense transcript. In fact, the formation
of dsRNA is recently being recognized as an important nuvhanism in post-transcriptional
gene silencing in higher eukaryotes (27, 35, 54). A role for antisense transcripts in the
regulation of herpes virus gene expression, inhibition of viral replication, and establishment
of latent infection, has been suggested for herpes simplex virus type-1 (18, 22, 41), Epstein
Barr virus (51) as well as Marek's disease virus (16,17). Nevertheless, no direct evidence for
the existence of dsRNA formation during herpesvirus infection has yet been reported.
Clearly, the subject of future studies will be the elucidation of the function of the RCMV IE-
AS transcripts during RCMV infections in vitro and in vivo.
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GENERAL DISCUSSION
Infections with HCMV are very common. In general, infections of immuntvompetent
individuals remain asymptomatic. In contrast, infection of immunocompromised
individuals, such as patients with AIDS, solid organ and bom- marrow transplant
recipients, can result in a symptomatic infection and may even load to death. Currently,
effective antiviral treatment is possible. Ganciclovir is the most commonly used antiviral
drug for the prevention and treatment of symptomatic HCMV infection. However, antiviral
treatment is most effective when the patient is treated at an early stage of infection. In
general, the preferred approach is therefore to initiate antiviral treatment before onset ot
apparent symptoms of infection. This preemptive strategy relies on the early detection ot
aberrant HCMV activity using a diagnostic assay (24). On the other hand, due to the
adverse side effects of the drug and possible development of viral resistance against the
drug, treatment of patients should be limited. Hurthermore, delayed initiation ol therapy
may allow priming of host antiviral immune responses which may contribute to recovery
and long-term control of the infection. Therefore, the assay should not only be sensitive but
also have a high positive predictive value (IM'V) for the onset of symptomatic infection.
Detection of infectious virus in blood is considered as the hallmark for development of
symptomatic infection. The assays used in most routine diagnostics laboratories for the
detection of HCMV in blood samples are based either on the detection of infectious virus,
viral antigen, or viral DNA (see also chapter 1). The detection of infectious virus by cell
culture is relatively slow and insensitive and therefore not suitable to act as a guide for
preemptive antiviral therapy. The pp65-antigenemia assay is the most commonly used
assay for the detection of viral antigen. This assay is more sensitive than viral culture,
although its specificity for the onset of symptomatic infection can be low. The qualitative
detection of viral DNA by PCR is highly sensitive. However, since PCR can also detect
latent viral DNA, the specificity of this test is very low. Alternatively, the viral DNA load
can be measured using quantitative PCR. The dynamics of the viral load in the blood are
better correlated with disease progression. Nevertheless, quantitation of DNA in blood is
not consistently correlated with actual virus replication in vivo (7). The detection of viral
mRNA expression by RT-PCR or NASBA is expected to reflect viral activity more directly,
due to high turnover of RNA molecules and the possibility to detect viral transcripts that
are selectively expressed during active viral replication. Previously, various studies on the
detection of viral mRNA expression as markers for viral activity were performed. However,
these studies are difficult to compare due to the lack of standardization between the
different assays. In this thesis, the development of standardized NASBA assays is described
for the detection of two different viral transcripts: the immediate-early (IE)-1 and the late
pp67 mRNA. The IE-1 mRNA is expressed during the very early stages of viral lytic gene
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expression (26). In contrast, the pp67 mRNA is abundantly expressed in the late phase of
infection (.1,4). The diagnostic value of the NASBA assays for the detection of IE-1 and pp67
mRNA in blood samples of renal and liver allograft recipients was determined. In studies
by other groups, these assays were also evaluated for other patient groups as outlined
below.
Initially, the use of monitoring pp67 mRNA expression in whole blood samples was
investigated for renal transplant patients (chapter 2). From this study it was concluded that
the sensitivity of the pph7 NASBA assay is higher than that of the antigenemia assay for the
detection of active CMV infection (50% versus 34%). In a subsequent study, the evaluation
of the pp67 NASBA assay was extended for a larger group of renal transplant patients. This
study had a similar outcome (8,9). A higher sensitivity of the pp67 NASBA assay compared
to the .intigenemia assay for the detection of active CMV infection was also reported in a
study for thoracic organ transplant recipients by Oldenburg et al. (21). In the studies on
renal and thoracic organ transplant patients, active CMV infection was defined by the
combined positive results for cell culture, antigenemia and serological assays. Since renal
transplant patients receive relatively low doses of immunosuppressive drugs they are at
lower risk for the development of symptomatic infection compared to other organ
transplant recipients (22). The antigenemia or cell culture results were therefore not used to
guide early preemptive antiviral treatment (chapter 2). If possible, the dosage of
immunosuppressive drugs was diminished upon detection of HCMV, to allow the
development of an adequate immune response by the patient. Antiviral treatment with
ganciclovir was only initiated based on the first clinical symptoms of a symptomatic
infection, confirmed by positive results for viral culture and/or the antigenemia assay. In
these symptomatic patients, both pp67 mRNA and pp65-antigen could be detected. This
demonstrated that the diagnostic value of these assays for monitoring HCMV infection in
renal transplant patients was comparable. In the study with thoracic organ transplant
patients described by Oldenburg et al. (21), the start of antiviral treatment was based on
clinical symptoms or antigenemia results of >10 pp65-antigen positive cells per 2 x 10^
leukocytes. The expression of ppf>7 mRNA was found 1.1 weeks before this treshold was
reached. It was therefore suggested that the pp67 NASBA assay could be used to guide
preemptive antiviral treatment in these patients (21). These results are in agreement with
the findings of Cerna et al. (6), who used a cut-tiff level of >100 pp65-antigen positive cells
per 2 x 10^  leukocytes for the initiation of antiviral therapy in solid organ transplant
recipients with a secondary infection. Positive pp67 NASBA results also preceded this cut-
off value by several days. In contrast, ppf>7 NASBA positive results were found to be
delayed compared to the first antigenemia positive results in bone marrow and solid organ
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transplant recipients with a primary infection. Antiviral therapy in these patients was
initiated upon the finding of the first positive antigenemia results. IVI.i\i-d detection of
pp67 mRNA compared to clinically relevant levels of ppt>5 antigen were also reported for
a group of lung transplant patients (13). However, it should be noted that the reported
discrepancies between the antigenemia assay and the ppt>7 NASBA assay in the
retrospective studies are possibly related to the early start of antiviral taMtment based on
the first antigenemia-positive a*sults. Since ganciclovir exerts its antiviral effect by the
inhibition of the viral DNA polvmerase, it is expected that the expansion of late mRNA,
which is dependent upon viral application, is also inhibited. This notion is further
supported by the outcome of a study performed for liver transplant patients (chapter 3). In
this study, the start of antiviral therapy was based on the first clinical signs of a
symptomatic CMV infection and antigenemia positive adults. The sensitivity of the pp67
NASBA assay for the onset of a symptomatic infection in the liver transplant patients wns
found to be only M)';i. The pp*>7 NASBA assay was also found to be less sensitive than the
antigenemia assay in a study on renal transplant patients by I'ellegrin et al. (23). These
patients were preemptively treated with ganciclovir based on the first positive antigenemia
results.
In conclusion, the detection of pp67 mRNA appears to be mainly correlated with the
peak of systemic HCMV replication and spread and its detection can therefore be delayed
compared to the antigenemia assay. This raises the question whether the pp67 NASBA
assay results can be used to guide a preemptive therapy approach since this could result in
an unacceptable increase in the risk for the onset of a symptomatic infection. Conversely,
delayed initiation of antiviral therapy may be beneficial for the patient it this results in the
development of an adequate immune response that accelerates recovery and generates
improved long-term immunity against the virus. These issues should be investigated in
controlled prospective studies. It is expected that for some patients delayed initiation of
antiviral treatment could be justified, such as low risk solid organ transplant recipients with
a secondary infection. For the patients at high risk, such as bone marrow transplant patients
and specific groups of solid organ transplant recipients, delayed initiation of antiviral
therapy may be unacceptable.
In addition to the pp67 NASBA assay, the IE NASBA assay was used for monitoring
CMV infection in renal (chapter 3) and liver transplant patients (chapter 4). In studies
performed by other laboratories, the diagnostic value of the IE NASBA assay was also
evaluated for other solid organ and bone marrow transplant recipients (5, 13, 21). In all
these studies it was consistently found that the IE NASBA assay is very sensitive. However,
detection of IE mRNA is not necessarily correlated with the onset of aberrant viral activity
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or symptomatic infection. As a consequence, the specificity of the IE NASBA assay for the
onset of a symptomatic infection is low. Nevertheless, the IE NASBA assay was usually the
first assay that indicated the onset of CMV infection. In particular in those patients at high
risk for symptomatic infection, i.e. solid organ transplant recipients with a primary
infection, bone marrow transplant patients, or patients that receive anti-rejection therapy,
preemptive therapy could be based on the early detection of IE-1 mRNA (chapter 3 and 4;
(5)). In patients at low risk for symptomatic HCMV infection, this would result in the
unnecessary treatment of many patients, due to low ITV of the assay in these patients.
Recently, a quantitative assay for the detection of IE-1 mRNA was developed (11). Using
this assay, a good correlation between the levels of IE-1 mRNA expression and progression
of HCMV infection was found in lung transplant patients (13). More extensive studies are
needed to determine cut-off levels for IE-1 mRNA expression. Ideally, levels of mRNA
expression above the cut-oft should be predictive for the onset of symptomatic infection
and provide a rationale for the initiation of antiviral therapy. Expression levels below the
cut-off level could be indicative for low viral activity, whereas intensified monitoring of a
patient is needed if the IE-1 levels start to rise but have not reached the cut-off value yet. In
contrast to the quantification of IE-1 mRNA expression, quantification of the levels of pp67
mRNA did not appear to have additional value compared to the qualitative assay, since
detection of this mRNA is strongly correlated with the peak of infection, as discussed above
(13).
In conclusion, detection of CMV mRNA expression using NASBA is of added diagnostic
value compared to existing assays for monitoring the course of infection because of its
dynamic nature which more directly reflects viral activity. Simultaneous quantitation of the
levels of IE-1 mRNA expression, and qualitative determination of the presence of pp67
mRNA in a multiplex assay as recently described (10), may result in an assay that is highly
sensitive and predictive for the onset of a symptomatic HCMV infection. Monitoring the
expression ot other viral genes, such as the immune evasion genes US3, US6 and US11 did
not appear to have much additional diagnostic value compared to the IE and pp67 NASBA
assays (12). However, it may be useful to investigate the diagnostic value of detection of
other viral transcripts or transcripts generated by the host in response to viral infection. It
is expected that broad analysis of viral and host gene expression in microarrays may result
in the identification of several of these transcripts and further fine-tuning of diagnostic
parameters in transplant populations.
The second aim of this thesis was to monitor viral activity of RCMV in
imnunuvompetent rats during acute and latent infection (chapter 5). In previous studies,
rats were usually immunocompromised by gamma-irradiation before infection to allow
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efficient replication of the virus. Under these conditions, pathogenic effects of RCMV
infection are more pronounced and can be studied more easily. In contrast, similar to
HCMV infection in humans, RCMV infection of immimocompotent rats remains
asymptomatic and is not lethal, even when high a dosis ol virus is administered. In this
respect, the RCMV infection model is a better animal model for HCMV infection than
MCMV infection, since infection of healthy mice a*sults in high virus titers in different
organs and can even be lethal (1, 27).
Using PCR, RT-IX.R and plaque assay, it was found that RCMV replication is severely
restricted in immunocompetent rats (chapter 5). Although the expression ol early and late
mRNA could be detected at 7 days pi in various organs and blood, detectable levels of
infectious virus were not found. In addition, IE-1 mRNA expression was only occasionally
detected. At 120 days pi, virus persisted in the salivary glands as indicated by the presence
of infectious virus, whereas in other organs exclusively viral DNA was delected in a limited
number of cases. The presence of latent virus in multiple organs during long-term RCMV
infection has also been reported for MCMV (2, 17) and parallels observations in autopsy
specimens of humans (15, 16, 30). In contrast, molecular studies on mechanisms of latent
HCMV infection focussed primarily on blood and bone-marrow cells (20, 28, 29, 31). This
could merely reflect the problem to obtain biopsies of other organs and tissues from healthy
individuals to study latent HCMV infection.
The inability to detect RCMV IE-1 mRNA during acute infection in blood cells of
immunocompetent rats appears to contradict the findings reported above for monitoring
HCMV IE-1 mRNA expression in blood using NASBA. From these studies it was concluded
that detection of HCMV IE-1 mRNA is not necessarily correlated with the production of
detectable levels of infectious virus. In contrast, RCMV IE-1 mRNA was mainly detected
during productive infection in salivary glands and during lytic infection of REF in vitro.
Importantly, the studies for HCMV were performed with immunocompromised patients
after organ transplantation, whereas the infected rats were healthy and immunocompetent.
In this respect, it is relevant to note that in healthy HCMV-infected humans also no HCMV
transcripts could be detected (12, 13). This suggest that the presence of a fully functional
immune system is responsible for the restriction of IE-1 mRNA expression. It may well be
that HCMV IE-1 mRNA expression is also restricted upon primary infection in healthy
subjects, however this is difficult to investigate due to the limited availability of samples
during this phase of infection.
The mechanisms that are directly involved in the restriction of RCMV IE-1 mRNA
expression are currently unknown. Interestingly, two novel antisense mRNAs were
identified in the MIE region. These transcripts are complementary to and partly overlap
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with the 1E-1 transcript (chaper 5). The role of these transcripts is still enigmatic. A similar
antisense transcript was detected for HCMV (18). Interestingly, the expression of this
transcript was reported to be strictly associated with a latent HCMV infection. By contrast,
the detection of the KCMV antisense transcripts was detected at 7 days pi in blood cells,
and in productively infected salivary glands at 120 days pi. It is tempting to speculate that
direct hybridization of antisense to sense mRNA is involved in the downregulation of IE-1
mKNA expression. Formation of double stranded RNA was recently recognized as an
important mechanism in post-transcriptional gene silencing in higher eukaryotes (14, 19,
25). f lowever, the existence of such a mechanism in herpesvirus gene expression has not yet
been demonstrated.
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SUMMARY
Human cytomegalovirus (HCMV) is an important cause of mi>rbidity and mortality in
immunocompromised patients. Effective antiviral treatment is possible provided that it is
initiated in the early phase of infection. In the first part of this thesis, the expression of the viral
immediate early (IE)-1 and late ppft7 mKNA in whole blood sunples of renal and liver
transplant patients was monitored using nucleic acid sequence-based amplification (NASBA).
The IE-1 and pp67 transcripts represent different stages in the replication cycle of the virus. Tho
diagnostic value of these two assays for detection of CMV infection was investigated.
In chapter 2, the pp67 NASBA assay results obtained for renal transplant patients were
compared in a retrospective study to the results of the pph5-antigenemia assay and viral
culture. The sensitivity of the pp67 NASBA assay for the detection of active CMV inlivtion
appeared to be higher compared to the sensitivity of the antigenemia assay, whereas it was
similar to that of viral culture. Active CMV infection was defined by combined positive
results for antigenemia, viral culture and serological assays. Some patients developed
clinical symptoms as a consequence of the onset of active CMV inlcction and received
antiviral therapy. For these patients it was found that the sensitivity of the ppf»7 NASBA
assay was similar to that of the pp65 antigenemia assay as well as viral culture. Finally, the
pp67 NASBA assay appeared to be suitable for monitoring the effect of antiviral therapy.
Taken together, it was concluded that the diagnostic value of the pp67 NASBA ass.iy for
detecting HCMV infection in renal transplant patients is comparable to that of the
antigenemia assay and viral culture.
The blood samples of the same group of renal transplant patients as described in chapter
2, were also used for a retrospective evaluation of the diagnostic value of the IF NASBA assay
(chapter 3). This assay proved to be the most sensitive assay, detecting the onset of both
primary and secondary infection significantly earlier than viral culture, the pp67 NASBA and
antigenemia assay. However, the specificity of this assay was low, indicating that the
detection of IE-1 mRNA in blood of renal transplant patients is not necessarily correlated with
the onset of a clinically relevant HCMV infection. It was therefore concluded that only for
patients at high risk for the development of a symptomatic infection, i.e. patients with a
primary infection or under rejection therapy, early detection of CMV transcriptional activity
is valuable and could possibly be used as a parameter for the start of preemptive antiviral
treatment.
A similar evaluation as described for renal transplant patients using the IE and pp67
NASBA assays was performed for liver transplant patients and is described in chapter 4. In
general, liver transplant patients are at higher risk for the onset of symptomatic infection than
kidney transplant patients. Liver transplant patients are usually in a critical clinical condition
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at the moment of transplantation and frequently require anti-rejection treatment. As a
consequence, these patients are highly susceptible to infections with opportunistic pathogens,
such as CMV. Nevertheless, the specificity of the IE NASBA assay for the onset of a
symptomatic infection in liver transplant patients was low. Thus, as was concluded for
kidney transplant patients, IE NASBA results are not suitable as a guide to initiate antiviral
therapy, except for those patients that are at high risk for the onset of symptomatic infection.
In i'onlr.ist to what was reported for renal transplant patients, pp67 NASBA appeared to be
less sensitive than the antigenemia assay for the detection of a symptomatic infection.
I lowever, in this study, initiation of antiviral therapy was based on the first clinical signs of a
symptomatic infection confirmed by antigenemia-positive results. Since antiviral treatment
using ganciclovir rapidly results in the inhibition of viral replication and late mRNA
expression, it is possible that an early start of antiviral therapy prevented subsequent
detection of late pph7 mKNA by NASBA. Prospective studies should be performed to
investigate whether delayed initiation of antiviral therapy for these liver transplant patients
kisi-d on positive ppf>7 NASBA results would still allow the start of effective antiviral
therapy, without an unacceptable increased risk on the onset of severe symptomatic infection.
In contrast to IICMV infection in immunocompromised transplant patients, infection of
healthy, immunocompetent individuals with HCMV usually remains asymptomatic.
Studies to investigate the course of HCMV infection in healthy individuals are difficult to
perform due to the limited availability of tissues and blood samples. Alternatively, infection
of rats with rat cytomegalovirus (KCMV) is a useful model to perform these studies.
Intection ot immunocompromised rats results in active virus replication in various organs
and can be lethal, whereas infection of immunocompetent rats remains asymptomatic and
is not lethal even when a high dose of virus is injected. In chapter 5, dissemination and viral
activity was investigated after infection of immunocompetent rats with RCMV. Rats were
infected with RCMV and sacrificed at defined time-points post infection (pi). Several organs
and tissues were collected from the rats and analyzed for the presence of viral DNA, IE-1
(R123), early (R44) and late (R32) mRNA, as well as infectious virus. It was found that both
II'-1 mRNA expression and production of infectious virus are restricted during acute
infection at 7 days pi, although early and late mRNA could be detected. In general, IE-1
mRNA was only detected in the presence of detectable amounts of infectious virus, in
particular in the salivary glands and during productive infection in vitro. The mechanims
that are involved in the restriction of IE-1 mRNA expression in immunocompetent rats are
currently unknown. Interestingly, we identified two novel transcripts, that are
complementary to the IE-1 transcript. The elucidation of the function of these antisense
transcripts and their putatively encoded proteins will be the subject of future investigations.
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SAMENVATTING
Humaan cytomegalovirus (HCMV) is eon belangrijko oorzaak van ziokte on storfto in
immuungecompromiteerde patiönton. Fffoctiovo antiviralo bohandoling is mogolijk n\its
deze wordt gestart in de vnx-ge fas*.« van infoctic. In hot oorsto dool van dit prootschrilt word
de expressie van het virale "immodiato early" (IE)-1 en "late" ppf>7 mRNA in volblood
monsters van nier-, en levertransplantatie patienten gomonitord mot bohulp van "nucleic
acid sequence-based amplification" (NASBA). De 1E-1 en pp67 transcripten
vertegenwoordigen ioder verschillende fases in do roplicatio cyclus van hot virus. IV
diagnostische waarde van deze twee tosten voor do detectie van 11CMV int'ectie word
onderzocht.
In hix>fdstuk 2 werden in eon rctrospectievo studio vix>r niertransplantatio pationten de
resultaton van do pp(»7 NASBA tost vergeleken mot do resultaten van do ppt>^ anligenemio
test en viruskweek. Do gevivlighoid van do ppf>7 NASBA tost voor do doloctio van eon
actieve HCMV infectio blook hoger to /ijn dan do govoolighoid van do anligonemio tost, en
was vergelijkbaar met de gevooligheid van de viruskweek. Actieve HCMV infivtie word in
deze studie gedefinieerd door gecombineerde positieve resultaten voor viruskweek,
antigenemie en serologische testen. Sommige patienten ontwikkolden ook klinische
Symptomen als gevolg van een actieve HCMV infectie en werden daarvoor behandeld met
antivirale middelen. Voor deze patienten werd gevonden dat de gevoeligheid van de pp67
NASBA test vergelijkbaar was met de gevoeligheid van zowel de antigenemie test als
viruskweek. De pp67 NASBA test bleek tenslotte ook geschikt voor het monitoren van de
effectiviteit van de antivirale therapie. Samenvattend kon gesteld worden dat de
diagnostische waarde van de pp67 NASBA test voor de detectie van HCMV infectie in
niertransplantatie patienten vergelijkbaar is met die van de antigenemie test en viruskweek.
De bloedmonsters van dezelfde groep van niertransplantatie patienten als beschreven in
hoofdstuk 2 werden ook gebruikt voor een retrospectieve evaluatie van de diagnostische
waarde van de IE NASBA test (hoofdstuk 3). Deze test bleek zeer gevoelig to /ijn en
detecteerde de ontwikkeling van een primaire of secundaire infectie significant eerder dan
viruskweek, de pp67 NASBA en antigenemie test. De speeificiteit van de IE NASBA test was
echter Iaag. Dit houdt in dat de detectie van IE-1 mRNA in het bloed van niertransplantatie
patienten niet noodzakelijk gecorreleerd is met de ontwikkeling van een klinisch relevante
HCMV infectie. Er werd daarom geconcludeerd dat alleen patienten met een hoog risico op
de ontwikkeling van een symptomatische infectie, in het bijzonder patienten met een
primaire infectie of patienten die antivirale therapie krijgen, gebaad zijn bij een vroege
detectie van transcriptie door HCMV. Voor deze patienten kan de uitslag van de IE NASBA
test mogelijk dienen als een parameter voor de start van preventieve antivirale therapie.
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Een vergelijkbare cvaluatie voor de IE en pp67 NASBA testen als zojuist beschreven
vcM>r niertransplantatie patienten werd uitgevoerd voor levertransplantatie patienten, en is
beschreven in h(x>fdstuk 4. In het algemeen hebben levertransplantatie patienten een hoger
risico op de ontwikkeling van een symptomatische infectie dan niertransplantatie
patienten. Levertransplantatie patienten zijn meestal in een kritieke klinische conditie op
het moment van transplantatie en krijgen vaak anti-rejectie therapie. Als gevolg hiervan
zijn deze patienten zeer gevoelig voor infecties met opportunistische pathogenen zoals
IICMV. Desondanks was de specificiteit van de IE NASBA test voor de ontwikkeling van
een symptomatische infectie in levertransplantatie patienten laag. Dus, zoals werd
gecondudeerd voor de niertransplantatie patienten, blijken IE NASBA test resultaten niet
geschikt te zijn als leidraad voor de start van preventieve antivirale therapie, behalve voor
specifieke patienten die een hoog risico hebben op de ontwikkeling van een
symptomatische infectie. In tegenstelling tot de gerapporteerde bevindingen voor
niertransplantatie patienten, bleek de ppfr7 NASBA test minder gevoelig te zijn dan de
antigenemie test voor de detectie van een symptomatische infectie. In de/e Studie werd de
start van antivirale therapie echter gebaseerd op het optreden van de eerste klinische
verschijnselen van een symptomatische infectie, bevestigd door positieve antigenemie
resultaten. Omdat antivirale therapie met ganciclovir direct tot een remming leidt van de
virale replicatie en "late" mKNA expressie, is het mogelijk dat een vroege start van de
antivirale therapie als gevolg had dat de detectie van het "late" ppf>7 mKNA door NASBA
werd verhinderd. I'rospectieve studies zouden moeten uitwijzen of een vertraagde start
van antivirale therapie voor deze levertransplantatie patienten gebaseerd op positieve
pp(v NASHA resultaten nog steeds effectief is, of dat dit resulteert in een onacceptabele
verhoging van de kans op de ontwikkeling van een ernstige symptomatische infectie.
In tegenstelling tot HCMV infectie in immuungecompromiteerde transplantatie
patienten blijtt de infectie van immuuncompetente individuen met HCMV in het algemeen
asymptomatisch. Studies om het verloop van een HCMV infectie te onderzoeken in
gezonde individuen zijn moeilijk uit te voeren vanwege de beperkte beschikbaarheid van
weetsel- en bloedmonsters. Als alternatief is de infectie van ratten met rat cytomegalovirus
(KCMV) een zeer bruikbaar diermodel voor het uitvoeren van dergelijke studies. Infectie
van immuungecompromiteerde ratten resulteert in actieve virus replicatie en kan lethaal
zijn. In tegenstelling. infectie van immuuncompetente ratten verloopt asymptomatisch en
is niet dodelijk, zelfs wanneor een zeer hoge virus dosis wordt toegediend. In hoofdstuk 5
werd de verspreiding en activiteit van het virus onderzocht na infectie van
immuuncompetente ratten met RCMV. Ratten werden geinfecteerd met RCMV en
opgeofferd op gespecificeerde tijden na infectie. Verschiliende rat organen en weefsels
140
werden verzameld en getest op de aanwezigheid van viraal DNA, IE-1 (R123), "early"
(R44) en "late" (R32) mRNA, en infectious virus. Er bleek een restrictie op to tredon van
zowel IE-1 mRNA expressie als productio van infectious vims tijdons acute infivtie op dag
7 na infectie, alhoewel "early" en "late" mRNA wel op dat moment konden worden
gedetecteerd. In het algemeen werd IE-1 mRNA alleon godotocttvrd in de aanwo/.ighoid
van detecteerbare hoevoolheden van infectious virus, in het bijzonder in de ^viksolklioron
en tijdens pnxiuctieve infectie in vitm. De mechanismen die betrokken /ijn bij de rostrictio
van IE-1 mRNA expressie in immuuncompotento ratten /ijn op dit moment onbekond. I'en
interessante bevinding hierbij is het feit dat twee niouwe transcripten konden worden
geidentificeerd die complementair zijn aan het IE-1 transcript. Do opholdoring van de
functie van dczc antisense transcripton en do eiwitten die mogelijk door de/e transcripten
worden gecodeerd, zal het onderwcrp zijn van vervolgondor/oek.
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Voor de praktische uitvoering van de ratproeven heb ik kunnen profiteren van de ruime
ervaring van Gert Grauls. Voor iemand die eigenlijk niet graag een levende rat aanraakt is
het verwonderlijk dat ze het al zo lang volhoudt met deze beestjes, maar misschien dat er
daarom .iltijd een bonx*p op haar kan worden gedaan om er eentje op te offeren. Verder vvil
ik Joanne van Dam, Marjorie Nelissen en Jeroen Kloover bedanken voor hun hulp bij de
ratproeven.
Voor het opzetten en uitvoeren van de testen die nodig waren om de verzamelde
ratorganen te analyseren verdient Kim Savelkouls een eervolle vermelding. Ze heeft zieh
met sum's een wog gebaand door een grote hoeveelheid testen waarbij het gevaar van
contaminate voortdurend op de loer lag. I'CK controles en de logische gedachte 6 x 8 = 48
hidden haar op de been. Een jaar geleden heeft deze prestatie haar al de "1-2-3 RT-PCR"
award opgeleverd. Ik hoop dat zij de körnende tijd deze titel zal blijven verdedigen. Er
waren ook andere holden in hot KCMV verhaal, met name Monique Coomans vanwege de
volo KCMV IX Ks on Martine Hulsbosch vanwege haar inzet tijdens het ontwikkelen van
Piotocollon voor KT-PCR on PNA/RNA isolatie.
Na de ontberingen in het lab was het goed om weer thuis te komen in de zitkamer waar
hi't vrijwel altijd, en soms te, gezellig was. Ik wil Erik, Joanne, Patrick, Suzanne, Yvonne,
Jemen, Kim, Koon en I.ieve bedanken voor de ple/.ierige samenwerking in de afgelopen
tijd. Ik vind dat door het contact zowol op, als buiten het werk er een bijzondere collegiale
hand is ontstaan die elk cKhtendhumeur met succes kan doorstaan. Ook andere mensen die
in de loop van de jaren in de zitkamer en op het lab hun sporen hebben achtergelaten
hobbon hier een bijdrage in gehad, zoals Edward, Servi, Mohammed, Jim, Saskia, Susan,
Hram, Jasper, Carola, Wil, Aafke en Regine. 1 also would like thank Timi, for the pleasant
collaboration and his friendship.
Tenslotte gaat mijn dank uit naar het secretariaat van de afdeling Medische
Microbiologie, met name Fia, voor het uit handen nemen van de administratieve taken
rondom mijn promotie en naar het gehele team van ANDI Drukvverk Industrie te Geleen
voor do mooie \-ormgeving en productie van het proefschrift. Familie en vrienden kunnen
mi eindelijk rüstig nalezen waar ik mee bezig ben geweest en wat het resultaat is geworden
van al dat schrijven.
Rest mij nog om Marije te bedanken voor haar geduld, steun en liefde in de afgelopen
periode. Zo is toch wel mijn bolangrijksto ontdekking gewoest in de afgelopen 4 jaar. De
Resultaten van doze ontdekking zijn zelfs onlangs geregistreerd bij de burgerlijke stand van
Maastricht. Nu is het mijn taak om een eervolle vermelding te verwerven in het dankwoord
van haar proefsehrift.
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CURRICULUM VITAE
Rien Blok word geboren op 26 april 1972 te Halstoren. In 1984 begon zijn middolbai«
schoolopleiding aan do scholengemeenschap t Rijks in Bergen op Zoom. Hot oindexamon
VWO word in 1990 behaald. In datzelfde jaar begon hij met do studio Bioprvvostochnologio
aan de Universiteit Wageningen. In 1994 word do eerste afstudooropdracht verricht bij do
vakgroep Experimentolo Diermorl'ologie on Celbiologio, met als ondorworp do
ontwikkeling van monoclonalo antilichamen tegon T-lymfocyten on macrofagon van do
karper. Later dat jaar vertrok hij naar hot Pasteur Instituut in I'arijs, on deed daar onderzoek
bij het "Laboratoire dos Bunyavirides" aan hot Rift Valley fever virus. Fen laalMc --t.ir,«'
werd verricht bij de afdoling Porcine en Exotische Virusziokton, van hot Instituut \oor
Dierhouderij en Diergezondheid te Lelystad. Hier werd gewerkt aan do moloculairo
karakterisatie van een vaccin stam van het varkenspest virus. Eind 199!> bohaalde hij cum
laude de Ir. titel en in 19% begun hij als AIO bij do afdoling Modische Microbiologio van
het Academisch Ziekonhuis in Maastricht. In 2(XX) word do aanstolling bij dozo atdoling
verlengd en werden de werkzaamheden uitgebreid met het opzetten en implementereii
van nieuwe testen voor de moleculaire diagnostiek.
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